



US010130701B2

(12) **United States Patent**
Bickerton et al.

(10) **Patent No.: US 10,130,701 B2**

(45) **Date of Patent: Nov. 20, 2018**

(54) **CORONAVIRUS**

OTHER PUBLICATIONS

- (71) Applicant: **THE PIRBRIGHT INSTITUTE**,
Pirbright, Woking (GB)
- (72) Inventors: **Erica Bickerton**, Woking (GB); **Sarah Keep**, Woking (GB); **Paul Britton**,
Woking (GB)
- (73) Assignee: **THE PIRBRIGHT INSTITUTE**,
Woking, Pirbright (GB)
- (*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

Sperry Journal of Virology, 2005, vol. 79, No. 6, pp. 3391-3400.*
Altschul et al., Basic local alignment search tool. *J. Mol. Biol.* 215:
403-10 (1990).
Ammayappan et al., Identification of sequence changes respon-
sible for the attenuation of avian infectious bronchitis virus strain
Arkansas DPI, *Arch. Virol.*, 154(3):495-9 (2009).
Anonymous: "EM_STD:KF377577", Oct. 30, 2013.
Armesto et al., A recombinant avian infectious bronchitis virus
expressing a heterologous spike gene belonging to the 4/91 serotype,
PLoS One, 6(8):e24352 (2011).
Armesto et al., The replicase gene of avian coronavirus infectious
bronchitis virus is a determinant of pathogenicity, *PLoS One*,
4(10):e7384 (2009).
Armesto et al., Transient dominant selection for the modification
and generation of recombinant infectious bronchitis coronaviruses,
Methods Mol. Biol., 454:255-73 (2008).
Ausubel et al., *Short Protocols in Molecular Biology*, 4th edition,
Chapter 18 (1999).
Britton et al., Generation of a recombinant avian coronavirus
infectious bronchitis virus using transient dominant selection, *J.*
Virol. Methods, 123(2):203-11 (2005).
Britton et al., Modification of the avian coronavirus infectious
bronchitis virus for vaccine development, *Bioeng. Bugs.*, 3(2):114-9
(2012).
Casais et al., Recombinant avian infectious bronchitis virus express-
ing a heterologous spike gene demonstrates that the spike protein is
a determinant of cell tropism, *J. Virol.*, 77(16):9084-9 (2003).
Casais et al., Reverse genetics system for the avian coronavirus
infectious bronchitis virus, *J. Virol.*, 75(24):12359-69 (2001).
Devereux et al., A comprehensive set of sequence analysis programs
for the VAX. *Nucl. Acids Res.* 12: 387-95 (1984).
Cavanagh et al., Manipulation of the infectious bronchitis coronavirus
genome for vaccine development and analysis of the accessory
proteins, *Vaccine*, 25(30):5558-62 (2007).
International Preliminary Report on Patentability, International Appli-
cation No. PCT/GB2015/052124, dated Jan. 24, 2017.
International Search Report and Written Opinion, International
Application No. PCT/GB2015/052124, dated Oct. 9, 2015.
Larkin et al., Clustal W and Clustal X version 2.0, *Bioinformatics*,
23(21):2947-8 (2007).
Menachery et al., Attenuation and restoration of severe acute
respiratory syndrome coronavirus mutant lacking 2'-o-
methyltransferase activity, *J. Virol.*, 88(8):4251-64 (2014).
Tatusova et al., BLAST 2 Sequences, a new tool for comparing
protein and nucleotide sequences, *FEMS Microbiol. Lett.*, 174(2):247-
50 (1999).

(Continued)

- (21) Appl. No.: **15/328,179**
- (22) PCT Filed: **Jul. 23, 2015**
- (86) PCT No.: **PCT/GB2015/052124**
§ 371 (c)(1),
(2) Date: **Jan. 23, 2017**
- (87) PCT Pub. No.: **WO2016/012793**
PCT Pub. Date: **Jan. 28, 2016**
- (65) **Prior Publication Data**
US 2017/0216427 A1 Aug. 3, 2017
- (30) **Foreign Application Priority Data**
Jul. 23, 2014 (GB) 1413020.7

- (51) **Int. Cl.**
A61K 39/215 (2006.01)
C12N 7/00 (2006.01)
C12N 9/12 (2006.01)
A61K 39/00 (2006.01)
- (52) **U.S. Cl.**
CPC **A61K 39/215** (2013.01); **C12N 7/00**
(2013.01); **C12N 9/127** (2013.01); **C12Y**
207/07048 (2013.01); **A61K 2039/5254**
(2013.01); **A61K 2039/54** (2013.01); **C12N**
2770/20021 (2013.01); **C12N 2770/20022**
(2013.01); **C12N 2770/20034** (2013.01); **C12N**
2770/20051 (2013.01); **C12N 2770/20062**
(2013.01)
- (58) **Field of Classification Search**
CPC **A61K 39/215**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,452,542 B2 * 11/2008 Denison C07K 14/005
424/221.1

FOREIGN PATENT DOCUMENTS

WO WO-2004/092360 A2 10/2004
WO WO-2005/049814 A2 6/2005
WO WO-2007/078203 A1 7/2007
WO WO-2011/004146 A1 1/2011

Primary Examiner — Bao Q Li
(74) Attorney, Agent, or Firm — Marshall, Gerstein &
Borun LLP

(57) **ABSTRACT**

The present invention provides a live, attenuated coronavi-
rus comprising a variant replicase gene encoding polypro-
teins comprising a mutation in one or more of non-structural
protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The corona-
virus may be used as a vaccine for treating and/or preventing
a disease, such as infectious bronchitis, in a subject.

25 Claims, 15 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited

OTHER PUBLICATIONS

Wang et al., Attenuation of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric construction with vaccine sequence, *Virology*, 371(2):418-29 (2008).

Wei et al., Development and characterization of a recombinant infectious bronchitis virus expressing the ectodomain region of S1 gene of H120 strain, *Appl. Microbiol. Biotechnol.*, 98(4):1727-35 (2014).

* cited by examiner

FIGURE 1




FIGURE 2





FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8





FIGURE 9

A



B





Fig. 10



Nsp14

[illegible]

Fig. 10 (cont.)

Nsp15

M41 Nsp15 * 20 40 60 80
Mod Nsp15 * 60 80

M41 Nsp15 * 100 120 140 160
Mod Nsp15 * 140 160

M41 Nsp15 * 180 200 220 240
Mod Nsp15 * 240

M41 Nsp15 * 260 280 300 320
Mod Nsp15 * 320

*
M41 Nsp15 *
Mod Nsp15 *

Fig. 10 (cont.)

Nsp16

M41 Nsp16	*	20	*	40	*	60	*	80
Mod Nsp16	SETHGGNNMTHAKVQNCWEPCHHNGVGHLPSSGMMVAATHQICQHSKTHKTPHHMRVHIREGSGINGVAPES							
M41 Nsp16	*	100	*	120	*	140	*	180
Mod Nsp16	IVPKCTPEEGGNNVNDNDVSDHVSLSISGKATGTHGGQNVISITATDIDSGHREEVANGSDUVEINISSSTH							
M41 Nsp16	*	180	*	200	*	220	*	240
Mod Nsp16	IRPAIGSSFAVKVTEISZHLVYDIPQDCAPMPHPCAVASSSPAH							
M41 Nsp16	*	260	*	280	*	300		
Mod Nsp16	QTSAYSIFHWAKFDRLKATEVWNLKEDKTHLVHMKCCGAAVWVGSISFISISVNCIL							




Fig. 11A**Fig. 11B**

Fig. 11C

1

CORONAVIRUS**FIELD OF THE INVENTION**

The present invention relates to an attenuated coronavirus comprising a variant replicase gene, which causes the virus to have reduced pathogenicity. The present invention also relates to the use of such a coronavirus in a vaccine to prevent and/or treat a disease.

BACKGROUND TO THE INVENTION

Avian infectious bronchitis virus (IBV), the aetiological agent of infectious bronchitis (IB), is a highly infectious and contagious pathogen of domestic fowl that replicates primarily in the respiratory tract but also in epithelial cells of the gut, kidney and oviduct. IBV is a member of the Order Nidovirales, Family Coronaviridae, Subfamily Coronavirinae and Genus *Gammacoronavirus*; genetically very similar coronaviruses cause disease in turkeys, guinea fowl and pheasants.

Clinical signs of IB include sneezing, tracheal rales, nasal discharge and wheezing. Meat-type birds have reduced weight gain, whilst egg-laying birds lay fewer eggs and produce poor quality eggs. The respiratory infection predisposes chickens to secondary bacterial infections which can be fatal in chicks. The virus can also cause permanent damage to the oviduct, especially in chicks, leading to reduced egg production and quality; and kidney, sometimes leading to kidney disease which can be fatal.

IBV has been reported to be responsible for more economic loss to the poultry industry than any other infectious disease. Although live attenuated vaccines and inactivated vaccines are universally used in the control of IBV, the protection gained by use of vaccination can be lost either due to vaccine breakdown or the introduction of a new IBV serotype that is not related to the vaccine used, posing a risk to the poultry industry.

Further, there is a need in the industry to develop vaccines which are suitable for use in ovo, in order to improve the efficiency and cost-effectiveness of vaccination programmes. A major challenge associated with in ovo vaccination is that the virus must be capable of replicating in the presence of maternally-derived antibodies against the virus, without being pathogenic to the embryo. Current IBV vaccines are derived following multiple passage in embryonated eggs, this results in viruses with reduced pathogenicity for chickens, so that they can be used as live attenuated vaccines. However such viruses almost always show an increased virulence to embryos and therefore cannot be used for in ovo vaccination as they cause reduced hatchability. A 70% reduction in hatchability is seen in some cases.

Attenuation following multiple passage in embryonated eggs also suffers from other disadvantages. It is an empirical method, as attenuation of the viruses is random and will differ every time the virus is passaged, so passage of the same virus through a different series of eggs for attenuation purposes will lead to a different set of mutations leading to attenuation. There are also efficacy problems associated with the process: some mutations will affect the replication of the virus and some of the mutations may make the virus too attenuated. Mutations can also occur in the S gene which may also affect immunogenicity so that the desired immune response is affected and the potential vaccine may not protect against the required serotype. In addition there are problems associated with reversion to virulence and stability of vaccines.

2

It is important that new and safer vaccines are developed for the control of IBV. Thus there is a need for IBV vaccines which are not associated with these issues, in particular vaccines which may be used for in ovo vaccination.

SUMMARY OF ASPECTS OF THE INVENTION

The present inventors have used a reverse genetics approach in order to rationally attenuate IBV. This approach is much more controllable than random attenuation following multiple passages in embryonated eggs because the position of each mutation is known and its effect on the virus, i.e. the reason for attenuation, can be derived.

Using their reverse genetics approach, the present inventors have identified various mutations which cause the virus to have reduced levels of pathogenicity. The levels of pathogenicity may be reduced such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo. Such viruses may be suitable for in ovo vaccination, which is a significant advantage and has improvement over attenuated IBV vaccines produced following multiple passage in embryonated eggs.

Thus in a first aspect, the present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polypeptides comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16.

The variant replicase gene may encode a protein comprising one or more amino acid mutations selected from the list of:

Pro to Leu at position 85 of SEQ ID NO: 6;
Val to Leu at position 393 of SEQ ID NO: 7;
Leu to Ile at position 183 of SEQ ID NO: 8;
Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may encode a protein comprising the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

The replicase gene may encode a protein comprising the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7; Leu to Ile at position 183 of SEQ ID NO: 8; and Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may encode a protein comprising the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6; Val to Leu at position 393 of SEQ ID NO: 7; Leu to Ile at position 183 of SEQ ID NO: 8; and Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may comprise one or more nucleotide substitutions selected from the list of:

C to T at nucleotide position 12137;
G to C at nucleotide position 18114;
T to A at nucleotide position 19047; and
G to A at nucleotide position 20139;
compared to the sequence shown as SEQ ID NO: 1.

The coronavirus may be an infectious bronchitis virus (IBV).

The coronavirus may be IBV M41.

The coronavirus may comprise an S protein at least part of which is from an IBV serotype other than M41.

For example, the S1 subunit or the entire S protein may be from an IBV serotype other than M41.

The coronavirus according to the first aspect of the invention has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo.

3

In a second aspect, the present invention provides a variant replicase gene as defined in connection with the first aspect of the invention.

In a third aspect, the present invention provides a protein encoded by a variant coronavirus replicase gene according to the second aspect of the invention.

In a fourth aspect, the present invention provides a plasmid comprising a replicase gene according to the second aspect of the invention.

In a fifth aspect, the present invention provides a method for making the coronavirus according to the first aspect of the invention which comprises the following steps:

- (i) transfecting a plasmid according to the fourth aspect of the invention into a host cell;
- (ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;
- (iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and
- (iv) selecting for recombining virus comprising the modified replicase gene.

The recombining virus may be a vaccinia virus.

The method may also include the step:

- (v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

In a sixth aspect, the present invention provides a cell capable of producing a coronavirus according to the first aspect of the invention.

In a seventh aspect, the present invention provides a vaccine comprising a coronavirus according to the first aspect of the invention and a pharmaceutically acceptable carrier.

In an eighth aspect, the present invention provides a method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to the seventh aspect of the invention to the subject.

Further aspects of the invention provide:

the vaccine according to the seventh aspect of the invention for use in treating and/or preventing a disease in a subject.

use of a coronavirus according to the first aspect of the invention in the manufacture of a vaccine for treating and/or preventing a disease in a subject.

The disease may be infectious bronchitis (IB).

The method of administration of the vaccine may be selected from the group consisting of: eye drop administration, intranasal administration, drinking water administration, post-hatch injection and in ovo injection.

Vaccination may be by in ova vaccination.

The present invention also provides a method for producing a vaccine according to the seventh aspect of the invention, which comprises the step of infecting a cell according to the sixth aspect of the invention with a coronavirus according to the first aspect of the invention.

DESCRIPTION OF THE FIGURES

FIG. 1—Growth kinetics of M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) on CK cells

FIG. 2—Clinical signs, snicking and wheezing, associated with M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) and Beau-R (Bars show mock, Beau-R, M41-R 6, M41-R 12, M41-CK EP4 from left to right of each timepoint).

4

FIG. 3—Ciliary activity of the viruses in tracheal rings isolated from tracheas taken from infected chicks. 100% ciliary activity indicates no effect by the virus; apathogenic, 0% activity indicates complete loss of ciliary activity, complete ciliostasis, indicating the virus is pathogenic (Bars show mock, Beau-R, M41-R 6, M41-R 12, M41-CK EP4 from left to right of each timepoint).

FIG. 4—Clinical signs, snicking, associated with M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK (M41 EP5) (Bars show mock, M41-R12; M41R-nsp10rep; M41R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

FIG. 5—Ciliary activity of M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock; M41-R12; M41R-nsp10rep; M41R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

FIG. 6—Clinical signs, snicking, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14, 15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 7—Clinical signs, wheezing, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14, 15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 8—Ciliary activity of M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14,15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 9—Growth kinetics of rIBVs compared to M41-CK on CK cells. FIG. 9A shows the results for M41-R and M41-K. FIG. 9B shows the results for M41-nsp10 rep; M41R-nsp14, 15, 16 rep; M41R-nsp10, 15 rep; M41R-nsp10, 15, 16 rep; M41R-nsp10, 14, 15 rep; and M41R-nsp10, 14, 16.

FIG. 10—Position of amino acid mutations in mutated nsp10, nsp14, nsp15 and nsp16 sequences.

FIG. 11—A) Snicking; B) Respiratory symptoms (wheezing and rales combined) and C) Ciliary activity of rIBV M41R-nsp 10,14 rep and rIBV M41R-nsp 10,16 rep compared to M41-CK (Bars show mock, M41R-nsp10,14rep; M41R-nsp10,16rep and M41-K from left to right of each timepoint).

DETAILED DESCRIPTION

The present invention provides a coronavirus comprising a variant replicase gene which, when expressed in the coronavirus, causes the virus to have reduced pathogenicity compared to a corresponding coronavirus which comprises the wild-type replicase gene.

Coronavirus

Gammacoronavirus is a genus of animal virus belonging to the family Coronaviridae. Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetry.

The genomic size of coronaviruses ranges from approximately 27 to 32 kilobases, which is the longest size for any known RNA virus.

Coronaviruses primarily infect the upper respiratory or gastrointestinal tract of mammals and birds. Five to six different currently known strains of coronaviruses infect humans. The most publicized human coronavirus, SARS-CoV which causes severe acute respiratory syndrome (SARS), has a unique pathogenesis because it causes both upper and lower respiratory tract infections and can also cause gastroenteritis. Middle East respiratory syndrome coronavirus (MERS-CoV) also causes a lower respiratory tract infection in humans. Coronaviruses are believed to cause a significant percentage of all common colds in human adults.

Coronaviruses also cause a range of diseases in livestock animals and domesticated pets, some of which can be serious and are a threat to the farming industry. Economically significant coronaviruses of livestock animals include infectious bronchitis virus (IBV) which mainly causes respiratory disease in chickens and seriously affects the poultry industry worldwide; porcine coronavirus (transmissible gastroenteritis, TGE) and bovine coronavirus, which both result in diarrhoea in young animals. Feline coronavirus has two forms, feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality.

There are also two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease. Mouse hepatitis virus (MHV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice.

Coronaviruses are divided into four groups, as shown below:

Alpha

- Canine coronavirus (CCoV)
- Feline coronavirus (FeCoV)
- Human coronavirus 229E (HCoV-229E)
- Porcine epidemic diarrhoea virus (PEDV)
- Transmissible gastroenteritis virus (TGEV)
- Human Coronavirus NL63 (NL or New Haven)

Beta

- Bovine coronavirus (BCoV)
- Canine respiratory coronavirus (CRCoV)—Common in SE Asia and Micronesia
- Human coronavirus OC43 (HCoV-OC43)
- Mouse hepatitis virus (MHV)
- Porcine haemagglutinating encephalomyelitis virus (HEV)
- Rat coronavirus (Roy). Rat Coronavirus is quite prevalent in Eastern Australia where, as of March/April 2008, it has been found among native and feral rodent colonies.
- (No common name as of yet) (HCoV-HKU1)
- Severe acute respiratory syndrome coronavirus (SARS-CoV)
- Middle East respiratory syndrome coronavirus (MERS-CoV)

Gamma

- Infectious bronchitis virus (IBV)
- Turkey coronavirus (Bluecomb disease virus)
- Pheasant coronavirus
- Guinea fowl coronavirus

Delta

- Bulbul coronavirus (BuCoV)
- Thrush coronavirus (ThCoV)
- Munia coronavirus (MuCoV)
- Porcine coronavirus (PorCoV) HKU15

The variant replicase gene of the coronavirus of the present invention may be derived from an alphacoronavirus such as TGEV; a betacoronavirus such as MHV; or a *gammacoronavirus* such as IBV.

As used herein the term “derived from” means that the replicase gene comprises substantially the same nucleotide sequence as the wild-type replicase gene of the relevant coronavirus. For example, the variant replicase gene of the present invention may have up to 80%, 85%, 90%, 95%, 98% or 99% identity with the wild type replicase sequence. The variant coronavirus replicase gene encodes a protein comprising a mutation in one or more of non-structural protein (nsp)-10, nsp-14, nsp-15 or nsp-16 when compared to the wild-type sequence of the non-structural protein.

IBV

Avian infectious bronchitis (IB) is an acute and highly contagious respiratory disease of chickens which causes significant economic losses. The disease is characterized by respiratory signs including gasping, coughing, sneezing, tracheal rales, and nasal discharge. In young chickens, severe respiratory distress may occur. In layers, respiratory distress, nephritis, decrease in egg production, and loss of internal egg quality and egg shell quality are common.

In broilers, coughing and rattling are common clinical signs, rapidly spreading in all the birds of the premises. Morbidity is 100% in non-vaccinated flocks. Mortality varies depending on age, virus strain, and secondary infections but may be up to 60% in non-vaccinated flocks.

The first IBV serotype to be identified was Massachusetts, but in the United States several serotypes, including Arkansas and Delaware, are currently circulating, in addition to the originally identified Massachusetts type.

The IBV strain Beaudette was derived following at least 150 passages in chick embryos. IBV Beaudette is no longer pathogenic for hatched chickens but rapidly kills embryos.

H120 is a commercial live attenuated IBV Massachusetts serotype vaccine strain, attenuated by approximately 120 passages in embryonated chicken eggs. H52 is another Massachusetts vaccine, and represents an earlier and slightly more pathogenic passage virus (passage 52) during the development of H120. Vaccines based on H120 are commonly used.

IB QX is a virulent field isolate of IBV. It is sometimes known as “Chinese QX” as it was originally isolated following outbreaks of disease in the Qingdao region in China in the mid 1990s. Since that time the virus has crept towards Europe. From 2004, severe egg production issues have been identified with a very similar virus in parts of Western Europe, predominantly in the Netherlands, but also reported from Germany, France, Belgium, Denmark and in the UK.

The virus isolated from the Dutch cases was identified by the Dutch Research Institute at Deventer as a new strain that they called D388. The Chinese connection came from further tests which showed that the virus was 99% similar to the Chinese QX viruses. A live attenuated QX-like IBV vaccine strain has now been developed.

IBV is an enveloped virus that replicates in the cell cytoplasm and contains an non-segmented, single-stranded, positive sense RNA genome. IBV has a 27.6 kb RNA genome and like all coronaviruses contains the four structural proteins; spike glycoprotein (S), small membrane pro-

tein (E), integral membrane protein (M) and nucleocapsid protein (N) which interacts with the genomic RNA.

The genome is organised in the following manner: 5'UTR—polymerase (replicase) gene—structural protein genes (S-E-M-N)—UTR 3'; where the UTR are untranslated regions (each ~500 nucleotides in IBV).

The lipid envelope contains three membrane proteins: S, M and E. The IBV S protein is a type I glycoprotein which oligomerizes in the endoplasmic reticulum and is assembled into homotrimer inserted in the virion membrane via the transmembrane domain and is associated through non-covalent interactions with the M protein. Following incorporation into coronavirus particles, the S protein is responsible for binding to the target cell receptor and fusion of the viral and cellular membranes. The S glycoprotein consists of four domains: a signal sequence that is cleaved during synthesis; the ectodomain, which is present on the outside of the virion particle; the transmembrane region responsible for anchoring the S protein into the lipid bilayer of the virion particle; and the cytoplasmic tail.

All coronaviruses also encode a set of accessory protein genes of unknown function that are not required for replication in vitro, but may play a role in pathogenesis. IBV

encodes two accessory genes, genes 3 and 5, which both express two accessory proteins 3a, 3b and 5a, 5b, respectively.

The variant replicase gene of the coronavirus of the present invention may be derived from an IBV. For example the IBV may be IBV Beaudette, H120, H52, IB QX, D388 or M41.

The IBV may be IBV M41. M41 is a prototypic Massachusetts serotype that was isolated in the USA in 1941. It is an isolate used in many labs throughout the world as a pathogenic lab stain and can be obtained from ATCC (VR-21™). Attenuated variants are also used by several vaccine producers as IBV vaccines against Massachusetts serotypes causing problems in the field. The present inventors chose to use this strain as they had worked for many years on this virus, and because the sequence of the complete virus genome is available. The M41 isolate, M41-CK, used by the present inventors was adapted to grow in primary chick kidney (CK) cells and was therefore deemed amenable for recovery as an infectious virus from a cDNA of the complete genome. It is representative of a pathogenic IBV and therefore can be analysed for mutations that cause either loss or reduction in pathogenicity.

The genome sequence of IBV M41-CK is provided as SEQ ID NO: 1.

IBV M41-CK Sequence

SEQ ID NO: 1

```

ACTTAAGATAGATATTAATATATATCTATCACACTAGCCTTGCCTAGATTTCACACTTA
ACAAAACGGACTTAAATACCTACAGCTGGTCTCATAGGTGTTCCATTGCAGTGCACCTT
AGTGCCCTGGATGGACCTGGCCACCTGTCAGGTTTTTGTATTAAATCTTATTGTTGC
TGGTATCACTGCTTGTCTTTCGCGTGTCTCACTTTATACATCCGTTGCTTGGGCTACCTAG
TATCCAGCGTCTACGGGCGCGTGGCTGGTTCGAGTGCGAAGAACCTCTGGTTCATCTA
GCGGTAGGCGGGTGTGTGAAGTAGCACTTCAGACGTACCGGTTCTGTTGTGTGAAATAC
GGGGTCACCTCCCCCACATACCTCTAAGGGCTTTTGAGCCTAGCGTTGGGCTACGTTCT
CGCATAAGGTGCGGTATACGACGTTTGTAGGGGTAGTGCCAAACAACCCCTGAGGTGAC
AGGTTCTGGTGGTGTGTAGTGAGCAGACATACAATAGACAGTGACAACATGGCTTCAAGC
CTAAACAGGGAGTATCTCGAAACTAAGGATGTCATTGTTGTATCCAAAGAGATTGCT
GAACAACCTTTGTGACGCTTTGTTTTCTATACGTACACAAACCTAAGGATTACGCTGAT
GCTTTTGAGTTAGGCAGAAGTTGATCGTAATCTGCAGACTGGGAAACAGTTCAAATTT
GAAACTGTGTGTGCTCTCTCTCTTGAAGGGAGTTGACAAAATAACACCTGGCGTCCCA
GCAAAAGTCTTAAAGCCACTTCTAAGTTGGCAGATTAGAAGACATCTTTGGTGTCTCT
CCCTTTGCAAGAAAATATCGTGAACCTTTGAAGACAGCATGCCAGTGGTCTCTTACTGTA
GAAACACTGGATGCTCGTGCAAACTCTTGATGAAATTTTGACCTACTGAAATACTT
TGGCTTCAAGTGGCAGCAAAATCCAAGTTTCGGCTATGGCGATGCGCAGGCTTGTGGGA
GAAGTAAGTGCAAAAGTCATGGATGCTTTGGGCTCAAATATGAGTGCTCTTTCCAGATT
TTTAAACAACAAATAGTCAGAATTTTCAAAAAGCGCTGGCTATTTTGTAGAAATGTGAGT
GAATTACCACAGCGTATTGCAGCACTTAAGATGGCTTTTGCTAAGTGTGCCAAGTCCATT
ACTGTTGTGGTTATGGAGAGGACTCTAGTTGTTAGAGAGTTTCGAGGAAGTGTCTTGTGA
AGCATTAAATGGTGTGTTGCAAAATCTTTGAAGAACTCCCAATGGTTTCATGGGTGCT
AAAATTTTCACTACACTTGCCTTCTTTAGGAGGCTGCAGTGAATTTGTGGATAACATA
CCAAATGCACCGAGAGGCACTAAAGGGTTTGAAGTCGTTGGTAATGCCAAAGGTACACAA

```

- continued

GTGTTGTGCGTGGCATGGGAAATGACTTAACACTGGTTGAGCAAAAAGCTGAAATTGCT
GTGGAGTCAGAAGGTGGTCTGCAATTTTGGGTGGACATCTTGTCTATGCTTTAAGAGT
GGTGATCGCTTTTACGCGGCACCTCTTTCAGGAAATTTGCATTGCATGATGTGCATTGT
TGTGAGCGTGTGTCTGTCTTCTGATGGTGTAAACCCGGAGATAAATGATGGACTTATT
CTTGACAGCAATCTACTCTTCTTTTAGTGTGCGAGAACTTGTGGCAGCCATTAAAAGGGT
GAACCATTAAAGTTTCTGGGTATAAATTTGTGTATGCAAGGATGCAGCAGTTTCTTTT
ACATTAGCGAAGGCTGCTACTATTGCAGATGTTTTGAAGCTGTTCAATCAGCGCGTGTG
AAAGTAGAAGATGTTTGGTCTTCACTTACTGAAAAGTCTTTTGAATTCTGGAGGCTTGCA
TATGGAAGAGTGCCTAATCTCGAAGAATTTGTTAAGACTTGTTTTGTAAAGCTCAAATG
GCGATTGTGATTTTAGCGACAGTGTCTGGAGAGGGCATTGGCATCTTGTTCGCAAGTC
ATCTATAAGTAGGTGGTCTTTTACTAAAGTTGTTGACTTTTGTGAAAAATATTGGAAA
GGTTTTTGTGCACAGTTGAAAAGAGCTAAGCTCATTGTCACTGAAACCCCTCTGTGTTTTG
AAAGGAGTTGCACAGCATTGTTTTCAACTATTGCTGGATGCAATACAGTTTATGTATAAA
AGTTTTAAGAAGTGTGCACCTTGGTAGAATCCATGGAGACTTGCTCTTCTGGAAAGGAGGT
GTGCACAAAAATTATTCAAGAGGGCGATGAAATTTGGTTGAGGGCATTGATAGTATTGAT
GTTGAAGATCTGGGTGTTGTTCAAGAAAAATTGATTGATTTTGATGTTTGTGATAATGTG
ACACTTCCAGAGAACCAACCCGGTCATATGGTTCAAATCGAGGATGACGGAAGAACTAC
ATGTTCTTCCGCTTCAAAAAGGATGAGAACATTTATTATACCAATGTACAGCTTGGT
GCTATTAAATGTGGTTTGCAAAGCAGGCGGTAAACTGTCACCTTTGGAGAACTACTGTG
CAAGAAATACCACCACCTGATGTTGTGTTTATTAAGGTTAGCATTGAGTGTGTGGTGAA
CCATGGAATACAATCTTCAAAAAGGCTTATAAGGAGCCATTGAAGTAGAGACAGACCTC
ACAGTTGAACAATTGCTCTCTGTGGTCTATGAGAAAATGTGTGATGATCTCAAGCTGTTT
CCGGAGGCTCCAGAACCACCACCATTTGAGAATGTCACACTTGTGATAAGAATGGTAAA
GATTTGGATTGCATAAAATCATGCCATCTGATCTATCGTGATTATGAGAGCGATGATGAC
ATCGAGGAAGAAGATGCAGAAGAATGTGACACGGATTGAGGTGATGCTGAGGAGTGTGAC
ACTAATTCAGAATGTGAAGAAGAAGATGAGGATACTAAAGTGTGGCTCTTATACAAGAC
CCGGCAAGTAACAAATATCCTCTGCCTCTTGATGATGATTATAGCGTCTACAATGGATGT
ATTGTTTATAAGGACGCTCTCGATGTTGTGAATTTACCATCTGGTGAAGAAACCTTTGTT
GTCAATAACTGCTTTGAAGGGGCTGTTAAAGCTCTTCCGAGAAAGTTATTGATGTTCTA
GGTGACTGGGGTGAGGCTGTTGATGCGCAAGAACAATTGTGTCAACAAGAATCAACTCGG
GTCATATCTGAGAAATCAGTTGAGGGTTTTACTGGTAGTTGTGATGCAATGGCTGAACAA
GCTATTGTTGAAGAGCAGGAAATAGTACCTGTTGTTGAACAAAGTCAGGATGTAGTTGTT
TTTACACCTGCAGACCTAGAAGTTGTTAAAGAAACAGCAGAAGAGGTTGATGAGTTTATT
CTCATTTCTGCTGTCCCTAAAGAAGAAGTTGTGTCTCAGGAGAAAAGAGGACACAGGTT
GAGCAAGAGCCTACCCTAGTTGTTAAAGCACAACGTGAGAAGAAGGCTAAAAGTTCAA
GTTAAACCAGCTACATGTGAAAAACCCAAATTTTGGAGTACAAAACATGTGTGGGTGAT
TTGGCTGTTGTAATTGCCAAAGCATGGATGAGTTTAAAGAGTTCTGCATTGTAACGCT
GCAAATGAGCACATGTCGCATGGTGGTGGCGTTGCAAAGGCAATTGCAGACTTTTGTGGA
CCGGACTTTGTTGAATATTGCGCGACTATGTTAAGAAACATGGTCCACAGCAAAAACCTT
GTCACACCTTCATTTGTTAAAGGCATTCAATGTGTGAATAATGTTGTAGGACCTCGCCAT
GGAGACAGCAACTTGCCTGAGAAGCTTGTGCTGCTTACAAGAGTGTTCTTGTAGGTGGA

-continued

GTGGTTAACTATGTTGTGCCAGTTCTCTCATCAGGGATTTTGGTGTAGATTTTAAAAATA
TCAATAGATGCTATGCGCGAAGCTTTTAAAGGTTGTGCCATACGCGTTCTTTTATTTTCT
CTGAGTCAAGAACACATCGATTATTTGATGCAACTTGTAGCAGAAGACAATTTATCTT
ACGGAGGATGGTGTAAATACCGCTCTGTTGTTTTAAACCTGGTGATTCCTTGGGTCAA
TTTGGACAGGTTTTTGCAAGAAATAAGGTAGTCTTTTCGGCTGATGATGTTGAGGATAAA
GAAATCCTCTTTATACCCACAACCTGACAAGACTATTCTGAATATTATGGTTTAGATGCG
CAAAAGTATGTAACATATTTGCAAACGCTTGCGCAGARATGGGATGTTCAATATAGAGAC
AATTTTGTATATTAGAGTGGCGTGACGGAATTGCTGGATTAGTTCAGCAATAGTTCTC
CTTCAAGCTGCTAAAATTAGATTTAAAGGTTTCTTGCAGAAGCATGGGCTAACTGTTG
GGTGGAGATCCTACAGACTTTGTGCGCTGGTGTATGCAAGTTGCAATGCTAAAGTAGGT
GATTTTTCAGATGCTAATTGGCTTTTGGCCAATTTAGCAGAACATTTTGACGCAGATTAC
ACAAATGCACTTCTTAAGAAGTGTGTCTGTCGAATTGTGGTGTAAAGTTATGAACCT
AGGGGTCTTGAAGCCTGTATTAGCCAGTTTCGAGCACCTAATCTTCTACATTTTAAACG
CAATATTCAAATTGCCCAACCTGTGGTGCAAGTAGTACGGATGAAGTAATAGAAGCTTCA
TTACCGTACTTATTGCTTTTGTCTACTGATGGTCTGCTACAGTTGATTGTGATGAAAA
GCTGTAGGAGCTGTTGTTTTCATTGGCTCTACTAATAGTGGCCATTGTTATACACAAGCC
GATGGTAAGGCTTTTGACAATCTTGCTAAGGATAGAAAAATTGGAAGGAAGTCGCCTTAC
ATTACAGCAATGTATACACGTTTTTCTCTTAGGAGTGAAAAATCCCTACTTGTGTTGAA
CATAGTAAGGGTAAAGCTAAAGTAGTAAAGAAGATGTTTCTAACCTTGCTACTAGTTCT
AAAGCCAGTTTGTACGATCTTACTGACTTTGAACACTGGTATGATAGCAACATCTATGAG
AGTCTTAAAGTGACAGGAGACACCTGATAATCTTGATGAATATGTGTCATTTACGACAAAG
GAAGATTCTAAGTTGCCACTGACACTTAAAGTTAGAGGTATCAAATCAGTTGTTGACTTT
AGGTCTAAGGATGGTTTTACTTATAAGTTAACACCTGATACTGATGAAAAATCAAAAACA
CCAGTCTACTACCCAGTCTTGGATTCTATTAGTCTTAGGGCAATATGGGTTGAAGGCAGT
GCTAATTTTGTGTTGGGCATCCAAATTATTATAGTAAGTCTCTCCGAATTTCCACGTTT
TGGGAAAAATGCCGAGAGCTTTGTTAAATGGGTTATAAAATTGATGGTGTAACATATGGGC
CTTTGGCGTGACAGAACACCTTAATAAACCTAATTTGGAGAGAATTTTAAACATTGCTAAG
AAAGCTATTGTTGGATCTAGTGTGTTACTACGCAGTGTGGTAAATACTAGTTAAAGCA
GCTACATACGTTGCCGATAAAGTAGGTGATGGTGTAGTTCGCAATATTACAGATAGAATT
AAGGGTCTTTGTGATTACACGTGGCCATTTGAAAAGAAAATGTCCCTACAATTTCTA
AAGACACTTGTGTTCTTTTCTTTTATTCTTAAAGGCTAGTGCTAAGAGTTAGTTTCT
AGCTATAAGATTGTGTTATGTAAGGTGGTGTGCTACCTTACTTATAGTGTGGTTTATA
TACACAAGTAATCCAGTAGTGTACTGGAATACGTGTGCTAGACTTCCTATTTGAAGGT
TCTTTATGTGGTCCTTATAATGACTACGGTAAAGATTCTTTTGATGTGTACGGTATTGT
GCAGGTGATTTTACTTGTGCTGTGTTTACATGATAGAGATTCACCTCATCTGTACAAA
CATGCTTATAGCGTAGAACAAATTTATAAGGATGCAGCTTCTGGCATTAACTTTAATTGG
AATTGGCTTTATTGTTCTTTCTAATATTATTGTTAAGCCAGTGGCAGGTTTTGTTATT
ATTTGTTATTGTGTTAAGTATTGGTATTGAGTTCAACTGTGTTGCAAACTGGTGTAGGT
TTTCTAGATTGGTTTGTAAAAACAGTTTTTACCCATTTTAATTTTATGGGAGCGGGATT
TATTTCTGGCTCTTTTACAAGATATACGTACAAGTGCATCATATATTGTACTGTAAGGAT

- continued

GTAACATGTGAAGTGTGCAAGAGAGTTGCACGCAGCAACAGGCAAGAGGTTAGCGTTGTA
GTTGGTGGACGCAAGCAAATAGTGCATGTTTACACTAATTCTGGCTATAACTTTTGTAAAG
AGACATAATTGGTATTGTAGAAATTGTGATGATTATGGTCACCAAAATACATTTATGTCC
CCTGAAGTTGCTGGCGAGCTTTCTGAAAAGCTTAAGCGCCATGTTAAACCTACAGCATAT
GCTTACCACGTTGTGTATGAGGCATGCGTGGTTGATGATTTTGTTAATTTAAAAATAAAG
GCTGCAATTGCTGGTAAGGATAATGCATCTTCTGCTGTTAAGTGTTCAGTGTACAGAT
TTTTTAAAGAAAGCTGTTTTCTTAAGGAGGCATTGAAATGTGAACAAATATCTAATGAT
GGTTTTATAGTGTGTAATACACAGAGTGCGCATGCACTAGAGGAAGCAAAGAATGCAGCC
GTCTATTATGCGCAATATCTGTGTAAGCCAATACTTATACTTGACCAGGCACCTTATGAG
CAATTAATAGTAGAGCCTGTGTCTAAGAGTGTATAGATAAAGTGTGTAGCATTTTGTCT
AATATAATATCTGTAGATACTGCAGCTTTAAATTATAAGGCAGGCACACTTCGTGATGCT
CTGCTTTCTATTACTAAAGACGAAGAAGCCGTAGATATGGCTATCTTCTGCCACAATCAT
GAAGTGAATACACTGGTGACGGTTTTACTAATGTGATACCGTCATATGGTATGGACACT
GATAAGTTGACACCTCGTGATAGAGGTTTTTGATAAATGCAGATGCTTCTATTGCTAAT
TTAAGAGTCAAAAATGCTCCTCCGGTAGTATGGAAGTTTTCTGATCTTATTAATTGTCT
GACAGTTGCCTTAAATATTTAATTTAGCTACTGTCAAGTCAGGAGGTCGTTTCTTTATA
ACAAAGTCTGGTGCTAAACAAGTTATTTCTGTGCATACCCAGAACTGTTGGTAGAGAAA
AAGGCAGGTGGTGTTATTAATAACACTTTTAAATGGTTATGAGTTGTTTTAAATGGCTT
TTTGTCTTTTATATACTTTTTACAGCATGTTGTTGGGTTACTACTATATGGAGATGAAT
AAAAGTTTTGTTCACCCCATGTATGATGTAACTCCACACTGCATGTTGAAGGGTTCAA
GTTATAGACAAAGGTGTTATTAGAGAGATTGTGTGAGAAGATAATTGTTTCTCTAATAAG
TTTGTTAATTTTGACGCCTTTTGGGGTAAATCATATGAAAATAATAAAACTGTCCAATT
GTTACAGTTGTTATAGATGGTGACGGGACAGTAGCTGTTGGTGTTCCTGGTTTTGTATCA
TGGGTTATGGATGGTGTTATGTTTGTGCATATGACACAGACTGATCGTAGACCTTGGTAC
ATTCTACCTGGTTTAAATAGAGAAATTGTTGGTTACACTCAGGATTCAATTATCACTGAG
GGTAGTTTTTATACATCTATAGCATTATTTCTGCTAGATGTTTATATTTAACAGCCAGC
AATACACCTCAATTGTATTGTTTTAATGGCGACAATGATGCACCTGGAGCCTTACCATT
GGTAGTATTATTCCTCATAGAGTATACTTCCAACCTAATGGTGTTAGGCTTATAGTTCCA
CAACAAATACTGCATACACCTACATAGTGAAGTTGTTTCAGACAGCTATTGTAGAGGT
AGTGTATGTGAGTATACTAAACCAGGTTACTGTGTGTCACTAGACTCCCAATGGGTTTTG
TTTAATGATGAATACATTAGTAAACCTGGCGTTTTCTGTGGTTCTACTGTTAGAGAACTT
ATGTTAATATGGTTAGTACATTCTTTACTGGTGCAACCCTAATATTTATATTCAGCTA
GCAACTATGTTTTTAATACTAGTTGTTATTGTGTTAATTTTGCAATGGTTATAAAGTTT
CAAGGTGTTTTTAAAGCTTATGCGACCATTGTGTTTACAATAATGTTAGTTTGGGTTATT
AATGCATTTGTTTTGTGTGTACATAGTTATAATAGTGTTTTAGCTGTTATATTATTAGTA
CTCTATTGCTATGCATCATTGGTTACAAGTCGCAATACTGCTATAATAATGCATTGTTGG
CTTGTTTTTACCTTTGGTTTAAATAGTACCCACATGGTTGGCTTGTGCTATCTGGGATTT
ATTCCTTATATGTACACACCGTTGGTTTTCTGGTGTTACGGTACTACTAAAAATACTCGT
AAGTTGTATGATGGCAACGAGTTTGTGTTAATTATGACCTTGCTGCGAAGAGCACTTTT
GTTATTCGTGGTACTGAATTTGTTAAGCTTACGAATGAGATAGGTGATAAATTTGAAGCC
TATCTTTCTGCGTATGCTAGACTTAAATACTATTCAAGCACTGGTAGTGAGCAAGATTAC

TTGCAAGCTTGTGCGTCATGGTTAGCTTATGCTTTGGACCAATATAGAAATAGTGGTGTT
GAGGTTGTTTATACCCACCGCTTACTCTATTGGTGTTAGTAGACTACACGCTGGTTTT
AAAAAAGTAGTTTCTCCTAGTAGTGCTGTTGAGAAGTGCATTGTTAGTGTCTCTTATAGA
GGCAATAATCTTAATGGACTGTGGCTGGGTGATTCTATTACTGCCCACGCCATGTGTTA
GGTAAGTTTAGTGGTGACCAGTGGGGTGACGTACTAAACCTTGCTAATAATCATGAGTTT
GAAGTTGTAACCTCAAATGGTGTTACTTTGAATGTTGTCAGCAGGCGGCTTAAAGGAGCA
GTTTTAATTTTACAAACTGCAGTTGCCAATGCTGAAACTCCTAAGTATAAGTTTGTAA
GCTAATTGTGGTGATAGTTTCACTATAGCTTGTCTTATGGTGGTACAGTTATAGGACTT
TACCCTGTCACTATGCGTTCTAATGGTACTATTAGAGCATCTTCCCTAGCAGGAGCCTGT
GGCTCAGTTGGTTTTAATATAGAAAAGGGTAGTAAATTTCTTTTATATGCACCATCTT
GAGTTACCTAATGCATTACACACTGGAAGTACCTAATGGGTGAGTTTTATGGTGGTTAT
GTAGATGAAGAGGTTGCGCAAAGAGTGCCACCAGATAATCTAGTTACTAACAATATTGTA
GCATGGCTCTATGGGGCAATTATTAGTGTTAAAGAAAGTAGTTTTTACAACTTAAATGG
TTGGAGAGTACTACTGTTTCTATTGAAGATTACAATAGGTGGGCTAGTGATAATGGTTTT
ACTCCATTTTCCACTAGTACTGCTATTACTAAATTAAGTGCTATAACTGGGGTTGATGTT
TGTAAGTCCCTCGCACTATTATGGTAAAAAGTGCTCAATGGGGTAGTGATCCCATTTTA
GGACAATATAATTTGAAGACGAATTGACACCAGAATCTGTATTTAATCAAGTTGGTGGT
GTTAGGTTACAGTCTTCTTTTGAAGAAAAGCTACATCTTGGTTTGGAGTAGATGTGTA
TTAGCTTGCTTCTTGTGTTGTGTGCTATTGTCTTATTACGGCAGTGCCACTTAAG
TTTTATGTACATGCAGCTGTTATTTGTTGATGGCTGTGCTCTTATTTCTTTTACTGTT
AAACATGTTATGGCATACTGGACACTTTCCTATTGCCTACATTGATTACAGTTATTATT
GGAGTTTGTGCTGAAGTCCCTTTCATATACAATACTCTAATTAGTCAAGTTGTTATTTTC
TTAAGCCAATGGTATGATCCTGTAGTCTTTGATACTATGGTACCATTGGATGTTATTGCCA
TTAGTGTTGTACACTGCTTTTAAAGTGTGTACAAGGCTGCTATATGAATCTTTCAACT
TCTTTGTTAATGCTGTATCAGTTTATGAAGTTAGGTTTGTATTATTACACCTCTTGAAAC
ACTCTTACTGCATATACAGAAGGTAATTGGGAGTTATTCTTTGAGTTGGTTCACACTATT
GTGTTGGCTAATGTTAGTAGTAATCCTTAATTGGTTAATTGTTTTAAGTGTGCTAAG
TGGATTTTATATTATTGCAATGCAACATACTTTAATAATTATGTGTTAATGGCAGTCATG
GTTAATGGCATAGGCTGGCTTGCACCTGTACTTTGGATTGTATTGGTGGGTTAATAAA
GTTTTTGGTTTAACTTAGGTAAATACAATTTTAAAGTTTCAGTAGATCAATATAGGTAT
ATGTGTTTGCATAAGGTAAATCCACCTAAAAGTGTGGGAGGCTTTTACTACAAATATA
CTTATACAAGGAATTGGAGGCGATCGTGTGTTGCCTATAGCTACAGTGCAATCTAAATTG
AGTGATGTAAAGTGTACAAGTGTGTTTAAATGCAGCTTTTGACTAAGCTTAATGTTGAA
GCAAATTCAAAAATGCATGCTTATCTTGTGAGTTACACAATAAAATCCTCGCATCTGAT
GATGTTGGAGAGTGATGGATAATTTATTGGGTATGCTTATAACACTATTTTGTATAGAT
TCTACTATTGATTTTGGGTGAGTATTGTGATGATATACTTAAGAGGTCAACTGTATTACAA
TCGGTTACTCAAGAGTTTTTCGCACATACCCCTCGTATGCTGAATATGAAAGAGCTAAGAGT
ATTTATGAAAAGGTTTTAGCCGATTCTAAAAATGGTGGTGTAAACAGCAAGAGCTTGCT
GCATATCGTAAAGCTGCCAATATTGCAAAGTCAGTTTTTGATAGAGACTTGGCTGTTCAA
AAGAAGTTAGATAGCATGGCAGAACGTGCTATGACAACAATGTATAAAGAGGCGCGTGTA

-continued

ACTGATAGAAGAGCAAAATAGTTTCATCATTACATGCACTACTTTTTTCAATGCTTAAG
AAAAATAGATTCTGAGAAGCTTAATGTCTTATTGACCAGGCGAATAGTGGTGTGTACCC
CTAGCAACTGTTCCAATTGTTTGTAGTAATAAGCTTACCCTGTTATACCAGACCCAGAG
ACGTGGGTCAAGTGTGTGGAGGGTGTGCATGTTACATATTCAACAGTTGTTTGGAAATATA
GACTGTGTTACTGATGCCGATGGCACAGAGTTACACCCCACTTCTACAGGTAGTGGATTG
ACTTACTGTATAAGTGGTGATAATATAGCATGGCCTTTAAAGGTTAACTTGACTAGGAAT
GGGCATAATAAGGTTGATGTTGCCTTGCAAAATAATGAGCTTATGCCTCACGGTGTAAG
ACAAAGGCTTGCGTAGCAGGTGTAGATCAAGCACATTGTAGCGTTGAGTCTAAATGTTAT
TATACAAGTATTAGTGGCAGTTCAGTTGTAGCTGCTATTACCTCTTCAAATCCTAATCTG
AAAGTAGCCTCTTTTTGAATGAGGCAGGTAATCAGATTTATGTAGACTTAGACCGAGCA
TGTAATTTGGTATGAAAGTGGGTGATAAGGTTGAAGTGTTTACCTGTATTTTATAAAA
AATACGAGGTCTATTGTAAGAGGTATGGTACTTGGTGTCTATCTAATGTTGTGTGTTA
CAATCTAAAGGTCATGAGACAGAGGAAGTGGATGCTGTAGGCATTCTCTCACTTTGTTCT
TTTGCACTAGATCCTGCGGATACATATTGTAATATGTGGCAGCAGGTAATCAACCTTTA
GGTAACTGTGTTAAATGTTGACAGTACATAATGGTAGTGGTTTGCAATAACATCAAAG
CCAAGTCCAACCTCCGATCAGGATTCTTATGGAGGAGCTTCTGTGTCTTTATTGTAGA
GCACATATAGCACACCCCTGGCGAGCAGGAAATTTAGATGGACGCTGTCAATTTAAAGGT
TCTTTGTGCAAAATACCTACTACGGAGAAAGATCCTGTTGGATTCTGTCTACGTAAACAAG
GTTTGCAGTGTGTTGTCAGTGTGGATTGGTTATGGATGTCAGTGTGATTCACTTAGACAA
CCTAAACCTTCTGTTCACTGAGTGTCTGTTGCATCTGTTTGTATAAGAATTATTTAAAC
GGGTACGGGTAGCAGTGAAGGCTCGGCTGATACCCCTAGCTAATGGATGTGACCCCGATG
TTGTAAAGCGAGCCTTTGATGTTTGTAAATAAGGAATCAGCCGGTATGTTTCAAAATTTGA
AGCGTAACGTGCACGATTCCAAGAAGTACGTGATACTGAAGATGGAATCTTGAGTATT
GTGATTCTTATTTGTGTTAAACAAACCACTCCTAGTAATTATGAACATGAGAAAGCTT
GTTATGAAGACTTAAAGTCAGAAGTAACAGCTGATCATGATTTCTTTGTGTTCAATAAGA
ACATTTATAATATTAGTAGGCAGAGGCTTACTAAGTATACTATGATGGATTTTGTCTATG
CTTTGCGGCACCTTTGACCCAAAGGATTGCGAAGTTCTTAAAGAAATACTTGTCATTATG
GTTGTATAGAAGATTATCACCTAAGTGGTTTGAAGAGAATAAGGATTGGTACGACCCAA
TAGAAAACCTTAAATATTATGCCATGTTGGCTAAATGGGACCTATTGTACGAGGTGCTT
TATTGAATGCTATTGAGTTCGGAAACCTCATGGTTGAAAAAGGTTATGTTGGTGTATTAT
CACTTGATAACCAAGATCTTAATGGCAAATTTATGATTTTGGTGATTTTCAGAAGACAG
CGCCTGGTGCTGGTGTCTGTTTTTGATACGTATTATCTTACATGATGCCCATCATAG
CCATGACTGATGCGTTGGCACCTGAGAGGTATTTTGAATATGATGTGCATAAGGTTATA
AATCTTATGATCTCCTCAAGTATGATTATACTGAGGAGAAACAAGATTTGTTTCAGAAGT
ACTTTAAGTATTGGGATCAAGAGTATCACCTAACTGTGCGACTGTAGTGTGACAGGT
GTTTGATACATTGTGCAAACTTCAACATCTTGTCTTCTACACTTGTACCGCAGACTTCTT
TCGGTAATTTGTGTAGAAAGGTTTTTGTGTGATGGTGTAACATTTATAGCTACTTGTGGCT
ATCATTTCTAAGGAACCTGGTGTATTATGAATCAAGATAACACCATGTCATTTTCAAAA
TGGGTTTGAGTGAACATGAGGTTTGTGGAGATCGTGGCTTGTAGTGGGACATGCA
ATAAATTAGTGGATCTTAGAACGTCTTGTCTTAGTGTGCTTTAGCGTCTGGTATTA
CTCATCAAACGGTAAACAGGTCACTTTAACAAGGATTTCTACGATTTGCAGAGAAGG

CTGGTATGTTTAAAGGAAGTTCTTCTATACCACTTAAACATTTCTTCTACCCACAGACTG
GTAATGCTGCTATAAACGATTATGATTATTATCGTTATAACAGGCCTACCATGTTTGATA
TACGTCAACTTTTATTTTGTGTTAGAGTGAAGTCTTAAATATTTTGAATGTTATGAAGCG
GCTGTATACCAGCAAGCCAAGTTGTAGTTAACAATTAGATAAGAGTGCAGGTATCCGT
TCAATAAGTTTGGAAAGGCCCGTCTCTATTATGAAATGAGTCTAGAGGAGCAGGACCAAC
TCTTTGAGAGTACAAAGAAGAAGCTCCTGCCTACTATAACTCAGATGAATTTAAATATG
CCATATCCGCGAAAAATAGAGCGGTACAGTGGCAGGTGTCTATCCTTTCTACTATGA
CTAATAGGCAGTTTCATCAGAAGATTCTTAAGTCTATAGTCAACACTAGAAACGCTCCTG
TAGTTATTGGAACAACCAAGTTTATGGCGGTTGGGATAACATGTTGAGAAACCTTATTC
AGGGTGTGGAAGACCCGATTCTTATGGGTTGGGATTATCCAAAGTGTGATAGAGCAATGC
CTAATTTGTTGCGTATAGCAGCATCTTTAGTACTCGCTCGTAAACACACTAATTGTTGTA
CTTGCTGTGAACGCGTTTATAGGTTGTATAATGAATGCGCTCAGGTTTATCTGAACTG
TCTTAGCTACAGGTGGTATATATGTGAAACCTGGTGGTACTAGCAGTGGAGATGCTACTA
CTGCTTATGCAACAGTGTTCACACATAATACAAGCCACATCTGCTAATGTTGCGCGTC
TTTTGAGTGTATAACGCGTGATATTGTATATGATGACATTAAGAGCTTGCAGTATGAAT
TGTACCAGCAGGTTTATAGGCGAGTCAATTTTGACCCAGCATTGTTGAAAAGTTTATTT
CTTATTTGTGTAAGAATTTCTCATTGATGATCTTGTCTGACGACGGTGTGTTTGTGTTATA
ACAACACATTAGCCAAACAAGGTCTGTAGCAGATATTTCTGGTTTTAGAGAAGTTCTCT
ACTATCAGAACATGTTTTATGGCTGATTCTAAATGTTGGGTTGAACCAGATTAGAAA
AAGGCCACATGAATTTGTTTACAGCACACAATGTTAGTGGAGGTTGATGGTGAGCCTA
GATACTTGCCATATCCAGACCCATCAGTATTTTGTGTGATGTGTTTTGTAGATGATT
TGGATAAGACAGAATCTGTGGCTGTTATGGAGCGTTATATCGCTCTTGCCATAGATGCGT
ACCCACTAGTACATCATGAAATGAGGAGTACAAGAAGGTATTCTTTGTGCTTCTTTCAT
ACATCAGAAAACCTCTATCAAGAGCTTTCTCAGAATATGCTTATGGACTACTCTTTGTAA
TGGATATAGATAAGGGTAGTAAATTTTGGGAACAGGAGTTCTATGAAAATATGTATAGAG
CCCCTACAACATTACAGTGTGTTGGCGTTTGTGTAGTGTGTAATAGTCAAACCTATATTGC
GCTGTGTTAATGTATTCGCAACCATTTTTGTGTTGTAAGTGTGCTATGACCATGTCA
TGCACACAGACCACAAAAATGTTTGTCTATAAATCCTTACATTTGCTCAGCAGCAGGTT
GTGGTGAAGCAGATGTTACTAAATGTACCTCGGAGGTATGTCATACTTCTGCGGTAATC
ATAAACCAAAGTTATCAATACCGTTAGTATCTAATGGTACAGTGTGGAATTTACAGGG
CTAATTGTGAGGTAGCGAAAATGTTGATGATTTTAATCAACTAGCTACTACTAATTGGT
CTACTGTGGAACCTTATATTTTGGCAAATCGTTGTGTAGATTCGTTGAGACGCTTTGCTG
CAGAGACAGTAAAGCTACAGAAGAATTACATAAGCAACAATTTGCTAGTGCAGAAGTGA
GAGAAGTACTCTCAGATCGTGAATTGATTCTGTCTTGGGAGCCAGGTAACCAGGCCTC
CATTGAATAGAAATATGTTTTCACTGGCTTTCACTTTACTAGAACTAGTAAAGTTCAGC
TCGGTGATTTTACATTTGAAAAAGGTGAAGGTAAGGACGTTGTCTATTATCGAGCGACGT
CTACTGCTAAATGTCTGTGAGACATTTTGTGTTTAACTCAGACAAATGTTGTTTCTC
TTATAGCGCCAACGTTGTGCTCCTCAGCAAACCTTTTCTAGGTTTGTGAATTTAAGACCTA
ATGTGATGGTACCTGCGTGTGTTGTAATAACATTCCATTGTACCATTTAGTAGCAAGC
AGAAGCGTACTACAGTACAAGGCCCTCCTGGCAGTGGTAAATCCATTTTGCTATAGGAT

- continued

TGGCGGCTTACTTTAGTAACGCCCGTGTCTGTTTTACTGCATGCTCTCATGCAGCTGTTG
ATGCTTTATGTGAAAAAGCTTTTAAAGTTTCTTAAAGTAGATGATTGCACTCGTATAGTAC
CTCAAAGGACTACTATCGATTGCTTCTCTAAGTTTAAAGGTAATGACACAGGCAAAAAGT
ACATTTTTAGTACTATTAATGCCTTGCCAGAAGTTAGTTGTGACATTCTTTGGTTGACG
AGGTTAGTATGTTGACCAATTACGAATTGTCTTTTATTAATGGTAAGATAAACTATCAAT
ATGTTGTGTATGTAGGTGATCCTGCTCAATTACCGGCGCCTCGTACGTTGCTTAACGGTT
CACTCTCTCCAAAGGATTATAATGTTGTCACAAACCTTATGGTTTGTGTTAAACCTGACA
TTTTCTTGCAGAAAGTGTACCGTTGTCTTAAAGAAATTGTAGATACTGTTTCTACTCTTG
TATATGATGGAAAGTTTATTGCAAATAACCCGGAATCACGTCAGTGTTTCAAGGTTATAG
TTAATAATGGTAATTCTGATGTAGGACATGAAAGTGGCTCAGCCTACAACATAACTCAAT
TAGAATTTGTGAAAGATTTTGTCTGTGCAATAAGGAATGGCGGAAGCAACATTCATTT
CACCTTATAATGCTATGAACCAGAGAGCCTACCGTATGCTTGGACTTAATGTTTCAAGCAG
TAGACTCGTCTCAAGGTCGGAGTATGATTATGTTATCTTTTGTGTTACTGCAGATTTCGC
AGCATGCACTGAATATTAACAGATTCAATGTAGCGCTTACAAGAGCCAAGCGTGGTATAC
TAGTTGTCTATGCGTCAGCGTATGAACATATTCAGCTCTTAAAGTTTATAGAGCTTGATA
GTGTAGCAAGTCTGCAAGGTACAGGCTTGTTTAAAATTGCAACAAAGAGTTTAGTGGTG
TTCACCCAGCTTATGCAGTCACAACTAAGGCTCTTGCTGCAACTTATAAGTTAATGATG
AACTTGCTGCACTTGTTAACGTGGAAGCTGGTTCAGAAATAACATATAAACATCTTATTT
CTTTGTTAGGGTTTAAAGATGAGTGTTAATGTTGAAGGCTGCCACAACATGTTTATAACAC
GTGATGAGGCTATCCGCAACGTAAGAGGTTGGGTAGGTTTTGATGTAGAAGCAACACATG
CTTGCGGTACTAACATTGGTACTAACCTGCCTTTCCAAGTAGGTTTCTCTACTGGTGCAG
ACTTTGTAGTTACGCCTGAGGGACTTGTAGATACTTCAATAGGCAATAATTTGAGCCTG
TGAATTTCAAAGCACCTCCAGGTGAACAATTTAATCACTTGAGAGCGTTATTTCAAAGTG
CTAAACCTTGCGATGTTGTAAGGCCAAGGATTGTGCAAAATGTAGCGGATAACCTGTGCA
ACGTTTCAGATTGTGTAGTGTGTTGTACGTGGTGTGTCATGGCCTAGAACTAACCACTTTGC
GCTATTTTGTAAAATAGGCAAGGACCAAGTTTGTCTTGCGGTTCTAGAGCAACAACCTT
TTAATTTCTACTACTCAGGCTTATGCTTGTGGAAGCATTGCTTGGGTTTTGATTTTGT
ATAATCCACTCTTAGTGGATATTCAACAGTGGGGTTATTCTGGTAACCTACAATTTAACC
ATGATTTGCATTTGTAATGTGCATGGACACGCACATGTAGCTTCTGCGGATGCTATTATGA
CGCGTTGTCTGCAATTAATAATGCATTTTGTCAAGATGTCAACTGGGATTTAACTTACC
CTCATATAGCAAAATGAGGATGAAGTCAATTCTAGCTGTAGATATTTACAACGCATGTATC
TTAATGCATGTGTTGATGCTCTTAAAGTTAACGTTGTCTATGATATAGGCAACCCTAAAG
GTATAAAATGTGTTAGACGTGGAGACTTAAATTTTAGATTCTATGATAAGAATCCAATAG
TACCAATGTCAAGCAGTTTGAGTATGACTATAATCAGCACAAAGATAAGTTTGTGATG
GTCTTTGTATGTTTGGAAATTGTAATGTGGATTGTTATCCCGACAATTCCTTAGTTTGA
GGTACGACACAGAAATTTGAGTGTGTTTAACTACCTGGTTGTAATGGTGGTAGCTTGT
ATGTTAACAAGCATGCATTCCACACACCTAAATTTGATCGCACTAGCTTTCTGTAATTTGA
AAGCTATGCCATTCTTTTCTATGACTCATCGCCTTGCGAGACCATTCAATGGATGGAG
TTGCGCAAGACCTTGTGTCATTAGCTACGAAGATTGTATCACAAAATGCAACATAGGCG
GTGCTGTTTGTAAAAAGCACGCACAAATGTATGCAGATTTTGTGACTTCTTATAATGCAG
CTGTTACTGCTGGTTTTACTTTTTGGGTTACTAATAATTTTAAACCATATAATTTGTGGA

AAAGTTTTTCAGCTCTCCAGTCTATCGACAATATTGCTTATAATATGTATAAGGGTGGTC
ATTATGATGCTATTGCAGGAGAAATGCCCACTATCGTAACTGGAGATAAAGTTTTTGTTA
TAGATCAAGCGTAGAAAAAGCAGTTTTTTTTTAATCAACAATTCTGCCTAGATCTGTAG
CGTTTGAGCTGTATGCGAAGAGAAATATTCGCACACTGCCAAACAACCGTATTTTGAAAG
GTTTGGGTGTAGATGTGACTAATGGATTGTAAATTGGGATTACACGAACCAACACCAC
TATACCGTAATACTGTTAAGGTATGTGCATATACAGACATAGAACCAATGGCCTAATAG
TGCTGTATGATGATAGATATGGTGATTACCAGTCTTTCTAGCTGCTGATAATGCTGTTT
TAGTTTTCTACACAGTGTTACAAGCGGTATTCGTATGTAGAAATACCGTCAAACCTGCTTG
TTCAGAACGGTATTCGGTTAAAGATGGAGCGAACCTGTATGTTTATAAGCGTGTTAATG
GTGCGTTTTGTACGCTACCTAACACATTAAACACACAGGGTCGCAGTTATGAACTTTTG
AACCTCGTAGTGATGTTGAGCGTGATTTTCTCGACATGTCTGAGGAGAGTTTTGTAGAAA
AGTATGGTAAAGAATTAGGTCTACAGCACATACTGTATGGTGAAGTTGATAAGCCCCAAT
TAGGTGGTTTACACACTGTTATAGGTATGTGCAGACTTTTACGTGCGAATAAGTTGAACG
CAAAGTCTGTTACTAATTCTGATTCTGATGTCATGCAAAATTATTTGTATTGGCAGACA
ATGGTTCCTACAAGCAAGTGTGTACTGTTGTGGATTGCTGCTTGATGATTTCTTAGAAC
TTCTTAGGAACATACTGAAAGAGTATGGTACTAATAAGTCTAAAGTTGTAACAGTGTCAA
TTGATTACCATAGCATAAATTTTATGACTTGGTTTGAAGATGGCATTATTAACATGTT
ATCCACAGCTTCAATCAGCATGGACGTGTGGTTATAATATGCCTGAACTTTATAAGTTC
AGAATTGTGTTATGGAACCTTGCAACATTCCTAATTATGGTGTGGAATAGCGTTGCCAA
GTGGTATTATGATGAATGTGGCAAAGTATACACAACCTCTGTCAATACCTTTCGAAAACAA
CAATGTGTGTACCGCATAATATGCGAGTAATGCATTTTGGAGCTGGAAGTGACAAAGGAG
TGGCTCCAGGTAGTACTGTTCTTAAACAATGGCTCCAGAAAGGGACACTCCTTGTCGATA
ATGATATTGTAGACTATGTGTCTGATGCACATGTTTCTGTGCTTTCAGATTGCAATAAAT
ATAAGACAGAGCACAGTTTGATCTTGATATCTGATATGTATACAGACAATGATTCAA
AAAGAAAGCATGAAGCGTGATAGCCAATAATGGCAATGATGACGTTTTTCATATATCTCT
CAAGTTTTCTTCGTAATAATTTGGCTCTAGGTGGTAGTTTTGCTGTAAAAGTGACAGAGA
CAAGTTGGCACGAAGTTTATATGACATTGCACAGGATTGTGCATGGTGGACAATGTTTT
GTACAGCAGTGAATGCCCTTCTTCAGAAGCATTCTGGTTGGTGTTAATTATTGGGTG
CAAGTGAAAAGGTTAAGGTTAGTGGAAAAACGCTGCACGCAAATTATATATTTGGAGGA
ATTGTAATTATTTACAAACCTCTGCTTATAGTATATTTGACGTTGCTAAGTTTGATTTGA
GATTGAAAGCAACACCAGTTGTTAATTTGAAAACGAACAAAAGAGAGACTTAGTGTTTA
ATTTAATTAAGTGTGGTAAGTTACTGGTAAGAGATGTTGGTAACACCTCTTTTACTAGTG
TACCAAAGTGCCTTTTAGACCACCTAATGGTTGGCATTACACGGGGGTGCTTATGCGGTA
GTTAATATTTCTAGCGAATCTAATAATGCAGGCTCTTCACCTGGGTGATTGTTGGTACT
ATTCATGGTGGTCGTGTTGTTAATGCTTCTTCTATAGCTATGACGGCACCGTCATCAGGT
ATGGCTTGGTCTAGCAGTCAGTTTTGTACTGCACACTGTAACTTTTCAGATACTACAGTG
TTTGTACACATTGTTATAAATATGATGGGTGCTCTATAACTGGCATGCTTCAAAGAAT
TTTTTACGTGTTTCTGCTATGAAAAATGGCCAGCTTTTCTATAATTTAACAGTTAGTGTA
GCTAAGTACCCTACTTTTAAATCATTTTCAGTGTGTTAATAATTTAACATCCGTATATTTA
AATGGTGATCTTGTGTTACACCTCTAATGAGACCACAGATGTTACATCTGCAGGTGTTTAT

- continued

TTTAAAGCTGGTGGACCTATAACTTATAAAGTTATGAGAGAAGTTAAAGCCCTGGCTTAT
TTTGTTAATGCTACTGCACAAGATGTTATTTTGTGTGATGGATCACCTAGAGGCTTGTTA
GCATGCCAGTATAAATACTGGCAATTTTTCAGATGGCTTTTATCCTTTTATTAATAGTAGT
TTAGTTAAGCAGAAGTTTATTGTCTATCGTGAAAATAGTGTTAATACTACTTTTACGTTA
CACAAATTTCACTTTTCATAATGAGACTGGCGCCAACCTAATCCTAGTGGTGTTTCAAGAT
ATTCAAACCTTACCAAACACAAACAGCTCAGAGTGGTTATTATAATTTTAATTTTTCCTTT
CTGAGTAGTTTTGTTTATAAGGAGTCTAATTTTATGTATGGATCTTATCACCCAAGTTGT
AATTTTAGACTAGAACTATTAATAATGGCTTGTGGTTAATTCACCTTCAGTTTCAATT
GCTTACGGTCCTCTTCAAGGTGGTTGCAAGCAATCTGTCTTAGTGGTAGAGCAACTTGT
TGTTATGCTTATTCATATGGAGGTCCTTCGCTGTGTAAAGGTGTTTATTACAGGTGAGTTA
GATCTTAATTTTGAATGTGGACTGTAGTTTATGTTACTAAGAGCGGTGGCTCTCGTATA
CAAACAGCCACTGAACCGCCAGTTATAACTCGACACAATTATAATAATATTACTTTAAAT
ACTTGTGTTGATTATAATATATATGGCAGAACTGGCCAAGGTTTTATTACTAATGTAACC
GACTCAGCTGTTAGTTATAATTATCTAGCAGACGCAAGTTTGGCTATTTTAGATACATCT
GGTTCATAGACATCTTTGTTGTACAAGGTGAATATGGTCTTACTTATTATTAGGTTAAC
CCTTGCGAAGATGTCAACCAGCAGTTTGTAGTTTCTGGTGGTAAATTAGTAGGTATTCTT
ACTTCAGTAATGAGACTGGTTCTCAGCTTCTTGAGAACCAGTTTACATTAAATCACT
AATGGAACACGTCGTTTTAGACGTTCTATTACTGAAAATGTTGGAATTTGCCCTTATGTT
AGTTATGGTAAGTTTTGTATAAAACCTGATGGTTCAATTGCCACAATAGTACCAAAACAA
TTGGAACAGTTTGTGGCACCTTTACTTAAATGTTACTGAAAATGTGCTCATACCTAACAGT
TTTAATTTAACTGTTACAGATGAGTACATACAAACGCGTATGGATAAGGTCCAAATTAAT
TGTCTGCAGTATGTTTGTGGCAATTCTCTGGATTGTAGAGATTGTTTCAACAATATGGG
CCTGTTTGTGACAACATATTGTCTGTAGTAAATAGTATGGTCAAAAAGAAGATATGGAA
CTTTTGAAATTTCTATTCTTCTACTAAACCGGCTGGTTTTAATACACCATTTCTTAGTAAT
GTTAGCACTGGTGAGTTTAATATTTCTCTTCTGTTAACAACCTCCTAGTAGTCTTAGAAGG
CGTTCTTTTATTGAAGACCTTCTATTTACAAGCGTTGAATCTGTTGGATTACCAACAGAT
GACGCATACAAAAATTGCACCTGCAGGACCTTAGGTTTTCTTAAGGACCTTGCCTGTGCT
CGTGAATATAATGGTTTGCTTGTGTGCCTCCCATTTATAACAGCAGAAATGCAATTTTG
TATACTAGTTCTCTAGTAGCTTCTATGGCTTTTGGTGGTATTACTGCAGCTGGTGCTATA
CCTTTTGCACACAACCTGCAGGCTAGAATTAATCACTTGGGTATTACCCAGTCACTTTTG
TTGAAGAATCAAGAAAAAATTGCTGCTTCCTTTAATAAGGCCATTGGTCGTATGCAGGAA
GGTTTTAGAAGTACATCTCTAGCATTACAACAAATTCAAGATGTTGTTAATAAGCAGAGT
GCTATTCTTACTGAGACTATGGCATCACTTAATAAAAAATTTGGTGCTATTCTTCTATG
ATTCAAGAAATCTACCAGCAACTTGACGCCATACAAGCAATGCTCAAGTGGATCGTCTT
ATAACTGGTAGATTGTCATCACTTTCTGTTTTAGCATCTGCTAAGCAGCGGAGCATATT
AGAGTGTCAACACGCGTAGTTAGCTACTCAGAAAATTAATGAGTGTGTTAAGTCACAG
TCTATTAGTACTCCTTTTGTGGTAATGGACGACATGTTCTAACCATACCGCAAAATGCA
CCTAATGGTATAGTGTATACACTTTTCTTATACTCCAGATAGTTTTGTTAATGTACT
GCAATAGTGGGTTTTTGTGTAAAGCCAGCTAATGCTAGTCAGTATGCAATAGTACCCGCT
AATGGTAGGGGTATTTTATACAAGTTAATGGTAGTTACTACATCACAGCACGAGATATG
TATATGCCAAGAGCTATTACTGCAGGAGATATAGTTACGCTTACTTCTGTCAAGCAAT

TATGTAAGTGTAATAAGACCGTCATTACTACATTTCGTAGACAATGATGATTTTGATTTT
AATGACGAATTGTCAAATGGTGAATGACACTAAGCATGAGCTACCAGACTTTGACAAA
TTCAATTACACAGTACCTATACTTGACATTGATAGTGAAATTGATCGTATTCAGGCGTT
ATACAGGGTCTTAATGACTCTTTAATAGACCTTGAAAACTTCAATACTCAAACTTAT
ATTAAGTGGCCTTGGTATGTGTGGTTAGCCATAGCTTTTGCCACTATTATCTTCATCTTA
ATACTAGGATGGGTTTCTTCATGACTGGATGTTGTGGTTGTTGTGTGGATGCTTTGGC
ATTATGCCCTCTAATGAGTAAGTGTGGTAAGAAATCTTCTATTACACGACTTTTGATAAC
GATGTGGTAACCTTAACAATACAGACCTAAAAAGTCTGTTTAATGATTCAAAGTCCCACGT
CCTTCCTAATAGTATTAATTTTTCTTTGGTGTAACCTTGACTAAGTTGTTTTAGAGAGT
TTATTATAGCGCTCCAACAATAACAAAGTTTTACTCCAATATCAATAGTAACCTAC
AGCCTAGACTGACCCTTTGTACAGTCTAGACTAATGTTAACTTAGAAGCAATTATTGA
AACTGGTGAGCAAGTGATTCAAAAAATCAGTTTCAATTACAGCATATTCAGTGATT
AAACACAGAAGTATTGACCCCTTTGACTATTGTTATTACAGAGGAGTAATTTTGGA
AATAGAGTCAGCTGAAGATTGTTCAAGTGATGATGAATTTATTGAATAAGTCGCTAGAGG
AAAATGGAAGTTTCTAACAGCGCTTTATATATTGTAGGATTTTAGCACTTTATCTTC
TAGGTAGAGCACTTCAAGCATTGTACAGGCTGCTGATGCTTGTGTTATTTTGGTATA
CATGGGTAGTAATTCAGGAGCTAAGGGTACAGCCTTTGTATATAAGTATACATATGGTA
GAAAACCTTAACAATCGGAATTAGAAGCAGTTATTGTCAACGAGTTTCCTAAGAACGGTT
GGAATAATAAAAAATCCAGCAAATTTTCAAGATGTCCAACGAGACAAATTGTACTCTTGAC
TTTGAAACAGTCAGTTGAGCTTTTAAAGAGTATAATTTATTATAACTGCATTCTTGTTG
TTCTTAACCATAATACTTCAGTATGGCTATGCAACAAGAAGTAAGTTTATTATATACTG
AAAATGATAGTGTTATGGTGCTTTTGGCCCTTAACATTGCAGTAGGTGAATTCATGT
ATATACCCACCAAACACAGGAGGTCTTGTCGACGATAATACTTACAGTGTTTGCCTGT
CTGTCTTTTGTAGGTTATTGGATCCAGAGTATTAGACTCTTTAAGCGGTGAGGTCATGG
TGGTCATTTAACCCAGAATCTAATGCCGTAGGTTCAATACTCCTAATAAGGTCAACAA
TGTAATTTTGCTATAGAGAGTGTGCCAATGGTGCTTTCTCCAATTATAAAGAATGGTGTT
CTTTATTGTGAGGGTCAGTGGCTTGCTAAGTGTGAACCAGACCACTTGCCCTAAGATATA
TTTGTTTGTACACCGGATAGACGTAATATCTACCGTATGGTGCAGAAATATACTGGTGAC
CAAAGCGGAAATAAGAAACGGTTTGCTACGTTTGCTATGCAAAGCAGTCAGTAGATACT
GGCGAGCTAGAAAGTGTAGCAACAGGAGGAGTAGTCTTTACACCTAAATGTGTGTGTGT
AGAGAGTATTTAAATATTCTTTAATAGTGCCTCTATTTAAGAGCGCATAATAGTATT
ATTTTGTAGGATATTAATATAAATCCTCTCTGTTTATACTCTCTTTTCAAGAGCTATTA
TTTAAAAACAGTTTTTCCACTCTTTTGTGCCAAAACTATTGTTGTTAATGGTGTAACC
TTTCAAGTAGATAATGGAAAAGTCTACTACGAAGGAAACCAATTTTTCAGAAAGGTTGT
TGTAGGTTGTGGTTGAGTTATAAAAAAGATTAACTACCTACTACACTTATTTTATAAG
AGGCGTTTTATCTTACAAGCGCTTAATAAATACGGACGATGAAATGGCTGACTAGTTTTG
TAAGGCGAGTTATTTTCATGTTATAAACCCCTATTATTAACCTCAATTAAGAGTATTAGATA
GGTTAATCTTAGATCATGGACCAAAACACATCTTAACGTGTGTTAGGTGCGTGATTTTGT
TTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCTACTCAATCGTGATGAATAA
TAGTAAAGATAATCCTTTTTCGGGAGCAATAGCAAGAAAAGCGCGAATTTATCTGAGAGA

- continued

AGGATTAGATTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGTCTTGTCCTCCGCGTG
TACCTCTCTAGTATTCCAGGGGAAACTTGTGAGGAACACAAATATAATAATCTTTT
GTCATGGCAAGCGGTAAGGCAACTGGAAGACAGATGCCAGCTCCAGTCATCAAACATA
GGAGGACCAAGCCACCTAAAGTTGGTTCTTCTGGAAATGTATCTTGGTTTCAAGCAATA
AAAGCCAAGAAGTTAAATTACCTCCGCCTAAGTTTGAAGGTAGCGGTGTTCTGTATAAT
GAAAATCTAAAACCAAGTCAGCAGCATGGATATTGGAGACGCCAAGCTAGGTTTAAAGCCA
GGTAAAGGTGGAAGAAAACAGTCCCAGATGCTTGGTATTTTTAGTATACTGGAACAGGA
CCAGCCGCTAACCTGAATTGGGTGATAGCCAAGATGGTATAGTGTGGGTGCTGGTAAG
GGTGTGATATAAATTTAGATCTAATCAGGGTACTCGTGACTCTGACAAGTTTGACCAA
TATCCGCTACGGTTTTTTCAGACGGAGGACCTGATGGTAATTTCCGTTGGGATTTTATTCTT
CTGAATCGTGGCAGGAGTGGGAGATCAACAGCAGCTTCATCAGCAGCATCTAGTAGAGCA
CCATCACGTGAAGTTTCGCGTGGTCGCAGGAGTGGTTCTGAAGATGATCTTATGCTCGT
GCAGCAAGGATAATTCAGGATCAGCAGAAGAAGGGTTCTCGCATTACAAAGGCTAAGGCT
GATGAAATGGCTCACCGCCGGTATTGCAAGCGCAGTATTCACCTAATTATAAGGTTGAT
CAAGTGTTTGGTCCCGTACTAAAGGTAAGGAGGAAATTTGGTGATGACAAGATGAAT
GAGGAAGGTATTAAGGATGGGCGCGTTACAGCAATGCTCAACCTAGTTCCTAGCAGCCAT
GCTTGTCTTTTCGGAAGTAGAGTGACGCCAGACTTCAACCAGATGGGCTGCACCTTGAAA
TTTGAATTTACTACTGTGGTCCACGTGATGATCCGCAGTTTGATAATTATGTAATAATTT
TGTGATCAGTGTGTGATGGTGTAGGAACACGTCCAAAAGATGATGAACCAAGACCAAAG
TCACGCTCAAGTTCAAGACCTGCAACAAGAGGAAATTTCTCCAGCGCCAAGACAGCAGCGC
CCTAAGAAGGAGAAAAAGCCAAAGAAGCAGGATGATGAAGTGGATAAAGCATTGACCTCA
GATGAGGAGAGGAACAATGCACAGCTGGAATTTGATGATGAACCAAGGTAATTAAGTGG
GGGATTTCAGCGCTAGGAGAGAATGAACTTTGAGTAAATTTGAATAGTAAGAGTTAAGGA
AGATAGGCATGTAGCTTGATTACCTACATGTCTATCGCCAGGGAATGTCTAATTTGTCT
ACTTAGTAGCCTGGAACGAACGGTAGACCCTTAGATTTTAAATTTAGTTTAAATTTTAGT
TTAGTTTAAAGTTAGTTTAGAGTAGGTATAAAGATGCCAGTGGCGGGGCCACGGGAGTAC
GACCGAGGGTACAGCACTAGGACGCCATTAGGGGAAGAGCTAAATTTTAGTTTAAAGTTA
AGTTTAAATGGCTATGTATAGTTAAATTTATAGGCTAGTATAGAGTTAGAGCAAAAAAA
AAAAA

Replicase

In addition to the structural and accessory genes, two-thirds of a coronavirus genome comprises the replicase gene (at the 5' end of the genome), which is expressed as two polyproteins, pp1a and pp1ab, in which pp1ab is an extension product of pp1a as a result of a -1 ribosomal shift mechanism. The two polyproteins are cleaved by two types of virus-encoded proteinases usually resulting in 16 non-structural proteins (Nsp1-16); IBV lacks Nsp1 thereby encoding Nsp2-16.

Thus Gene 1 in IBV encodes 15 (16 in other coronaviruses) non-structural proteins (nsp2-16), which are associated with RNA replication and transcription.

The term 'replicase protein' is used herein to refer to the pp1a and pp1ab polyproteins or individual nsp subunits.

The term 'replicase gene' is used herein to refer to a nucleic acid sequence which encodes for replicase proteins.

A summary of the functions of coronavirus nsp proteins is provided in Table 1.

TABLE 1

Nsp Protein	Key features
1	Conserved within but not between coronavirus genetic groups; potential regulatory functions in the host cell.
2	Dispensable for MHV and SARS-CoV replication in tissue culture
3	Acidic domain; macro domain with ADRP and poly (ADP-ribose)-binding activities; one or two ZBD-containing papain-like proteases; Y domain
4	Transmembrane domain
5	3C-like main protease, homodimer
6	Transmembrane domain
7	Interacts with nsp8 to form a hexadecamer complex
8	Noncanonical RNA polymerase; interacts with nsp7 to form a hexadecameric complex
9	ssRNA-binding protein, dimer
10	RNA-binding protein, homododecamer, zinc-binding domain, known to interact with nsp14 and nsp16

TABLE 1-continued

Nsp Protein	Key features
11	Unknown
12	RNA-dependent RNA polymerase
13	Zinc-binding domain, NTPase, dNTPase, 5'-to-3' RNA and DNA helicase, RNA 5'-triphosphate
14	3'-to 5' exoribonuclease, zinc-binding domain and N7-methyltransferase
15	Uridylate-specific endoribonuclease, homohexamer
16	Putative ribose-2'-O-methyltransferase

The variant replicase gene encoded by the coronavirus of the present invention comprises a mutation in one or more of the sections of sequence encoding nsp-10, nsp-14, nsp-15 or nsp-16.

Nsp10 has RNA-binding activity and appears to be involved in homo and/or heterotypic interactions within other nsps from the pp1a/pp1ab region. It adopts an α/β fold comprised of five α -helices, one 3_{10} -helix and three β -strands. Two zinc-binding sites have been identified that are formed by conserved cysteine residues and one histidine residue (Cys-74/Cys-77/His-83/Cys-90; Cys-117/Cys-120/Cys-128/Cys-130). The protein has been confirmed to bind single-stranded and double-stranded RNA and DNA without obvious specificity. Nsp-10 can be cross-linked with nsp-9, suggesting the existing of a complex network of protein-protein interactions involving nsp-7, -8, -9 and -10. In addition, nsp-10 is known to interact with nsp-14 and nsp-16.

Nsp-14 comprises a 3'-to-5' exoribonuclease (ExoN) active domain in the amino-terminal region. SARS-CoV ExoN has been demonstrated to have metal ion-dependent 3'-to-5' exoribonuclease activity that acts on both single-stranded and double-stranded RNA, but not on DNA. Nsp-14 has been shown to have proof-reading activity. This nsp has also been shown to have N7-methyltransferase (MT) activity in the carboxyl-terminal region.

Nsp-15 associated NendoU (nidoviral endoribonuclease, specific for U) RNase activity has been reported for a number of coronaviruses, including SARS-CoV, MHV and IBV. The activities were consistently reported to be significantly enhanced by Mn^{2+} ions and there was little activity in the presence of Mg^{2+} and Ca^{2+} . NendoU cleaves at the 3' side of uridylate residues in both single-stranded and double-stranded RNA. The biologically relevant substrate(s) of coronavirus NendoUs remains to be identified.

Nsp-16 has been predicted to mediate ribose-2'-O-methyltransferase (2'-O-MTase) activity and reverse-genetics experiments have shown that the 2'-O-MTase domain is essential for viral RNA synthesis in HCoV-229E and SARS-CoV. The enzyme may be involved in the production of the cap 1 structures of coronavirus RNAs and it may also cooperate with NendoU and ExoN in other RNA processing pathways. 2'-O-MTase might also methylate specific RNAs to protect them from NendoU-mediated cleavage.

The genomic and protein sequences for nsp-10, -14, -15 and -16 are provided as SEQ ID NO: 2-5 and 6-9, respectively.

(nsp-10 nucleotide sequence- nucleotides 11884-12318 of SEQ ID NO: 1)
SEQ ID NO: 2

TCTAAAGGTCATGAGACAGAGGAAGTGGATGCTGTAGGCATTCTCTCACTTTGTTCTTTTGCAGTA
GATCCTGCGGATACATATTGTAAATATGTGGCAGCAGGTAATCAACCTTTAGGTAACGTGTGTAA
ATGTTGACAGTACATAATGGTAGTGGTTTTGCAATAACATCAAAGCCAAGTCCAACTCCGGATCAG
GATTCTTATGGAGGAGCTTCTGTGTGCTTTATTGTAGAGCACATATAGCACCTTGGCGGAGCA
GGAAATTTAGATGGACGCTGTCAATTTAAAGGTTCTTTTGTGCAAATACCTACTACGGAGAAAGAT
CCTGTTGGATTCTGTCTACGTAACAAGGTTTGCAGTGTGTGTCAGTGTGGATTGGTTATGGATGT
CAGTGTGATTCACTTAGACAACCTAAACCTTCTGTTCAG

(nsp-14 nucleotide sequence- nucleotides 16938-18500 of SEQ ID NO: 1)
SEQ ID NO: 3

GGTACAGGCTTGTTTAAATTTGCAACAAAGAGTTTAGTGGTGTTCACCCAGCTTATGCAGTCACA
ACTAAGGCTCTGTGCAACTTATAAAGTTAATGATGAACCTGCTGCACTGTGTAACGTGGAAGCT
GGTTCAGAAATAACATATAACATCTTATTTCTTTGTTAGGGTTAAGATGAGTGTAAATGTTGAA
GGCTGCCACAACATGTTTATAACACGTGATGAGGCTATCCGCAACGTAAGAGGTTGGTAGGTTTT
GATGTAGAAGCAACACATGCTTGCAGTACTAACATGGTACTAACCTGCCTTTCCAAGTAGGTTTT
TCTACTGGTGCACTTTGTAGTTACGCCTGAGGACTTGTAGATACTTCAATAGGCAATAATTTT
GAGCCTGTGAATTTCTAAAGCACCTCCAGGTGAACAATTTAATCACTTGAGAGCGTTATTCAAAGT
GCTAAACCTTGGCATGTTGTAAAGGCCAAGGATTGTGCAATGTAGCGGATAACCTGTGCAACGTT
TCAGATTGTGTAGTGTGTGTACGTGGTGTATGGCCTAGAACTAACCACTTTGCGCTATTTTGT
AAAATAGGCAAGGACCAAGTTTGTCTTGCAGTTCTAGAGCAACAACCTTTAATCTCATACTCAG
GCTTATGCTTGTGGAAGCATTGCTTGGGTTTTGATTTTGTATTATAATCCACTCTTAGTGGATATT
CAACAGTGGGTTATTCTGGTAACCTACAATTTAACCATGATTTCATTGTAATGTGCATGGACAC
GCACATGTAGCTTCTCGGATGCTATTATGACGCGTTGTCTTGCAATTAATAATGCATTTTGTCAA

-continued

GATGTCAACTGGGATTAACTTACCTCATATAGCAAATGAGGATGAAGTCAATCTAGCTGTAGA
TATTTACAACGCATGTATCTTAATGCATGTGTTGATGCTCTTAAAGTTAACGTTGTCTATGATATA
GGCAACCCCTAAAGGTATTAAATGTGTTAGACGTGGAGACTTAAATTTTAGATTCTATGATAAGAAT
CCAAATAGTACCCAATGTCAAGCAGTTTGAGTATGACTATAATCAGCACAAAGATAAGTTTGCTGAT
GGTCTTTGTATGTTTTGGAATTGTAATGTGGATTGTTATCCCGACAATTCCTTACTTTGTAGGTAC
GACACACGAAATTTGAGTGTGTTTAACTACCTGGTTGTAATGGTGGTAGCTTGTATGTTAACAAG
CATGCATTCCACACACCTAAATTTGATCGCACTAGCTTTCGTAATTTGAAAGCTATGCCATTCTTT
TTCTATGACTCATCGCCTTGCGAGACCATTCAATTGGATGGAGTTGCGCAAGACCTTGTGTCATTA
GCTACGAAAGATTGTATCACAATAATGCAACATAGCGGGTGTGTTTGTAAAAAGCACGCACAATG
TATGCAGATTTTGTGACTTCTTATAATGCAGCTGTACTGTGGTTTTACTTTTGGGTTACTAAT
AATTTTAACCCATATAATTTGTGGAAAAGTTTTTCAGCTCTCCAG

(nsp-15 nucleotide sequence- nucleotides 18501-19514 of SEQ ID NO: 1)
SEQ ID NO: 4
TCTATCGACAATATTGCTTATAATATGTATAAGGGTGGTCATTATGATGCTATTGCAGGAGAAATG
CCCCTATCGTAACTGGAGATAAAGTTTTTGTATAGATCAAGGCGTAGAAAAAGCAGTTTTTTTT
AATCAAACAATTTGCCTACATCTGTAGCGTTTGAGCTGTATCGAAGAGAAATATTGCACACTG
CCAAACAACCGTATTTTGAAGGTTTGGGTGTAGATGTGACTAATGGATTTGTAATTTGGGATTAC
ACGAACCAAACACCACTATACCGTAATACTGTAAAGGTATGTGCATATACAGACATAGAACCAAAT
GGCCTAATAGTCTGTATGATGATAGATATGGTGATTACCAGTCTTTCTAGCTGCTGATAATGCT
GTTTTAGTTTCTACACAGTGTTACAAGCGGTATTGCTATGTAGAAATACCGTCAAACCTGCTTGTT
CAGAACGGTATTCGGTTAAAAGATGGAGCGAACCTGTATGTTTATAAGCGTGTAAATGGTGCGTTT
GTTACGCTACCTAACACAATAAACACACAGGGTCGAAGTTATGAAACTTTTGAACCTCGTAGTGAT
GTTGAGCGTGATTTTCTCGACATGTCTGAGGAGAGTTTTGTAGAAAAGTATGGTAAAGAATTAGGT
CTACAGCACATACTGTATGGTGAAGTTGATAAGCCCCAATTAGGTGGTTTCCACACTGTTATAGGT
ATGTGCACTGCTTTTACGTGCGAATAAGTTGAACGCAAGTCTGTTACTAATCTGATTCTGATGTC
ATGCAAAATTATTTGTATTGGCAGACAATGGTTCCTACAAGCAAGTGTGACTGTTGTGGATTG
CTGCTTGATGATTTCTTAGAATCTCTTAGGAACATACTGAAAGAGTATGGTACTAATAAGTCTAAA
GTTGTAACAGTGTCAATTGATTACCATAGCATAAATTTTATGACTTGGTTTGAAGATGGCATTATT
AAAACATGTTATCCACAGCTTCAA

(nsp-16 nucleotide sequence- nucleotides 19515-20423 of SEQ ID NO: 1)
SEQ ID NO: 5
TCAGCATGGACGTGTGGTTATAATATGCCTGAACTTTATAAAGTTCAGAATTGTGTTATGGAACCT
TGCAACATTCCTAATTATGGTGTGGAATAGCGTTGCCAAGTGGTATTATGATGAATGTGGCAAAG
TATACACAACCTCTGTCAATACCTTTCGAAAACAACAATGTGTGTACCGCATAATATGCGAGTAATG
CATTTTGGAGCTGGAAGTGACAAAGGAGTGGTGCCAGGTAGTACTGTTCTTAAACAATGGCTCCCA
GAAGGGACACTCCTTGTGATAATGATATTGTAGACTATGTGTCTGATGCACATGTTCTGTGCTT
TCAGATTGCAATAAATATAAGACAGAGCACAAGTTTGATCTTGTGATATCTGATATGTATACAGAC
AATGATTCAAAAAGAAAGCATGAAGCGTGATAGCCAATAATGGCAATGATGACGTTTTTCATATAT
CTCTCAAGTTTTCTTCGTAATAATTTGGCTCTAGGTGGTAGTTTTGCTGTAAAAGTGACAGAGACA
AGTTGGCACGAAGTTTTATATGACATTGCACAGGATTGTGCATGGTGGACAATGTTTTGTACAGCA
GTGAATGCCTCTTCTCAGAAGCATTCTTGATTGGTGTAAATTATTTGGGTGCAAGTGAAAAGGTT
AAGGTTAGTGAAAAACGCTGCACGCAATATATATTTTGGAGGAATTGTAATTATTTACAAAAC

-continued

TCTGCTTATAGTATATTTGACGTTGCTAAGTTTGATTTGAGATTGAAAGCAACGCCAGTTGTTAAT
 TTGAAACTGAACAAAAGACAGACTTAGTCTTTAATTTAATTAAGTGTGGTAAGTTACTGGTAAGA
 GATGTTGGTAACACCTCTTTTACTAGTGACTCTTTTGTGTGTACTATGTAG

(nsp-10 amino acid sequence)

SEQ ID NO: 6

SKGHETEEVDVAVGILSLCSFAVDPAADTYCKYVAAGNQPLGNCVKMLTVKNGSGFAITSKPSPTPDQ
 DSYGGASVCLYCRAHIAHPGGAGNLDGRCQPKGSFVQIPTTEKDPVGFCLRNKVTVCQCWIGYGC
 QCDSLRLQPKPSVQ

(nsp-14 amino acid sequence)

SEQ ID NO: 7

GTGLFKICNKEFSGVHPAYAVTTKALAATYKVNDELAALVNVEAGSEITYKHLISLLGFKMSVNVE
 GCHNMFITRDEAIRNVRGVGFDVEATHACGTNIGTNLPPQVGFGSTGADFVVTPEGLVDTSIGNNF
 EPVNSKAPPGEQFNHLRALFKSAKPWHVVRPRIVQMLADNLCNVSDCVFVFWCHGLELTTLRYFV
 KIGKDQVCSCGRATTFNSHTQAYACWKHCLGFDFVYNPLLVDIQQWGYSGNLQFNHDLHCNVHGH
 AHVASADAIMTRCLAINNAFCQDVNWDLTYPHIANEDEVNSSCRYLQRMVNLNACVDALKVNVVYDI
 GNPKGIKCVRRGDLNFRFYDKNPVFNKQFEYDYNQHKDKFADGLCMFNCNVDCYPDNLVCRY
 DTRNLSVFNLPGCNGGSLYVNKHAFHTPKFDRTSFRNLKAMFFFFYDSSPCETIQLDGVAQDLVSL
 ATKDCITKCNICGAVCKKKAQMYADFVTSYNAAVTAGFTFWVTNNFNPYNLWKSFSALQ

(nsp-15 amino acid sequence)

SEQ ID NO: 8

SIDNIAYNMYKGGHYDAIAGEMPTIVTGDQVFDIDQGVKAVFFNQITLPTSVAFELYAKRNIRTL
 PNNRILKGLGVDVTNGFVIWDYTNQTPLYRNTVKVCAYTDIEPNGLIVLYDDRYQDYQSFLAADNA
 VLVSTQCYKRYSYVEIPSNLLVQNGIPLKDGANLYVYKRVNGAFVTLPTNTLTQGRSYETFEPRSD
 VERDFLDMSEESFVEYKQKELGLQHILYGEVDKPKQLGGLHTVIGMCRLLRANKLNAKSVTNSDSDV
 MQNYFVLADNGSYKQVCTVVDLLDDFLELLRNILKEYGTNKSQVTVSIDIHYSINFMTWFEDGII
 KTCYPQLQ

(nsp-16 amino acid sequence)

SEQ ID NO: 9

SAWTCGYNMPELYKVQNCVMEPCNIPNYGVGIALPSGIMMNVAKYTQLCQYLSKTTMCVPHNMVRM
 HFGAGSDKGAVPGSTVLKQWLPEGTLVDNDIVDVSDAHVSVLSDCNKYKTEHKFDLVISDMYTD
 NDSKRKHEGVIANNGNDVFIYLSFSLRNALGGSFAVKVTETSWHEVLYDIAQDCAWWTMFCTA
 VNASSSEAFVGVNYLGASEKVIWSGKTLHANYIFWRNCNYLQTSAYSIFDVAKFDLRLKATPVVN
 LKTEQKTDLVFNLIKCGKLLVRDVGNTSFTSDSFVCTM

Reduced Pathogenicity

The live, attenuated coronavirus of the present invention comprises a variant replicase gene which causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type gene.

The term “attenuated” as used herein, refers to a virus that exhibits said reduced pathogenicity and may be classified as non-virulent. A live, attenuated virus is a weakened replicating virus still capable of stimulating an immune response and producing immunity but not causing the actual illness.

The term “pathogenicity” is used herein according to its normal meaning to refer to the potential of the virus to cause disease in a subject. Typically the pathogenicity of a coronavirus is determined by assaying disease associated symptoms, for example sneezing, snicking and reduction in tracheal ciliary activity.

The term “reduced pathogenicity” is used to describe that the level of pathogenicity of a coronavirus is decreased, lessened or diminished compared to a corresponding, wild-type coronavirus.

In one embodiment, the coronavirus of the present invention has a reduced pathogenicity compared to the parental M41-CK virus from which it was derived or a control coronavirus. The control coronavirus may be a coronavirus with a known pathogenicity, for example a coronavirus expressing the wild-type replicase protein.

The pathogenicity of a coronavirus may be assessed utilising methods well-known in the art. Typically, pathogenicity is assessed by assaying clinical symptoms in a subject challenged with the virus, for example a chicken.

As an illustration, the chicken may be challenged at 8-24 days old by nasal or ocular inoculation. Clinical symptoms, associated with IBV infection, may be assessed 3-10 days post-infection. Clinical symptoms commonly assessed to

determine the pathogenicity of a coronavirus, for example an IBV, include gasping, coughing, sneezing, snicking, depression, ruffled feathers and loss of tracheal ciliary activity.

The variant replicase of the present invention, when expressed in a coronavirus, may cause a reduced level of clinical symptoms compared to a coronavirus expressing a wild-type replicase.

For example a coronavirus expressing the variant replicase may cause a number of snicks per bird per minute which is less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of snicks caused by a virus expressing the wild type replicase.

A coronavirus expressing a variant replicase according to the present invention may cause wheezing in less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of birds in a flock infected with the a virus expressing the wild type replicase.

A coronavirus expressing a variant replicase according to the present invention may result in tracheal ciliary activity which is at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the level of tracheal ciliary activity in uninfected birds.

A coronavirus expressing a variant replicase according to the present invention may cause clinical symptoms, as defined in Table 2, at a lower level than a coronavirus expressing the wild type replicase.

TABLE 2

IBV severity limits based on clinical signs:	
Snicking (sneezing) Nasal exudate Watery eyes Swollen infraorbital sinuses Rales (vibration in trachea or bronchi region)	IBV specific: Mild (N.B. Respiratory signs become apparent from 2-3 dpi if they are going to occur and can continue for up to 7d).
Hunched posture/depressed Fluffed up feathers Eating and drinking less	Mild, if exceed 2d increase to moderate
Drinking in excess: evident by fluid filled crop or measured water intake	IBV specific: Mild, if exceed 24h increase to moderate for a max of 2d. If still drinking in excess then kill by schedule 1 method.
Less active but still evade capture Weight loss Not eating or drinking	Mild, if exceed 1d increase to moderate.
Birds sit alone and does not evade capture Severe respiratory distress: e.g. excessive gasping Snicking and/or rales for 7d in total	Moderate: birds at end point. Kill by schedule 1 method.
Found dead	Severe: report to project license holder. Full post-mortem to be performed.

The variant replicase of the present invention, when expressed in a coronavirus, may cause the virus to replicate at non-pathogenic levels in ovo.

While developing vaccines to be administered in ovo to chicken embryos, attention must be paid to two points: the effect of maternal antibodies on the vaccines and the effect of the vaccines on the embryo. Maternal antibodies are known to interfere with active immunization. For example, vaccines with mild strains do not induce protective antibody

levels when administered to broiler chickens with maternal antibodies as these strains are neutralized by the maternal antibody pool.

Thus a viral particle must be sufficiently efficient at replicating and propagating to ensure that it is not neutralized by the maternally-derived antibodies against the virus. Maternally-derived antibodies are a finite pool of effective antibodies, which decrease as the chicken ages, and neutralization of the virus in this manner does not equate to the establishment of long-term immunity for the embryo/chick. In order to develop long-term immunity against the virus, the embryo and hatched chicken must develop an appropriate protective immune response which is distinct to the effect of the maternally-derived antibodies.

To be useful for in ovo vaccination, the virus must also not replicate and propagate at a level which causes it to be pathogenic to the embryo.

Reduced pathogenicity in terms of the embryo may mean that the coronavirus causes less reduction in hatchability compared to a corresponding, wild-type control coronavirus. Thus the term "without being pathogenic to the embryo" in the context of the present invention may mean "without causing reduced hatchability" when compared to a control coronavirus.

A suitable variant replicase may be identified using methods which are known in the art. For example comparative challenge experiments following in ovo vaccination of

embryos with or without maternally-derived antibodies may be performed (i.e. wherein the layer has or has not been vaccinated against IBV).

If the variant replicase enables the virus to propagate at a level which is too high, the embryo will not hatch or will not be viable following hatching (i.e. the virus is pathogenic to the embryo). A virus which is pathogenic to the embryo may kill the embryo.

If the variant replicase causes a reduction in viral replication and propagation which is too great, the virus will be

neutralised by the maternally-derived antibodies. Subsequent challenge of the chick with IBV will therefore result in the development of clinical symptoms (for example wheezing, snickering, loss of ciliary activity) and the onset of disease in the challenged chick; as it will have failed to develop effective immunity against the virus.

Variant

As used herein, the term 'variant' is synonymous with 'mutant' and refers to a nucleic acid or amino acid sequence which differs in comparison to the corresponding wild-type sequence.

A variant/mutant sequence may arise naturally, or may be created artificially (for example by site-directed mutagenesis). The mutant may have at least 70, 80, 90, 95, 98 or 99% sequence identity with the corresponding portion of the wild type sequence. The mutant may have less than 20, 10, 5, 4, 3, 2 or 1 mutation(s) over the corresponding portion of the wild-type sequence.

The term "wild type" is used to mean a gene or protein having a nucleotide or amino acid sequence which is identical with the native gene or protein respectively (i.e. the viral gene or protein).

Identity comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % identity between two or more sequences. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 *ibid*—Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410) and the GENWORKS suite of comparison tools, ClustalX (see Larkin et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics, 23:2947-2948). Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 *ibid*, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov).

The sequence may have one or more deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent molecule. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the activity is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P I L V
	Polar- uncharged	C S T M N Q

-continued

Polar- charged	D E K R
AROMATIC	H F W Y

The coronavirus of the present invention may comprise a variant replicase gene which encodes a protein which comprises a mutation compared to any one of SEQ ID NO: 6, 7, 8 or 9 which, when expressed in a coronavirus, causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type replicase.

The variant replicase gene may encode a protein which comprises at least one or more amino acid mutations in any combination of nsp-10, nsp-14, nsp-15 and nsp-16.

The variant replicase gene of the coronavirus of the present invention may encode a protein comprising a mutation as defined in the M41 mod sequences presented in FIG. 10.

The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises one or more amino acid mutations selected from the list of:

- Pro to Leu at position 85 of SEQ ID NO: 6,
- Val to Leu at position 393 of SEQ ID NO: 7;
- Leu to Ile at position 183 of SEQ ID NO: 8;
- Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp-2, nsp-3, nsp-6 or nsp-13.

The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp10 which corresponds to the threonine to isoleucine mutation caused by a mutation at nucleotide position 12,008 in the gene reported by Ammayappan et al. (Arch Virol (2009) 154:495-499).

Ammayappan et al (as above) reports the identification of sequence changes responsible for the attenuation of IBV strain Arkansas DPI. The study identified 17 amino acid changes in a variety of IBV proteins following multiple passages, approx. 100, of the virus in embryonated eggs. It was not investigated whether the attenuated virus (Ark DPI 101) is capable of replicating in the presence of maternally-derived antibodies against the virus in ovo, without being pathogenic to the embryo. Given that this virus was produced by multiple passage in SPF embryonated eggs, similar methodology for classical IBV vaccines, it is likely that this virus is pathogenic for embryos. The virus may also be sensitive to maternally-derived antibodies if the hens were vaccinated with a similar serotype.

The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises any combination of one or more amino acid mutations provided in the list above.

The variant replicase gene may encode a protein which comprises the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

The variant replicase gene may encode a protein which comprises the amino acid mutation Val to Leu at position 393 of SEQ ID NO: 7.

The variant replicase gene may encode a protein which comprises the amino acid mutation Leu to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutation Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, and Val to Leu at position 393 of SEQ ID NO: 7.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7 and Leu to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may also be defined at the nucleotide level.

For example the nucleotide sequence of the variant replicase gene of the coronavirus of the present invention may comprise one or more nucleotide substitutions within the regions selected from the list of: 11884-12318, 16938-18500, 18501-19514 and 19515-20423 of SEQ ID NO:1.

For example the nucleotide sequence of the variant replicase gene of the coronavirus of the present invention may comprise one or more nucleotide substitutions selected from the list of:

C to Tat nucleotide position 12137;
G to C at nucleotide position 18114;
T to A at nucleotide position 19047; and
G to A at nucleotide position 20139;

compared to the sequence shown as SEQ ID NO: 1.

As used herein, the term "substitution" is synonymous with the term mutation and means that the nucleotide at the identified position differs to that of the wild-type nucleotide sequence.

The nucleotide sequence may comprise any combination of the nucleotide substitutions selected from the list of:

C to Tat nucleotide position 12137;
G to Cat nucleotide position 18114;
T to A at nucleotide position 19047; and
G to A at nucleotide position 20139;

5 compared to the sequence shown as SEQ ID NO: 1.

The nucleotide sequence may comprise the substitution C12137T.

The nucleotide sequence may comprise substitution G18114C.

10 The nucleotide sequence may comprise the substitution T19047A.

The nucleotide sequence may comprise the substitution G20139A.

The nucleotide sequence may comprise the substitutions C12137T and G18114C.

15 The nucleotide sequence may comprise the substitutions C12137T and T19047A.

The nucleotide sequence may comprise the substitutions C12137T and G20139A.

20 The nucleotide sequence may comprise the substitutions G18114C and T19047A.

The nucleotide sequence may comprise the substitutions G18114C and G20139A.

25 The nucleotide sequence may comprise the substitutions T19047A and G20139A.

The nucleotide sequence may comprise the substitutions C12137T, G18114C and T19047A.

The nucleotide sequence may comprise the substitutions C12137T, T19047A and G20139A.

30 The nucleotide sequence may comprise the substitutions C12137T, G18114C and G20139A.

The nucleotide sequence may comprise the substitutions G18114C, T19047A and G20139A.

35 The nucleotide sequence may comprise the substitutions C12137T, G18114C, T19047A and G20139A.

The nucleotide sequence may not comprise a substitution which corresponds to the C12008T substitution reported by Ammayappan et al. (as above).

40 The nucleotide sequence may be natural, synthetic or recombinant. It may be double or single stranded, it may be DNA or RNA or combinations thereof. It may, for example, be cDNA, PCR product, genomic sequence or mRNA.

The nucleotide sequence may be codon optimised for production in the host/host cell of choice.

45 It may be isolated, or as part of a plasmid, virus or host cell.

Plasmid

A plasmid is an extra-chromosomal DNA molecule separate from the chromosomal DNA which is capable of replicating independently of the chromosomal DNA. They are usually circular and double-stranded.

Plasmids, or vectors (as they are sometimes known), may be used to express a protein in a host cell. For example a bacterial host cell may be transfected with a plasmid capable of encoding a particular protein, in order to express that protein. The term also includes yeast artificial chromosomes and bacterial artificial chromosomes which are capable of accommodating longer portions of DNA.

60 The plasmid of the present invention comprises a nucleotide sequence capable of encoding a defined region of the replicase protein. It may also comprise one or more additional coronavirus nucleotide sequence(s), or nucleotide sequence(s) capable of encoding one or more other coronavirus proteins such as the S gene and/or gene 3.

65 The plasmid may also comprise a resistance marker, such as the guanine xanthine phosphoribosyltransferase gene (gpt) from *Escherichia coli*, which confers resistance to

mycophenolic acid (MPA) in the presence of xanthine and hypoxanthine and is controlled by the vaccinia virus P7.5 early/late promoter.

Recombinant Vaccinia Virus

The present invention also relates to a recombinant vaccinia virus (rVV) comprising a variant replicase gene as defined herein.

The recombinant vaccinia virus (rVV) may be made using a vaccinia-virus based reverse genetics system.

In this respect, the present invention also provides a method for making a viral particle by:

- (i) transfecting a plasmid as described in the previous section into a host cell;
- (ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;
- (iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene;
- (iv) selecting for recombining virus comprising the modified replicase gene.

The term 'modified replicase gene' refers to a replicase gene which comprises a variant replicase gene as described in connection with the first aspect of the present invention. Specifically, the term refers to a gene which is derived from a wild-type replicase gene but comprises a nucleotide sequence which causes it to encode a variant replicase protein as defined herein.

The recombination may involve all or part of the replicase gene. For example the recombination may involve a nucleotide sequence encoding for any combination of nsp-10, nsp-14, nsp-15 and/or nsp-16. The recombination may involve a nucleotide sequence which encodes for an amino acid mutation or comprises a nucleotide substitution as defined above.

The genome of the coronavirus strain may lack the part of the replicase protein corresponding to the part provided by the plasmid, so that a modified protein is formed through insertion of the nucleotide sequence provided by the plasmid.

The recombining virus is one suitable to allow homologous recombination between its genome and the plasmid. The vaccinia virus is particularly suitable as homologous recombination is routinely used to insert and delete sequences for the vaccinia virus genome.

The above method optionally includes the step:

- (v) recovery of recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

Methods for recovering recombinant coronavirus, such as recombinant IBV, are known in the art (See Britton et al (2005) see page 24; and PCT/GB2010/001293).

For example, the DNA from the recombining virus from step (iv) may be inserted into a plasmid and used to transfect cells which express cytoplasmic T7 RNA polymerase. The cells may, for example be pre-infected with a fowlpox virus expressing T7 RNA polymerase. Recombinant coronavirus may then be isolated, for example, from the growth medium.

When the plasmid is inserted into the vaccinia virus genome, an unstable intermediate is formed. Recombinants comprising the plasmid may be selected for e.g. using a resistance marker on the plasmid.

Positive recombinants may then be verified to contain the modified replicase gene by, for example, PCR and sequencing.

Large stocks of the recombining virus including the modified replicase gene (e.g. recombinant vaccinia virus, (rVV) may be grown up and the DNA extracted in order to carry out step (v)).

Suitable reverse genetics systems are known in the art (Casais et al (2001) J. Virol 75:12359-12369; Casais et al (2003) J. Virol. 77:9084-9089; Britton et al (2005) J. Virological Methods 123:203-211; Armesto et al (2008) Methods in Molecular Biology 454:255-273).

Cell

The coronavirus may be used to infect a cell.

Coronavirus particles may be harvested, for example from the supernatant, by methods known in the art, and optionally purified.

The cell may be used to produce the coronavirus particle. Thus the present invention also provides a method for producing a coronavirus which comprises the following steps:

- (i) infection of a cell with a coronavirus according to the invention;
- (ii) allowing the virus to replicate in the cell; and
- (iii) harvesting the progeny virus.

The present invention also provides a cell capable of producing a coronavirus according to the invention using a reverse genetics system. For example, the cell may comprise a recombining virus genome comprising a nucleotide sequence capable of encoding the replicase gene of the present invention.

The cell may be able to produce recombinant recombining virus (e.g. vaccinia virus) containing the replicase gene.

Alternatively the cell may be capable of producing recombinant coronavirus by a reverse genetics system. The cell may express or be induced to express T7 polymerase in order to rescue the recombinant viral particle.

Vaccine

The coronavirus may be used to produce a vaccine. The vaccine may be a live attenuated form of the coronavirus of the present invention and may further comprise a pharmaceutically acceptable carrier. As defined herein, "pharmaceutically acceptable carriers" suitable for use in the invention are well known to those of skill in the art. Such carriers include, without limitation, water, saline, buffered saline, phosphate buffer, alcohol/aqueous solutions, emulsions or suspensions. Other conventionally employed diluents and excipients may be added in accordance with conventional techniques. Such carriers can include ethanol, polyols, and suitable mixtures thereof, vegetable oils, and injectable organic esters. Buffers and pH adjusting agents may also be employed. Buffers include, without limitation, salts prepared from an organic acid or base. Representative buffers include, without limitation, organic acid salts, such as salts of citric acid, e.g., citrates, ascorbic acid, gluconic acid, histidine-Hel, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid, Iris, trimethanmine hydrochloride, or phosphate buffers. Parenteral carriers can include sodium chloride solution, Ringer's dextrose, dextrose, trehalose, sucrose, and sodium chloride, lactated Ringer's or fixed oils. Intravenous carriers can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose and the like. Preservatives and other additives such as, for example, antimicrobials, antioxidants, chelating agents (e.g., EDTA), inert gases and the like may also be provided in the pharmaceutical carriers. The present invention is not limited by the selection of the carrier. The preparation of these pharmaceutically acceptable compositions, from the above-described components, having appropriate pH isotonicity, stability and other conventional char-

acteristics is within the skill of the art. See, e.g., texts such as Remington: The Science and Practice of Pharmacy, 20th ed, Lippincott Williams & Wilkins, pub!., 2000; and The Handbook of Pharmaceutical Excipients, 4.sup.th edit., eds. R. C. Rowe et al, APhA Publications, 2003.

The vaccine of the invention will be administered in a “therapeutically effective amount”, which refers to an amount of an active ingredient, e.g., an agent according to the invention, sufficient to effect beneficial or desired results when administered to a subject or patient. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition according to the invention may be readily determined by one of ordinary skill in the art. In the context of this invention, a “therapeutically effective amount” is one that produces an objectively measured change in one or more parameters associated Infectious Bronchitis condition sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations. For purposes of this invention, an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to reduce the incidence of Infectious Bronchitis. As used herein, the term “therapeutic” encompasses the full spectrum of treatments for a disease, condition or disorder. A “therapeutic” agent of the invention may act in a manner that is prophylactic or preventive, including those that incorporate procedures designed to target animals that can be identified as being at risk (pharmacogenetics); or in a manner that is ameliorative or curative in nature; or may act to slow the rate or extent of the progression of at least one symptom of a disease or disorder being treated.

The present invention also relates to a method for producing such a vaccine which comprises the step of infecting cells, for example Vero cells, with a viral particle comprising a replicase protein as defined in connection with the first aspect of the invention.

Vaccination Method

The coronavirus of the present invention may be used to treat and/or prevent a disease.

To “treat” means to administer the vaccine to a subject having an existing disease in order to lessen, reduce or improve at least one symptom associated with the disease and/or to slow down, reduce or block the progression of the disease.

To “prevent” means to administer the vaccine to a subject who has not yet contracted the disease and/or who is not showing any symptoms of the disease to prevent or impair the cause of the disease (e.g. infection) or to reduce or prevent development of at least one symptom associated with the disease.

The disease may be any disease caused by a coronavirus, such as a respiratory disease and and/or gastroenteritis in humans and hepatitis, gastroenteritis, encephalitis, or a respiratory disease in other animals.

The disease may be infectious bronchitis (IB); Porcine epidemic diarrhoea; Transmissible gastroenteritis; Mouse hepatitis virus; Porcine haemagglutinating encephalomyelitis; Severe acute respiratory syndrome (SARS); or Bluecomb disease.

The disease may be infectious bronchitis.

The vaccine may be administered to hatched chicks or chickens, for example by eye drop or intranasal administration. Although accurate, these methods can be expensive e.g. for large broiler flocks. Alternatives include spray inoculation of administration to drinking water but it can be difficult to ensure uniform vaccine application using such methods.

The vaccine may be provided in a form suitable for its administration, such as an eye-dropper for intra-ocular use.

The vaccine may be administered by in ovo inoculation, for example by injection of embryonated eggs. In ovo vaccination has the advantage that it provides an early stage resistance to the disease. It also facilitates the administration of a uniform dose per subject, unlike spray inoculation and administration via drinking water.

The vaccine may be administered to any suitable compartment of the egg, including allantoic fluid, yolk sac, amnion, air cell or embryo. It may be administered below the shell (aircell) membrane and chorioallantoic membrane.

Usually the vaccine is injected into embryonated eggs during late stages of embryonic development, generally during the final quarter of the incubation period, such as 3-4 days prior to hatch. In chickens, the vaccine may be administered between day 15-19 of the 21-day incubation period, for example at day 17 or 18.

The process can be automated using a robotic injection process, such as those described in WO 2004/078203.

The vaccine may be administered together with one or more other vaccines, for example, vaccines for other diseases, such as Newcastle disease virus (NDV). The present invention also provides a vaccine composition comprising a vaccine according to the invention together with one or more other vaccine(s). The present invention also provides a kit comprising a vaccine according to the invention together with one or more other vaccine(s) for separate, sequential or simultaneous administration.

The vaccine or vaccine composition of the invention may be used to treat a human, animal or avian subject. For example, the subject may be a chick, chicken or mouse (such as a laboratory mouse, e.g. transgenic mouse).

Typically, a physician or veterinarian will determine the actual dosage which will be most suitable for an individual subject or group of subjects and it will vary with the age, weight and response of the particular subject(s).

The composition may optionally comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as (or in addition to) the carrier, excipient or diluent, any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase the delivery or immunogenicity of the virus.

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

EXAMPLES

Example 1—Generation of an IBV Reverse Genetics System Based on M41-CK

A M41-CK full-length cDNA was produced by replacement of the Beaudette cDNA in the Vaccinia virus reverse genetics system previously described in PCT/GB2010/001293 (herein incorporated by reference) with synthetic cDNA derived from the M41 consensus sequence.

The IBV cDNA within recombinant Vaccinia virus (rVV) rVV-BeauR-Rep-M41 structure described in Armesto, Cavanagh and Britton (2009). PLoS ONE 4(10): e7384. doi:10.1371/journal.pone.0007384, which consisted of the replicase derived from IBV Beaudette strain and the struc-

tural and accessory genes and 3' UTR from IBV M41-CK, was further modified by replacement of the Beaudette 5' UTR-Nsp2-Nsp3 sequence with the corresponding sequence from IBV M41-CK. The resulting IBV cDNA consisted of 5' UTR-Nsp2-Nsp3 from M41, Nsp4-Nsp16 from Beaudette and the structural and accessory genes and 3' UTR from M41. This cDNA was further modified by the deletion of the Beaudette Nsp4-Nsp16 sequence. The resulting cDNA, lacking Nsp4-16, was modified in four further steps in which the deleted Nsps were sequentially replaced with the corresponding sequences from M41-CK, the replacement cDNAs represented M41-CK Nsp4-8, Nsp9-12, Nsp12-14 and finally Nsp15-16. Each replacement cDNA contained approx. 500 nucleotides at the 5' end corresponding to the 3' most M41 sequence previously inserted and approx. 500 nucleotides at the 3' end corresponding to the M41 S gene sequence. This allowed insertion of the M41 cDNA sequence by homologous recombination and sequential addition of contiguous M41 replicase gene sequence. The synthetic cDNAs containing the M41-derived Nsp sequences were added by homologous recombination utilising the inventor's previous described transient dominant selection (IDS) system (see PCT/GB2010/001293). The M41-derived cDNAs containing sequence corresponding to the M41 Nsps-10, -14, -15 and -16 contained the modified amino acids at positions 85, 393, 183 and 209, respectively, as indicated in FIG. 10.

A full-length cDNA representing the genome of M41-CK was generated in Vaccinia virus representing the synthetic sequences. Two rIBVs, M41-R-6 and M41-R-12, were rescued and shown to grow in a similar manner as M41-CK (FIG. 1).

Example 2—Determining the Pathogenicity of Rescued M41 Viruses

The viruses rescued in Example 1 were used to infect 8-day-old specific pathogen free (SPF) chicks by ocular and nasal inoculation to test them for pathogenicity, as observed by clinical signs on a daily basis 3-7 days post-infection and for ciliary activity days 4 and 6 post-infection. Loss of ciliary activity is a well-established method for determining the pathogenicity of IBV. The two M41-R viruses were found to be apathogenic when compared to M41-CK though they did show some clinical signs in comparison to uninfected control chicks (FIG. 2) and some but inconsistent loss in ciliary activity (FIG. 3).

Thus, the M41-R molecular clones of M41-CK were not pathogenic when compared to the parental virus M41-CK.

The inventors identified several nucleotide differences in the M41-R compared to the M41-CK sequences. The majority of these were synonymous mutations, as the nucleotide change did not affect the amino acid sequence of the protein associated with the sequence. However, four non-synonymous mutations were identified in the IBV replicase gene specific to Nsp-10, Nsp-14, Nsp-15 and Nsp-16 components of the replicase gene, these mutations resulted in amino acid changes (Table 3).

TABLE 3

Non-Synonymous mutations identified in the Nsps of M41-R full-length genome			
Region of Replicase	Nucleotide position	Nucleotide Mutation	Amino Acid Change
Nsp10	12137	C→T	Pro→Leu
Nsp14	18114	G→C	Val→Leu

TABLE 3-continued

Non-Synonymous mutations identified in the Nsps of M41-R full-length genome			
Region of Replicase	Nucleotide position	Nucleotide Mutation	Amino Acid Change
Nsp15	19047	T→A	Leu→Ile
Nsp16	20139	G→A	Val→Ile

Example 3—Repair of M41-R rIBVs

In order to determine whether the identified mutations were responsible for the loss of pathogenicity associated with M41-R, the Nsp10 mutation was repaired and the mutations in Nsp-14, -15 & -16 were repaired and shown to grow in a similar manner as M41-CK (FIG. 9). The inventors thus generated the rIBVs, M41R-nsp10rep and M41R-nsp14, 15, 16rep, using synthetic cDNAs containing the correct nucleotides utilising the inventor's previous described (TDS) system (see PCT/GB2010/001293).

The rIBVs were assessed for pathogenicity in chicks as described previously. Both rIBVs showed increased pathogenicity when compared to M41-R but not to the level observed with M41-CK (FIGS. 4 and 5). M41R-nsp14, 15, 16rep gave more clinical signs and more reduction in ciliary activity than M41R-nsp10rep, overall these results indicated that the changes associated with the four Nsps appear to affect pathogenicity.

To determine the roles of the Nsps in pathogenicity the full-length cDNA corresponding to M41R-nsp10rep was used to repair the mutations in Nsps14, 15 & 16 using a synthetic cDNA containing the correct nucleotides utilising the TDS system.

The following rIBVs were produced:

- M41R-nsp10, 15rep—M41-R with the mutations in Nsp-10 and Nsp-15 repaired
- M41R-nsp10, 14, 15rep—M41-R with mutations in Nsp-10, -14 and -15 repaired
- M41R-nsp10, 14, 16rep—M41-R with mutations in Nsp-10, -14 and -16 repaired
- M41R-nsp10, 15, 16rep—M41-R with mutations in Nsp-10, -15 and -16 repaired
- M41-K—All four mutations, Nsp-10, -14, -15 & -16 repaired in M41-R

The rIBVs were shown to grow in a similar manner as M41-CK (FIG. 9) and assessed for pathogenicity as described previously. M41-K (in which all four mutations had been repaired) resulted in clinical signs and 100% loss of ciliary activity (complete ciliostasis) by 4 days post-infection (FIGS. 6, 7 & 8). The other rIBVs demonstrated varying levels of pathogenicity, apart from M41R-nsp10, 15, 16rep, which was essentially apathogenic. These results confirmed that repair of all four Nsps restored pathogenicity to M41-R; again supporting the previous evidence that the mutations described in the four Nsps are implicated in attenuating M41-CK.

The inventors also generated rIBV M41R-nsp 10, 14 rep (nsp 10 and 14 are repaired, nsp 15 and 16 contain mutations) and rIBV M41R-nsp 10, 16 rep (nsp 10 and 16 are repaired, nsp 14 and 15 contain mutations) and assessed the pathogenicity of these viruses.

rIBV M41R-nsp 10, 14 rep less pathogenic than M41-K but caused around 50% ciliostasis on days 4-6 post-infection. rIBV M41R-nsp 10, 16 rep was almost apathogenic and caused no ciliostasis (see FIG. 11a-c).

Thus the genome associated with M41-R is a potential backbone genome for a rationally attenuated IBV.

Example 4—Vaccination/Challenge Study with M41-R

Candidate vaccine viruses were tested in studies in which fertilized chicken eggs were vaccinated in ovo at 18 days embryonation and in which the hatchability of the inoculated eggs was determined. The clinical health of the chickens was investigated and the chickens were challenged at 21 days of age with a virulent IB M41 challenge virus at $10^{3.65}$ EID₅₀ per dose.

Clinical signs were investigated after challenge protection by the vaccine and a ciliostasis test was performed at 5 days after challenge to investigate the effect of the challenge viruses on movement of the cilia and protection by the vaccine against ciliostasis (inhibition of cilia movement).

In Ovo Vaccination in Commercial Broiler Eggs

The design of the experiment is given in Table 4 and the clinical results are given in Table 5. Hatchability of the eggs inoculated with IB M41-R was good and chickens were healthy. IB M41-R protected against clinical signs after challenge in the broilers (placebo: 19/19 affected, IB M41-R: 3/18 affected and 1 dead). The results of the ciliostasis test are given in Table 6. IB M41-R generated protection against ciliostasis.

TABLE 4

Design of a hatchability, safety, efficacy study in commercial eggs							
Treatment	Description	EID ₅₀ ¹ per dose	Route of Admin	Day(s) of Admin	Day(s) of Challenge ²	End of Study	Nr. of eggs per treatment
T01	None	NA	NA	NA	NA	NA	30
T02	IB M41-R	10^4	In ovo	18 days	At 21 days	At 26	30
NTX	Saline	NA	In ovo	embryo- nation	of age, 20 chickens per group	days of age	30

¹Dose volume 0.1 ml, NA, not applicable.

² $10^{3.65}$ EID₅₀ per dose.

TABLE 5

Hatch percentages and clinical data before and after challenge in commercial chickens, for design see Table 1.						
Treatment	Hatch/ total	Vital/ total	Before challenge		After challenge	
			Deaths/ total	Symptoms/ total	Deaths/ total	Symptoms/ total
None	28/30	Euthanized directly after hatch for blood collection				
IB M41-R	28/30	28/28	1/20	0/19	1/19	3/18 ^{1, 7}
Saline	29/30	29/29	1/20	0/19	0/19	19/19 ^{1, 2, 3, 4, 5, 6, 7}

¹Disturbed respiratory system

²Whizzing

³Change of voice

⁴Breathing difficult

⁵Swollen intra-orbital sinuses

⁶Uneven growth

⁷Weak

TABLE 6

Results of the ciliostasis test after challenge, for design see Table 1.		
Treatment	Protected/total	Percentage protection
Saline	0/19	0%
IB M41R	5/18	28%

In Ovo Vaccination in Specific Pathogen-Free (SPF) Eggs

The design of the study in SPF eggs is given in Table 7 and is similar with the design of the studies with commercial broilers, but the vaccination dose for IB M41-R was higher, (10^5 EID₅₀ per dose).

The results (Table 8) show that the hatch percentage for IB M41-R hatch was low, and 19 of 40 hatched and the chicks were weak. Eight chicks died. The remaining 11 chickens were challenged and 11 of the chicks hatched from the eggs which had been inoculated with saline were challenged.

In the ciliostasis test after challenge it appeared that all chickens vaccinated in ovo with IB M41-R were protected, whereas none of the controls was protected, see Table 9.

TABLE 7

Design of a hatchability, safety, efficacy study in SPF eggs							
Treatment	Treatment Description	EID ₅₀ ¹ per dose	Route of Admin	Day of Admin	Day of Challenge ²	End of Study	Nr. of eggs per treatment
T01	IB M41-R	10 ⁵	In ovo	18 days embryo-nation	At 21 days of age	At 26 days of age	40
T04	Saline	NA	In ovo				40
NTX	NA	NA	NA		NA		10

¹Dose volume 0.1 ml, NA, not applicable.²Challenge dose 10^{3.3} EID₅₀ in 0.2 ml.

TABLE 8

Hatch percentages and clinical data before and after challenge in SPF chickens, for design see Table 7.						
Treatment	Hatch/total	Vital/total	Before challenge		After challenge	
			Deaths/total	Symptoms/total	Deaths/total	Symptoms/total
IB M41-R	19/40	11/40	8/40	weak	0	0
Saline	30/40	30/40	0	—	0	0
NA	9/10	9/10	0	—	—	—

TABLE 9

Results of the ciliostasis test after challenge, for design see Table 7.		
Treatment	Protected/total	Percentage protection
Saline	0/11	0%
IB M41R	11/11	100%

In conclusion, IB M41-R was safe in commercial eggs, generated protection against clinical signs and to an extent against ciliostasis.

In SPF eggs vaccinated with IB M41 R a relatively low number of chickens hatched. This may be due to the 10⁵ EID₅₀ per egg of IB M41-R used. This was 10-fold higher than the dose used in earlier studies in which there was a higher level of hatchability. The lower hatch percentages may also be caused by a particularly high susceptibility of

the batch of SPF eggs for viruses, as in other studies the level of embryo mortality was also higher that had previously been observed.

After challenge all surviving chickens after hatch were completely protected against ciliostasis. It is concluded that IB M41-R has great potential as vaccine to be administered in ovo.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology, virology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 13

<210> SEQ ID NO 1

<211> LENGTH: 27500

<212> TYPE: DNA

<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 1

```

acttaagata gatattaata tataatctatc acactagcct tgcgctagat ttccaactta      60
acaaaacgga cttaaatacc tacagctggg cctcataggt gttccattgc agtgcacttt      120
agtgccctgg atggcacctg gccacctgtc aggtttttgt tattaataac ttattgttgc      180
tggtatcact gcttggtttg ccgtgtctca cttatacat cgttgcttg ggtagcctag      240
tatccagcgt cctacgggag ccgtggctgg ttcgagtgcg aagaacctct ggttcactca      300

```

-continued

gcggtaggcg ggtgtgtgga agtagcactt cagacgtacc ggttctgttg tgtgaaatac	360
ggggtcacct cccccacat acctctaagg gcttttgagc ctagcgttg gctacgttct	420
cgcataaggt cggctatacg acgtttgtag ggggtagtgc caaacaaccc ctgaggtgac	480
aggttctggt ggtgtttagt gagcagacat acaatagaca gtgacaacat ggcttcaagc	540
ctaaaacagg gagtatctcc caaactaagg gatgtcattc ttgtatccaa agacattcct	600
gaacaacttt gtgacgcttt gtttttctat acgtcacaca accctaagga ttacgctgat	660
gcttttgagc ttaggcagaa gtttgatcgt aatctgcaga ctgggaaaca gttcaaattt	720
gaaactgtgt gtggtctctt cctcttgaag ggagttgaca aaataacacc tggcgtecca	780
gcaaaagtct taaaagccac ttctaagttg gcagatttag aagacatctt tgggtgtctt	840
ccctttgcaa gaaaatatcg tgaacttttg aagacagcat gccagtggc tcttactgta	900
gaaacactgg atgctcgtgc acaactctt gatgaaattt ttgaccctac tgaaatactt	960
tggcttcagg tggcagcaaa aatccaagtt tcggctatgg cgatgcgcag gcttgttgga	1020
gaagtaactg caaaagtcac ggatgctttg ggctcaaata tgagtgtctt ttccagatt	1080
tttaacaac aaatagtcag aatttttcaa aaagcgctgg ctatttttga gaatgtgagt	1140
gaattaccac agcgtattgc agcacttaag atggcttttg ctaagtgtgc caagtccatt	1200
actgttgttg ttatggagag gactctagtt gttagagagt tcgcaggaac ttgtcttgca	1260
agcattaatg gtgctgttgc aaaattcttt gaagaactcc caaatggttt catgggtgct	1320
aaaattttca ctacacttgc cttctttagg gaggtgcag tgaaaattgt ggataacata	1380
ccaaatgcac cgagaggcac taaagggttt gaagtcgttg gtaatgcaa aggtacacaa	1440
gttgttgtgc gtggcatgcg aaatgactta acaactgctg accaaaaagc tgaaattcct	1500
gtggagtcat aaggttggtc tgcaattttg ggtggacatc tttgctatgt ctttaagagt	1560
ggtgatcgct tttacgcggc acctctttca ggaaattttg cattgcatga tgtgcattgt	1620
tgtgagcgtg ttgtctgtct ttctgatggt gtaacaccgg agataaatga tggacttatt	1680
cttgacgcaa tctactcttc ttttagtgtc gcagaacttg tggcagccat taaaaggggt	1740
gaaccattta agtttctggg tcataaattt gtgtatgcaa aggatgcagc agtttctttt	1800
acattagcga aggctgtcac tattgcagat gttttgaagc tgtttcaatc agcgcgtgtg	1860
aaagtagaag atgtttggtc ttcacttact gaaaagtctt ttgaattctg gaggcttgca	1920
tatggaaaag tgcgtaatct cgaagaattt gttaagactt gtttttgtaa ggctcaaatg	1980
gcgatttgta ttttagcgac agtgcttgga gagggcattt ggcatcttgt ttcgcaagtc	2040
atctataaag taggtggtct ttttactaaa gttgttgact tttgtgaaaa atattggaaa	2100
ggtttttgtg cacagttgaa aagagctaag ctcatgttca ctgaaacctt ctgtgttttg	2160
aaaggagttg cacagcattg ttttcaacta ttgctggatg caatacagtt tatgtataaa	2220
agttttaaga agtgtgcact tggtagaatc catggagact tgctcttctg gaaaggaggt	2280
gtgcacaaaa ttattcaaga gggcgatgaa atttggtttg acgccattga tagtattgat	2340
gttgaagatc tgggtgttgt tcaagaaaaa ttgattgatt ttgatgtttg tgataatgtg	2400
acacttccag agaaccaacc cggtcatatg gttcaaatcg aggatgacgg aaagaactac	2460
atgttcttcc gcttcaaaaa ggatgagaac atttattata caccaatgtc acagcttggt	2520
gctattaatg tggtttgcaa agcaggcggg aaaactgtca cctttggaga aactactgtg	2580
caagaaatac caccacctga tgttgtgttt attaaggtta gcattgagtg ttgtggtgaa	2640
ccatggaata caatcttcaa aaaggcttat aaggagccca ttgaagtaga gacagacctc	2700

-continued

acagttgaac aattgctctc tgtggctctat gagaaaatgt gtgatgatct caagctgttt	2760
ccggaggctc cagaaccacc accatttgag aatgtcacac ttgttgataa gaatggtaaa	2820
gatttggatt gcataaaatc atgccatctg atctatcgtg attatgagag cgatgatgac	2880
atcgaggaag aagatgcaga agaatgtgac acggattcag gtgatgctga ggagtgtgac	2940
actaattcag aatgtgaaga agaagatgag gatactaaag tgttggctct tatacaagac	3000
ccggcaagta acaaatatcc tctgcctctt gatgatgatt atagcgtcta caatggatgt	3060
attgttcata aggacgctct cgatgttggt aatttaccat ctggtgaaga aacctttgtt	3120
gtcaataact gctttgaagg ggctgttaaa gctcttccgc agaaagtat tgatgttcta	3180
ggtgactggg gtgaggctgt tgatgcgcaa gaacaattgt gtcaacaaga atcaactcgg	3240
gtcatatctg agaaatcagt tgagggtttt actggtagt gtgatgcaat ggctgaacaa	3300
gctattgttg aagagcagga aatagtagct gttgttgaac aaagtcagga ttagtattgt	3360
tttacacctg cagacctaga agttgttaaa gaaacagcag aagaggttga tgagtttatt	3420
ctcatttctg ctgtccctaa agaagaagt gtgtctcagg agaaagagga gccacagggt	3480
gagcaagagc ctaccctagt tgttaaagca caacgtgaga agaaggctaa aaagttcaaa	3540
gttaaaccag ctacatgtga aaaacccaaa tttttggagt acaaaacatg tgtgggtgat	3600
ttggctgttg taattgcaa agcattggat gagtttaaag agttctgcat tgtaaacgct	3660
gcaaatgagc acatgtcgca tgggtgggtgc gttgcaaagg caattgcaga cttttgtgga	3720
ccggactttg ttgaatatgt cgcggactat gttaagaaac atgggtccaca gcaaaaactt	3780
gtcacacctt catttgtaa aggcatccta tgtgtgaata atgtttagg acctcgccat	3840
ggagacagca acttgcgtga gaagcttgtt gctgcttaca agagtgttct ttaggttga	3900
gtggtaact atgttgtgcc agttctctca tcagggtatt ttggtgtaga ttttaaaata	3960
tcaatagatg ctatgcgcga agcttttaaa ggttgtgcca tacgcgttct tttattttct	4020
ctgagtcaag aacacatcga ttatttcgat gcaacttgta agcagaagac aatttatctt	4080
acggaggatg gtgttaaaata ccgctctgtt gttttaaacc ctggtgatc tttgggtcaa	4140
tttgacagg tttttgcaag aaataaggta gtcttttcgg ctgatgatgt tgaggataaa	4200
gaaatcctct ttataccac aactgacaag actattcttg aatattatgg ttagatgcg	4260
caaaagtatg taacatatat gcaaacgctt gcgcagaaat gggatgttca atatagagac	4320
aattttgtta tattagagtg gcgtgacgga aattgctgga ttagttcagc aatagttctc	4380
cttcaagctg ctaaaattag atttaaagg tttcttgacg aagcatgggc taaactgttg	4440
ggtggagatc ctacagactt tgttgccctg tgttatgcaa gttgcaatgc taaagtaggt	4500
gatttttcag atgctaattg gcttttgccc aatttagcag aacattttga cgcagattac	4560
acaaatgcac ttctaagaa gtgtgtgtcg tgcaattgtg gtgttaagag ttatgaactt	4620
aggggtcttg aagcctgtat tcagccagtt cgagcaccta atcttctaca ttttaaaacg	4680
caatattcaa attgcccaac ctgtggtgca agtagtacgg atgaagtaat agaagcttca	4740
ttaccgtact tattgctttt tgcactgat ggtcctgcta cagttgattg tgatgaaaat	4800
gctgtaggga ctgttgtttt cattggctct actaatagtg gccattgtta tacacaagcc	4860
gatggtgaagg cttttgacaa tcttgctaag gatagaaaat ttggaaggaa gtcgccttac	4920
attacagcaa tgtatacacg tttttctctt aggagtgaat atccctact tgttgttgaa	4980
catagtaagg gtaaagctaa agtagtaaaa gaagatgttt ctaaccttgc tactagtctt	5040

-continued

aaagccagtt	ttgacgatct	tactgacttt	gaacagtggt	atgatagcaa	catctatgag	5100
agtcttaaag	tgcaggagac	acctgataat	cttgatgaat	atgtgtcatt	tacgacaaag	5160
gaagattcta	agttgccact	gacacttaaa	gttagaggta	tcaaatcagt	tgttgacttt	5220
aggctaaagg	atggttttac	ttataagtta	acacctgata	ctgatgaaaa	ttcaaaaaca	5280
ccagtctact	accagactct	ggattctatt	agtcttaggg	caatatgggt	tgaaggcagt	5340
gctaattttg	ttgttgggca	tccaaattat	tatagtaagt	ctctccgaat	tcccacgttt	5400
tgggaaaatg	ccgagagctt	tgttaaaatg	ggttataaaa	ttgatgggtg	aactatgggc	5460
ctttggcgtg	cagaacacct	taataaacct	aatttgagga	gaatttttaa	cattgctaag	5520
aaagctattg	ttggatctag	tgttgttact	acgcagtggt	gtaaaatact	agttaaagca	5580
gctacatacg	ttgcogataa	agtaggtgat	ggtgtagttc	gcaatattac	agatagaatt	5640
aaggggtctt	gtggattcac	acgtggccat	tttgaaga	aaatgtccct	acaatttcta	5700
aagacacttg	tgtctttttt	cttttatttc	ttaaaggcta	gtgctaagag	tttagtttct	5760
agctataaga	ttgtgttatg	taagggtgtg	tttgctacct	tacttatagt	gtggtttata	5820
tacacaagta	atccagtagt	gtttactgga	atacgtgtgc	tagacttccct	atttgaagggt	5880
tctttatgtg	gtccttataa	tgactacggt	aaagattctt	ttgatgtgtt	acgctattgt	5940
gcaggtgatt	ttacttgtcg	tgtgtgttta	catgatagag	attcacttca	tctgtacaaa	6000
catgcttata	gcgtagaaca	aattttataag	gatgcagctt	ctggcattaa	ctttaattgg	6060
aattggcttt	atttggctct	tctaataatta	tttgtaagc	cagtggcagg	ttttgttatt	6120
atttgttatt	gtgttaagta	tttggtattg	agttcaactg	tgttgcaaac	tggtgtagggt	6180
tttctagatt	ggtttgtaaa	aacagttttt	accattttta	attttatggg	agcgggattt	6240
tatttctggc	tcttttataa	gatatacgta	caagtgcac	atataattga	ctgtaaggat	6300
gtaacatgtg	aagtgtgcaa	gagagttgca	cgcagcaaca	ggcaagagggt	tagcgttgta	6360
gttggtggac	gcaagcaaat	agtgcagtgt	tacactaatt	ctggctataa	cttttgtaa	6420
agacataatt	ggattgttag	aaattgtgat	gattatgggc	acaaaatac	atttatgtcc	6480
cctgaagttg	ctggcgagct	ttctgaaaag	cttaagcgcc	atgttaaacc	tacagcatat	6540
gcttaccacg	ttgtgtatga	ggcatgctg	gttgatgatt	ttgttaattt	aaaataataag	6600
gttgcaattc	ctggtaagga	taatgcatct	tctgctgtta	agtgtttcag	tgttacagat	6660
tttttaaga	aagctgtttt	tcttaaggag	gcattgaaat	gtgaacaaat	atctaagat	6720
ggttttatag	tgtgtaatac	acagagtgcg	catgcactag	aggaagcaaa	gaatgcagcc	6780
gtctattatg	cgcaatatct	gtgtaagcca	atacttatac	ttgaccaggc	actttatgag	6840
caattaatag	tagagcctgt	gtctaagagt	gttatagata	aagtgtgtag	cattttgtct	6900
aatataatat	ctgtagatac	tgcagcttta	aattataagg	caggcacact	tcgtgatgct	6960
ctgctttcta	ttactaaaga	cgaagaagcc	gtagatatgg	ctatcttctg	ccacaatcat	7020
gaagtggaa	acactgggtga	cggttttact	aatgtgatac	cgtcatatgg	tatggacact	7080
gataagttga	cacctcgtga	tagaggggtt	ttgataaatg	cagatgcttc	tattgcta	7140
ttaaagagta	aaaatgctcc	tccggtagta	tgggaagttt	ctgatcttat	taaatgtct	7200
gacagttgcc	ttaaatat	aatttcagct	actgtcaagt	caggagggtcg	tttctttata	7260
acaaagtcg	gtgctaaaca	agttatttct	gtgcataccc	agaaactgtt	ggtagagaaa	7320
aaggcagggt	gtgttattaa	taacactttt	aaatgggtta	tgagttgttt	taaatggctt	7380
tttgtctttt	atatactttt	tacagcatgt	tgtttgggtt	actactatat	ggagatgaat	7440

-continued

aaaagttttg	ttcacccatt	gtatgatgta	aactccacac	tgcattgtga	agggttcaaa	7500
ggtatagaca	aagggtgttat	tagagagatt	gtgtcagaag	ataattgttt	ctctaataag	7560
tttgtaatt	ttgacgcctt	ttggggtaaa	tcatatgaaa	ataataaaaa	ctgtccaatt	7620
gttacagttg	ttatagatgg	tgacgggaca	gtagctgttg	gtgttcctgg	ttttgtatca	7680
tgggttatgg	atgggtgttat	gtttgtgcat	atgacacaga	ctgatcgtag	accttggtac	7740
attcctacct	ggtttaatat	agaaattgtt	ggttacactc	aggattcaat	tatcactgag	7800
ggtagttttt	atacatctat	agcattattt	tctgctagat	gtttatat	aacagccagc	7860
aatacacctc	aattgtattg	ttttaatggc	gacaatgatg	cacctggagc	cttaccattt	7920
ggtagtatta	ttcctcatag	agtatacttc	caacctaatg	gtgttaggct	tatagttcca	7980
caacaaatag	tgacataacc	ctacatagtg	aagtttggtt	cagacagcta	ttgtagaggt	8040
agtgtatgtg	agtatactaa	accaggttac	tgtgtgtcac	tagactccca	atgggttttg	8100
tttaatgatg	aatacattag	taaacctggc	gttttctgtg	gttctactgt	tagagaactt	8160
atgtttaata	tggttagtac	attctttact	gggtgcaacc	ctaataatta	tattcagcta	8220
gcaactatgt	ttttaatact	agttgttatt	gtgttaattt	ttgcaatggg	tataaagttt	8280
caagggtgtt	ttaaagctta	tgcgaccatt	gtgtttacaa	taatgttagt	ttgggttatt	8340
aatgcatttg	ttttgtgtgt	acatagttat	aatagtgttt	tagctgttat	attattagta	8400
ctctattgct	atgcatcatt	ggttacaagt	cgcaatactg	ctataataat	gcattgttgg	8460
cttggtttta	cctttggttt	aatagtacct	acatgggttg	cttggtgcta	tctgggattt	8520
attctttata	tgtacacacc	gttggttttc	tggtgttacg	gtactactaa	aaatactcgt	8580
aagttgtatg	atggcaacga	gtttgttggg	aattatgacc	ttgctgcgaa	gagcactttt	8640
gttattcgtg	gtactgaatt	tgttaagctt	acgaatgaga	taggtgataa	atttgaagcc	8700
tatctttctg	cgtatgctag	acttaaatag	tattcaggca	ctggtagtga	gcaagattac	8760
ttgcaagctt	gtcgtgcatg	gttagcttat	gctttggacc	aatatagaaa	tagtggtgtt	8820
gaggtgtgtt	ataccccacc	gcgttactct	attggtgtta	gtagactaca	cgctgggttt	8880
aaaaaactag	tttctcctag	tagtgctgtt	gagaagtgca	ttgttagtgt	ctcttataga	8940
ggcaataatc	ttaatggact	gtggctgggt	gattctat	actgccacg	ccatgtgtta	9000
ggtaagttaa	gtgggtgacca	gtgggtgtgac	gtactaaacc	ttgctaataa	tcattgagttt	9060
gaagttgtaa	ctcaaatagg	tgttactttg	aatgttgtca	gcaggcgggt	taaaggagca	9120
gttttaattt	tacaaactgc	agttgccaat	gctgaaactc	ctaagtataa	gtttgttaaa	9180
gctaattgtg	gtgatagttt	cactatagct	tgttcttatg	gtggtacagt	tataggactt	9240
tacctgtgca	ctatgcgttc	taatggtact	attagagcat	cttctcctagc	aggagcctgt	9300
ggctcagttg	gttttaatat	agaaaagggt	gtagttaatt	tcttttatat	gcaccatctt	9360
gagttaccta	atgcattaca	cactggaact	gacctaatgg	gtgagtttta	tggtggttat	9420
gtagatgaag	aggttgcgca	aagagtgcga	ccagataatc	tagttactaa	caatattgta	9480
gcatggctct	atgcggcaat	tattagtgtt	aaagaaagta	gtttttcaca	acctaaatgg	9540
ttggagagta	ctactgtttc	tattgaagat	tacaataggt	gggctagtga	taatggtttt	9600
actccatttt	ccactagtac	tgctattact	aaattaagtg	ctataactgg	ggttgatgtt	9660
tgtaaaactc	ttcgacttat	tatggtaaaa	agtgctcaat	ggggtagtga	tcccatttta	9720
ggacaatata	attttgaaga	cgaattgaca	ccagaatctg	tatttaataca	agttggtggt	9780

-continued

gttaggttac	agtcttcttt	tgtaaagaaa	gctacatctt	ggttttggag	tagatgtgta	9840
ttagcttgct	tcttggttgt	gttggtgct	attgtcttat	ttacggcagt	gccacttaag	9900
ttttatgtac	atgcagctgt	tattttgttg	atggctgtgc	tcctttatttc	ttttactgtt	9960
aaacatgtta	tggcatacat	ggacactttc	ctattgccta	cattgattac	agttattatt	10020
ggagtttggtg	ctgaagtcct	tttcatatac	aatactctaa	ttagtcaagt	tgttattttc	10080
ttaagccaat	ggtatgatcc	tgtagtcttt	gatactatgg	taccatggat	gttattgcca	10140
ttagtggtgt	acactgcttt	taagtgtgta	caaggctgct	atatgaattc	tttcaatact	10200
tccttggttaa	tgctgtatca	gtttatgaag	ttaggttttg	ttattttcac	ctcttcaaac	10260
actcttactg	catatacaga	aggtaattgg	gagttattct	ttgagttggg	tcacactatt	10320
gtgttggtcta	atgtagtag	taattcctta	attggtttta	ttgtttttta	gtgtgctaag	10380
tggattttat	attattgcaa	tgcaacatac	tttaataatt	atgtgttaat	ggcagtcagt	10440
gttaatggca	taggttggt	ttgcacctgt	tactttggat	tgtattgggtg	ggtaataaaa	10500
gtttttggtt	taaccttagg	taaatacaat	tttaaagttt	cagtagatca	atataggtat	10560
atgtgtttgc	ataaggtaaa	tccacctaaa	actgtgtggg	aggtctttac	tacaaatata	10620
cttatacaag	gaattggagg	cgatcgtgtg	ttgcctatag	ctacagtgca	atctaaattg	10680
agtgatgtaa	agtgatcaac	tgtgttttta	atgcagcttt	tgactaagct	taatgttgaa	10740
gcaaattcaa	aaatgcctgc	ttatcttggt	gagttacaca	ataaaatcct	cgcactctgat	10800
gatgttggtg	agtgcatgga	taattttattg	ggtatgctta	taacactatt	ttgtatagat	10860
tctactattg	atttgggtga	gtatttgtgat	gatatactta	agaggtcaac	tgtattacaa	10920
tcggttactc	aagagttttc	gcacatcccc	tcgtatgctg	aatatgaaa	agctaagagt	10980
atztatgaaa	aggttttagc	cgattctaaa	aatggtgggtg	taacacagca	agagcttgct	11040
gcatacgta	aagctgcaa	tattgcaaag	tcagtttttg	atagagactt	ggctgttcaa	11100
aagaagttag	atagcatggc	agaacgtgct	atgacaacaa	tgtataaaga	ggcgcgtgta	11160
actgatagaa	gagcaaaatt	agtttcatca	ttacatgcac	tacttttttc	aatgcttaag	11220
aaaatagatt	ctgagaagct	taatgtctta	tttgaccagg	cgaatagtgg	tgttgtacct	11280
ctagcaactg	ttccaattgt	ttgtagtaat	aagcttacct	ttgttatacc	agaccagag	11340
acgtgggtca	agtggtgga	gggtgtgcat	gttacatatt	caacagttgt	ttggaatata	11400
gactgtgtta	ctgatgccga	tggcacagag	ttacacccca	cttctacagg	tagtggttg	11460
acttactgta	taagtgtgta	taatatagca	tggcctttta	aggtttaact	gactaggaat	11520
gggcataata	aggttgatgt	tgccttgcaa	aataatgagc	ttatgcctca	cgggtgtaaa	11580
acaaaggctt	gcgtagcagg	tgtagatcaa	gcacattgta	gcgttgagtc	taaatgttat	11640
tatacaagta	ttagtgccag	ttcagttgta	gctgctatta	cctcttcaaa	tcctaactctg	11700
aaagtagcct	cttttttgaa	tgaggcaggt	aatcagattt	atgtagactt	agaccacca	11760
tgtaaatttg	gtatgaaagt	gggtgataag	gttgaagttg	ttacctgta	ttttataaaa	11820
aatacgaggt	ctattgtaag	aggtatggta	cttggtgcta	tatctaattg	tgttgtgtta	11880
caatctaaag	gtcatgagac	agaggaagtg	gatgctgtag	gcattctctc	actttgttct	11940
tttgagtag	atcctgcgga	tacatattgt	aaatatgtgg	cagcaggtaa	tcaaccttta	12000
ggtaactgtg	ttaaaatgtt	gacagtacat	aatggtagtgt	gttttgcaat	aacatcaaa	12060
ccaagtccaa	ctccggatca	ggattcttat	ggaggagctt	ctgtgtgtct	ttattgtaga	12120
gcacatatag	cacacctg	cggagcagga	aatttagatg	gacgtgtca	atttaaaggt	12180

-continued

```

tcttttgtgc aaatacctac tacggagaaa gatcctgttg gattctgtct acgtaacaag 12240
gtttgcaactg tttgtcagtg ttggattggt tatggatgtc agtgtgattc acttagacaa 12300
cctaaacctt ctgttcagtc agttgtctgt gcactctggt ttgataagaa ttattttaac 12360
gggtacgggg tagcagttag gctcggctga taccctagc taatggatgt gaccccgatg 12420
ttgtaaagcg agcctttgat gtttgaata aggaatcagc cggtatgttt caaaatttga 12480
agcgtaactg tgcacgattc caagaagtag gtgatactga agatggaaat cttgagtatt 12540
gtgattctta ttttgggtt aaacaaacca ctctagtaga ttatgaacat gagaaagctt 12600
gttatgaaga cttaaagtc gaagtaacag ctgatcatga tttctttgtg ttcaataaga 12660
acatttataa tatttagtagg cagaggctta ctaagtatac tatgatggat ttttgctatg 12720
ctttgcggca ctttgaccca aaggattgag aagttcttaa agaaatactt gtcacttatg 12780
gttgtataga agattatcac cctaagtggt ttgaagagaa taaggattgg tacgacccaa 12840
tagaaaacc taaatattat gccatgttgg ctaaaatggg acctattgta cgacgtgctt 12900
tattgaatgc tattgagtc ggaacacctc tgggtgaaaa aggttatgtt ggtgttatta 12960
cacttgataa ccaagatctt aatggcaaat tttatgattt tgggtatttt cagaagacag 13020
cgcttggtgc tgggttctct gtttttgata cgtattatct ttacatgatg cccatcatag 13080
ccatgactga tgcgttgga cctgagaggt attttgaata tgatgtgcat aagggttata 13140
aatcttatga tctcctcaag tatgattata ctgaggagaa acaagatttg ttcagaagt 13200
actttaagta ttgggatcaa gagtatcacc ctaactgtcg cgactgtagt gatgacaggt 13260
gtttgataca ttgtgcaaac ttcaacatct tgttttctac acttgtagcg cagacttctt 13320
tcggtaatth gtgtgaaaag gtttttgttg atggtgtacc atttatagct acttgtggct 13380
atcattctaa ggaacttggg gttattatga atcaagataa caccatgtca ttttcaaaaa 13440
tgggttttag tcaactcatg cagtttgttg gagatcctgc cttgttagtg gggacatcca 13500
ataaattagt ggatcttaga acgtcttggt ttagtggttg tgcttttagcg tctggtatta 13560
ctcatcaaac ggtaaaacca ggtcacttta acaaggattt ctacgatttt gcagagaagg 13620
ctggtatggt taaggaagggt tctctatata cacttaaaaa tttcttctac ccacagactg 13680
gtaatgctgc tataaacgat tatgattatt atcgttataa caggcctacc atgtttgata 13740
tacgtcaact tttattttgt ttagaagtga cttctaaata ttttgaatgt tatgaaggcg 13800
gtgtgatacc agcaagccaa gttgtagtta acaatttaga taagagtga gggtatccgt 13860
tcaataagtt tggaaggcc cgtctctatt atgaaatgag tctagaggag caggaccaac 13920
tctttgagag tacaagaag aacgtcctgc ctactataac tcagatgaat ttaaaatatg 13980
ccatattccg gaaaaataga gcgcgtacag tggcaggtgt gtctatcctt tctactatga 14040
ctaataggca gtttcatcag aagattctta agtctatagt caacactaga aacgctcctg 14100
tagttattgg aacaaccaag ttttatggcg gttgggataa catgttgaga aaccttattc 14160
aggggtgtga agaccgatt cttatgggtt gggattatcc aaagtgtgat agagcaatgc 14220
ctaatttgtt gcgtatagca gcactcttag tactcgctcg taaacacact aattgttgta 14280
cttggtctga acgcgtttat aggttggtata atgaatgcgc tcagggttta tctgaaactg 14340
tcttagctac aggtgggtata tatgtgaaac ctggtggtag tagcagtga gatgctacta 14400
ctgcttatgc aaacagtgtt ttcaacataa tacaagccac atctgcta atgtgcgcgtc 14460
ttttgaggtg tataacgcgt gatattgtat atgatgacat taagagcttg cagtatgaat 14520

```

-continued

tgtaccagca	ggtttatagg	cgagtcaatt	ttgaccacgc	attgttgtaa	aagttttatt	14580
cttattttgtg	taagaatttc	tcattgatga	tcttgtctga	cgacgggtgt	gtttgttata	14640
acaacacatt	agccaaacaa	ggctctgtag	cagatatttc	tggttttaga	gaagttctct	14700
actatcagaa	caatgttttt	atggctgatt	ctaaatgttg	ggttgaacca	gatttagaaa	14760
aaggccacac	tgaattttgt	tcacagcaca	caatgttagt	ggaggttgat	ggtgagccta	14820
gatacttgcc	atatocagac	ccatcacgta	ttttgtgtgc	atgtgttttt	gtagatgatt	14880
tggataagac	agaatctgtg	gctgttatgg	agcgttatat	cgctcttgcc	atagatgcgt	14940
accactagt	acatcatgaa	aatgaggagt	acaagaaggt	attctttgtg	cttctttcat	15000
acatcagaaa	actctatcaa	gagctttctc	agaatatgct	tatggactac	tcttttgtaa	15060
tggatataga	taagggtagt	aaattttggg	aacaggagtt	ctatgaaaat	atgtatagag	15120
ccctacaac	attacagtct	tgtggcggtt	gtgtagtgtg	taatagtaa	actatattgc	15180
gctgtggtaa	ttgtattcgc	aaaccatttt	tgtgttgtaa	gtgttctat	gacctgtca	15240
tgcacacaga	ccacaaaaat	gttttgtcta	taaatcctta	catttgctca	cagccagggt	15300
gtggtgaagc	agatgttact	aaattgtacc	tcggagggtat	gtcactcttc	tgccgtaatc	15360
ataaacacaa	gttatcaata	cgttagtat	ctaattgtac	agtggttgga	atttacaggg	15420
ctaattgtgc	aggtagcgaa	aattgtgatg	attttaatca	actagctact	actaattggt	15480
ctactgtgga	accttatatt	ttggcaaatc	gttgtgtaga	tcgttgaga	cgctttgctg	15540
cagagacagt	aaaagctaca	gaagaattac	ataagcaaca	atttgctagt	gcagaagtga	15600
gagaagtact	ctcagatcgt	gaattgattc	tgtcttgga	gccaggtaaa	accaggcttc	15660
cattgaatag	aaattatggt	ttcactggct	ttcactttac	tagaactagt	aaagttcagc	15720
tcggtgattt	tacatttgaa	aaagggtgaag	gtaaggacgt	tgtctattat	cgagcgacgt	15780
ctactgctaa	attgtctggt	ggagacattt	ttgttttaac	ctcacacaat	gttgtttctc	15840
ttatagcgcc	aacgttgtgt	cctcagcaaa	ccttttctag	gtttgtgaat	ttaagacctc	15900
atgtgatggt	acctgcgtgt	tttgtaaata	acattccatt	gtaccattta	gtaggcaagc	15960
agaagcgtac	tacagtacaa	ggccctcctg	gcagtggtaa	atcccatttt	gctataggat	16020
tggcggtcta	ctttagtaac	gcccggtcgc	tttttactgc	atgctctcat	gcagctggtg	16080
atgctttatg	tgaaaaagct	tttaagtctc	ttaaagtaga	tgattgcact	cgtatagtag	16140
ctcaaaggac	tactatcgat	tgcttctcta	agtttaagc	taatgacaca	ggcaaaaagt	16200
acatttttag	tactattaat	gccttgccag	aagtttagtg	tgacattctt	ttggttgacg	16260
aggtagtat	gttgaccaat	tacgaattgt	cttttattaa	tggttaagata	aactatcaat	16320
atgttgtgta	tgtagggtgat	cctgctcaat	taccggcgcc	tcgtacgttg	cttaacgggt	16380
cactctctcc	aaaggattat	aatgttgtca	caaaccttat	ggtttgtgtt	aaacctgaca	16440
ttttccttgc	aaagtgttac	cgttgtccta	aagaaattgt	agatactgtt	tctactcttg	16500
tatatgatgg	aaagtttatt	gcaaataacc	cggaatcacg	tcagtgtttc	aaggttatag	16560
ttaataatgg	taattctgat	gtaggacatg	aaagtggctc	agcctacaac	ataactcaat	16620
tagaatttgt	gaaagatttt	gtctgtcgca	ataaggaatg	gcgggaagca	acattcattt	16680
caccttataa	tgctatgaac	cagagagcct	accgtatgct	tggaactaat	gttcagacag	16740
tagactcgtc	tcaagggttcg	gagtatgatt	atgttatctt	ttgtgttact	gcagattcgc	16800
agcatgcact	gaatattaac	agattcaatg	tagcgttac	aagagccaag	cgtggtatac	16860
tagttgtcat	gcgtcagcgt	gatgaactat	attcagctct	taagtttata	gagcttgata	16920

-continued

gtgtagcaag	tctgcaaggt	acaggcttgt	ttaaaatttg	caacaaagag	tttagtggtg	16980
ttcaccacgc	ttatgcagtc	acaactaagg	ctcttgctgc	aacttataaa	gttaatgatg	17040
aacttgctgc	acttgtaaac	gtggaagctg	gttcagaaat	aacatataaa	catcttattt	17100
ctttgttagg	gtttaagatg	agtgtaaatg	ttgaaggctg	ccacaacatg	tttataaacac	17160
gtgatgaggc	tatccgcaac	gtaagagggt	gggtagggtt	tgatgtagaa	gcaacacatg	17220
cttgccgtac	taacattggg	actaacctgc	ctttccaagt	aggtttctct	actgggtgcag	17280
actttgtagt	tacgcctgag	ggacttgtag	atacttcaat	aggcaataat	tttgagcctg	17340
tgaattctaa	agcacctcca	ggtgaacaat	ttaatcactt	gagagcggtta	ttcaaaagtg	17400
ctaaaccttg	gcattgttga	aggccaagga	ttgtgcaaat	gttagcggat	aacctgtgca	17460
acgtttcaga	ttgtgtagtg	ttgtcacgt	ggtgtcatgg	cctagaacta	accactttgc	17520
gctattttgt	taaaaatagg	aaggaccaag	ttgttcttg	cggttctaga	gcaacaactt	17580
ttaattctca	tactcaggct	tatgcttgtt	ggaagcattg	cttgggtttt	gattttgttt	17640
ataatccact	cttagtggat	attcaacagt	gggtttatct	tggtaaccta	caatttaacc	17700
atgatttgca	ttgtaatgtg	catggacacg	cacatgtagc	ttctgcggat	gctattatga	17760
cgcgttgtct	tgcaattaat	aatgcatttt	gtcaagatgt	caactgggat	ttaacttacc	17820
ctcatatagc	aatgagggat	gaagtcaatt	ctagctgtag	atattttaca	cgcatgtatc	17880
ttaatgcatg	tggtgatgct	cttaaagtta	acgttgtcta	tgatataggc	aaccctaaag	17940
gtataaaatg	tgtagacgt	ggagacttaa	atttttagatt	ctatgataag	aatccaatag	18000
taccaaatgt	caagcagttt	gagtatgact	ataatcagca	caaagataag	ttgtctgatg	18060
gtctttgtat	gttttggaat	tgtaatgtgg	attgttatcc	cgacaattcc	ttagtttgta	18120
ggtacgacac	acgaaatttg	agtggttcta	acctacctgg	ttgtaatggt	ggtagcttgt	18180
atgttaacaa	gcattgcattc	cacacacctc	aatttgatcg	cactagcttt	cgtaatttga	18240
aagctatgcc	attctttttc	tatgactcat	cgccttgcca	gaccattcaa	ttggatggag	18300
ttgcgcaaga	ccttggtgca	ttagctacga	aagattgtat	cacaaaatgc	aacataggcg	18360
gtgctgtttg	taaaaagcac	gcacaaatgt	atgcagattt	tgtgacttct	tataatgcag	18420
ctgttactgc	tggttttact	ttttgggtta	ctaataattt	taaccatata	aatttggtga	18480
aaagtttttc	agctctccag	tctatcgaca	atattgctta	taatatgtat	aagggtgggtc	18540
attatgatgc	tattgcagga	gaaatgccca	ctatcgtaac	tgagataaaa	gtttttgtta	18600
tagatcaagg	cgtagaaaaa	gcagtttttt	ttaatcaaac	aattctgcct	acatctgtag	18660
cgtttgagct	gtatgcgaag	agaaatattc	gcacactgcc	aaacaaccgt	attttgaaag	18720
gtttgggtgt	agatgtgact	aatggatttg	taatttgga	ttacacgaac	caaacaccac	18780
tataccgtaa	tactgttaag	gtatgtgcat	atacagacat	agaaccaa	ggcctaatag	18840
tgctgtatga	tgatagatat	ggtgattacc	agtcctttct	agctgctgat	aatgctgttt	18900
tagtttctac	acagtgttac	aagcgggtatt	cgtatgtaga	aataccgtca	aacctgcttg	18960
ttcagaacgg	tattccgtta	aaagatggag	cgaacctgta	tgttttataag	cgtgttaatg	19020
gtgcgtttgt	tacgtacct	aacacattaa	acacacaggg	tcgcagttat	gaaacttttg	19080
aacctcgtag	tgatgttgag	cgtgattttc	tcgacatgtc	tgaggagagt	ttttagaaa	19140
agtatggtaa	agaattaggt	ctacagcaca	tactgtatgg	tgaagttgat	aagccccaat	19200
taggtgggtt	acacactggt	ataggatatgt	gcagactttt	acgtgcgaat	aagttgaacg	19260

-continued

caaagtcctgt	tactaattct	gattctgatg	tcatgcaaaa	ttattttgta	tggcagaca	19320
atgggtccta	caagcaagtg	tgtactgttg	tggatttgct	gcttgatgat	ttcttagaac	19380
ttcttaggaa	catactgaaa	gagtatggta	ctaataagtc	taaagttgta	acagtgtaa	19440
ttgattacca	tagcataaat	tttatgactt	ggtttgaaga	tggcattatt	aaaacatgtt	19500
atccacagct	tcaatcagca	tggacgtgtg	gttataatat	gcctgaactt	tataaagttc	19560
agaatttgtg	tatggaacct	tgcaacattc	ctaattatgg	tgttgaata	gcgttgccaa	19620
gtggtattat	gatgaatgtg	gcaaagtata	cacaactctg	tcaatacctt	tcgaaaacaa	19680
caatgtgtgt	accgcataat	atgcgagtaa	tgcatttttg	agctggaagt	gacaaaggag	19740
tggctccagg	tagtactgtt	cttaaacaa	ggctcccaga	agggacactc	ctgtcgata	19800
atgatattgt	agactatgtg	tctgatgcac	atgtttctgt	gctttcagat	tgcaataaat	19860
ataagacaga	gcacaagttt	gatcttgtga	tatctgatat	gtatacagac	aatgattcaa	19920
aaagaaagca	tgaaggcgtg	atagccaata	atggcaatga	tgacgttttc	atatatctct	19980
caagttttct	tcgtaataat	ttggctctag	gtggtagttt	tgctgtaaaa	gtgacagaga	20040
caagtggcga	cgaagtttta	tatgacattg	cacaggattg	tgcattggtg	acaatgtttt	20100
gtacagcagt	gaatgcctct	tcttcagaag	cattcttggt	tggtgttaat	tatttgggtg	20160
caagtgaaaa	ggtaaggtt	agtggaaaa	cgctgcacgc	aaattatata	tttggagga	20220
attgtaatta	tttcaaaacc	tctgcttata	gtataattga	cgttgctaag	tttgatttga	20280
gattgaaagc	aacaccagtt	gttaatttga	aaactgaaca	aaagacagac	ttagtcttta	20340
atttaattaa	gtgtggtaag	ttactggtaa	gagatgttgg	taacacctct	tttactagt	20400
actcttttgt	gtgtactatg	tagtgctgct	ttgtatgaca	gtagtcttta	cgtttactac	20460
taccaaagtg	ccttttagacc	acctaaggt	tggcatttac	acgggggtgc	ttatgcggta	20520
gttaatattt	ctagcgaatc	taataatgca	ggctcttcac	ctgggtgtat	tgttggtact	20580
attcatggtg	gtcgtgttgt	taatgcttct	tctatagcta	tgacggcacc	gtcatcaggt	20640
atggcttggt	ctagcagtc	gttttgtact	gcacactgta	acttttcaga	tactacagt	20700
tttgttacac	attgttataa	atatgatggg	tgctctataa	ctggcatgct	tcaaaagaat	20760
tttttacgtg	tttctgctat	gaaaaatggc	cagcttttct	ataatttaac	agttagtgt	20820
gctaagtacc	ctacttttaa	atcatttcag	tgtgttaata	atttaacatc	cgtatattta	20880
aatggtgac	ttgtttacac	ctctaagag	accacagatg	ttacatctgc	aggtgtttat	20940
tttaaagctg	gtggacatat	aacttataaa	gttatgagag	aagttaaagc	cctggcttat	21000
tttgtaaatg	gtactgcaca	agatgttatt	ttgtgtgatg	gatcacctag	aggcttggt	21060
gcatgccagt	ataaacttg	caatttttca	gatggctttt	atccttttat	taatagtagt	21120
ttagttaagc	agaagtttat	tgtctatcgt	gaaaatagtg	ttaatactac	ttttacgtta	21180
cacaatttca	cttttcataa	tgagactggc	gccaaacctc	atcctagtg	tggtcagaat	21240
attcaaaact	accaaacaca	aacagctcag	agtggttatt	ataattttaa	tttttccttt	21300
ctgagtagtt	ttgtttataa	ggagtcta	tttatgtatg	gatcttatca	cccaagttgt	21360
aatttttagac	tagaaactat	taataatggc	ttgtggttta	attcactttc	agtttcaatt	21420
gcttacggtc	ctcttcaagg	tggttgcaag	caatctgtct	ttagtggtag	agcaacttgt	21480
tgttatgctt	attcatatgg	aggctcttcg	ctgtgtaaag	gtgtttatc	aggtgagtta	21540
gatcttaatt	ttgaatgtgg	actgttagtt	tatgttacta	agagcgggtg	ctctcgata	21600
caaacagcca	ctgaaccgcc	agttataact	cgacacaatt	ataataatat	tacttttaat	21660

-continued

acttggttg	attataatat	atatggcaga	actggccaag	gttttattac	taatgtaacc	21720
gactcagctg	ttagttataa	ttatctagca	gacgcaggtt	tggetatttt	agatacatct	21780
ggttccatag	acatctttgt	tgtacaaggt	gaatatggtc	ttacttatta	taaggttaac	21840
ccttgogaag	atgtcaacca	gcagtttgta	gtttctgggtg	gtaaattagt	aggtattctt	21900
acttcacgta	atgagactgg	ttctcagctt	cttgagaacc	agttttacat	taaaatcact	21960
aatggaacac	gtcgtttttag	acgttctatt	actgaaaatg	ttgcaaattg	cccttatgtt	22020
agttatggta	agttttgtat	aaaacctgat	ggttcaattg	ccacaatagt	accaaaca	22080
ttggaacagt	ttgtggcacc	ttacttaat	gttactgaaa	atgtgctcat	acctaacagt	22140
tttaatttaa	ctgttacaga	tgagtacata	caaacgcgta	tggataaggt	ccaaattaat	22200
tgtctgcagt	atgtttgtgg	caattctctg	gattgtagag	atgtgtttca	acaatatggg	22260
cctgtttgtg	acaacatatt	gtctgtagta	aatagtattg	gtcaaaaaga	agatatggaa	22320
cttttgaatt	tctattcttc	tactaaaccg	gctggtttta	atacaccatt	tcttagtaat	22380
gtagcactg	gtgagtttaa	tatttctctt	ctgttaacaa	ctctagtag	tctagaagg	22440
cgttctttta	ttgaagacct	tctatttaca	agcgttgaat	ctgttggtt	accaacagat	22500
gacgcataca	aaaattgcac	tgacggacct	ttaggttttc	ttaaggacct	tgctgtgct	22560
cgtgaatata	atggtttgct	tgtgttgctt	cccattataa	cagcagaaat	gcaaattttg	22620
tatactagtt	ctctagtagc	ttctatggct	tttggtggta	ttactgcagc	tggtgctata	22680
ccttttgcca	cacaactgca	ggctagaatt	aatcacttgg	gtattaccca	gtcacttttg	22740
ttgaagaatc	aagaaaaaat	tgtgcttcc	tttaataagg	ccattggctg	tatgcaggaa	22800
ggttttagaa	gtacatctct	agcattacaa	caaattcaag	atgttggtta	taagcagagt	22860
gctattctta	ctgagactat	ggcatcactt	aataaaaaat	ttggtgctat	ttcttctatg	22920
attcaagaaa	tctaccagca	acttgacgcc	atacaagcaa	atgctcaagt	ggatcgtctt	22980
ataactggta	gattgtcatc	actttctggt	ttagcatctg	ctaagcaggc	ggagcatatt	23040
agagtgtcac	aacagcgtga	gttagctact	cagaaaatta	atgagtgtgt	taagtcacag	23100
tctattagggt	actccttttg	tggtaatgga	cgacatgttc	taaccatacc	gcaaatgca	23160
cctaattggta	tagtgtttat	acacttttct	tatactccag	atagttttgt	taatgttact	23220
gcaatagtgg	gtttttgtgt	aaagccagct	aatgctatgc	agtatgcaat	agtaccgct	23280
aatggtagggt	gtatttttat	acaagttaat	ggtagttaact	acatcacagc	acgagatatg	23340
tatatgcaa	gagctattac	tgacggagat	atagttacgc	ttacttcttg	tcaagcaaat	23400
tatgtaagt	taaataagac	cgctcattact	acattcgtag	acaatgatga	ttttgatttt	23460
aatgacgaat	tgtcaaaatg	gtggaatgac	actaagcatg	agctaccaga	ctttgacaaa	23520
ttcaattaca	cagtacctat	acttgacatt	gatagtga	ttgatcgtat	tcaaggcgtt	23580
atacagggtc	ttaatgactc	tttaatagac	cttgaaaaac	tttcaatact	caaaacttat	23640
attaagtggc	cttggtatgt	gtgggttagcc	atagcttttg	ccactattat	cttcacttta	23700
atactaggat	gggttttctt	catgactgga	tgttggtggt	gttggtgtgg	atgctttggc	23760
attatgcctc	taatgagtaa	gtgtggtaag	aaatcttctt	attacacgac	ttttgataac	23820
gatgtggtaa	cttaacaata	cagacctaaa	aagtctgttt	aatgattcaa	agtcccacgt	23880
ccttccta	agtattaatt	ttcttttggt	gtaaacttgt	actaagtgtg	tttagagagt	23940
ttattatagc	gctccaaaca	ctaatacaag	ttttactcca	aattatcaat	agtaacttac	24000

-continued

agcctagact gaccctttgt cacagtctag actaatgtta aacttagaag caattattga	24060
aactggtgag caagtgtatc aaaaaatcag tttcaattta cagcatattt caagtgtatt	24120
aaacacagaa gtatttgacc cctttgacta ttgttattac agaggaggta atttttggga	24180
aatagagtca gctgaagatt gttcagggtga tgatgaattt attgaataag tcgctagagg	24240
aaaatggaag ttttctaaca gcgctttata tattttagg atttttagca ctttatcttc	24300
taggttagagc acttcaagca ttgtacagg ctgctgatgc ttgttgttta ttttggata	24360
catgggtagt aattccagga gctaagggtga cagcctttgt atataagtat acatatggta	24420
gaaaacttaa caatccggaa ttagaagcag ttattgtcaa cgagtttctt aagaacgggt	24480
ggaataataa aaatccagca aattttcaag atgtccaacg agacaaattg tactcttgac	24540
tttgaacagt cagttgagct ttttaaagag tataatttat ttataactgc attcttggtg	24600
ttcttaacca taactactca gtatggctat gcaacaagaa gtaagtttat ttatatactg	24660
aaaatgatag tgttatgggtg cttttggccc cttaacattg cagtaggtgt aatttcatgt	24720
atataccac caaacacagg aggtcttgtc gcagcgataa tacttacagt gtttgcgtgt	24780
ctgtcttttg taggttattg gatccagagt attagactct ttaagcgggtg taggtcatgg	24840
tggtcattta acccagaatc taatgccgtg ggttcaatac tcctaactaa tggccaacaa	24900
tgtaattttg ctatagagag tgtgccaatg gtgctttctc caattataaa gaatggtgtt	24960
ctttattgtg agggctcagtg gcttgctaag tgtgaaccag accacttgcc taaagatata	25020
tttgtttgta caccggatag acgtaatatc taccgtatgg tgcagaaata tactggtgac	25080
caaagcggaa ataagaaacg gtttgctacg tttgtctatg caaagcagtc agtagatact	25140
ggcgagctag aaagtgtagc aacaggaggg agtagtcttt acacctaaat gtgtgtgtgt	25200
agagagtatt taaaattatt ctttaatagt gcctctattt taagagcgca taatagtatt	25260
atttttgagg atattaatat aaatcctctc tgttttatac tctcttttca agagctatta	25320
tttaaaaaac agtttttcca ctcttttgtg ccaaaaaacta ttgttgtaa tgggtgaacc	25380
tttcaagtag ataatggaaa agtctactac gaaggaaaac caatttttca gaaaggttgt	25440
tgtaggttgt ggttgagtta taaaaaagat taaactacct actacactta tttttataag	25500
aggcgtttta tcttacaagc gcttaataaa tacggacgat gaaatggctg actagttttg	25560
taagggcagt tatttcatgt tataaacccc tattattaac tcaattaaga gtattagata	25620
ggtaaatctt agatcatgga ccaaaacaca tcttaacgtg tgtaggtgc gtgattttgt	25680
ttcaattaga tttagtttat aggttggcgt atacgcctac tcaatcgctg gtatgaataa	25740
tagtaaagat aatccttttt gcggagcaat agcaagaaaa gcgcgaattt atctgagaga	25800
aggattagat tgtgtttact ttcttaacaa agcaggacaa gcagagtctt gtcccgcgtg	25860
tacctctcta gtattccagg ggaacttg tgaggaacac aaatataata ataactcttt	25920
gtcatggcaa gcggttaaggc aactggaaag acagatgccc cagctccagt catcaaaacta	25980
ggaggaccaa agccacctaa agttggttct tctggaatg tatcttggtt tcaagcaata	26040
aaagccaaga agttaaatc acctccgcct aagtttgaag gtagcggtgt tcctgataat	26100
gaaaatctaa aaccaagtca gcagcatgga tattggagac gccaagctag gtttaagcca	26160
ggtaaagggtg gaagaaaacc agtcccagat gcttggtatt tttactatac tggaacagga	26220
ccagccgcta acctgaattg gggtagatgc caagatggta tagtgggtg tgctggtgaag	26280
ggtgctgata ctaaatntag atctaactag ggtactcgtg actctgacaa gtttgaccaa	26340
tatccgctac gggtttcaga cggaggacct gatggtaatt tccgttgga tttcattcct	26400

-continued

```

ctgaatcgtg gcaggagtgg gagatcaaca gcagcttcat cagcagcatc tagtagagca 26460
ccatcacgtg aagtttcgcg tggtcgcagg agtggttctg aagatgatct tattgctcgt 26520
gcagcaagga taattcagga tcagcagaag aagggttctc gcattacaaa ggctaaggct 26580
gatgaaatgg ctacccgcgc gtattgcaag cgcactattc cacctaatta taaggttgat 26640
caagtgtttg gtccccgtac taaaggttaag gagggaaatt ttggtgatga caagatgaat 26700
gaggaaggtg ttaaggatgg gcgcggtaca gcaatgctca acctagttcc tagcagccat 26760
gcttggtcttt tcggaagtag agtgacgccc agacttcaac cagatgggct gcacttgaaa 26820
tttgaattta ctactgtggt cccacgtgat gatccgcagt ttgataatta tgtaaaaatt 26880
tgtgatcagt gtgttgatgg tgtaggaaca cgtccaaaag atgatgaacc aagaccaaag 26940
tcacgctcaa gttcaagacc tgcaacaaga ggaaattctc cagcgccaag acagcagcgc 27000
cctaagaagg agaaaaagcc aaagaagcag gatgatgaag tggataaagc attgacctca 27060
gatgaggaga ggaacaatgc acagctggaa ttgatgatg aaccaaggt aattaactgg 27120
ggggattcag ccctaggaga gaatgaactt tgagtaaaat tcaatagtaa gagttaagga 27180
agataggcat gtagcttgat tacctacatg tctatcgcca gggaaatgct taatttgtct 27240
acttagtagc ctggaaaacga acggtagacc cttagatttt aatttagttt aatttttagt 27300
ttagtttaag ttagtttaga gtaggtataa agatgccagt gccggggcca cgcggagtac 27360
gaccgagggc acagcactag gacgcccatt aggggaagag ctaaatttta gtttaagtta 27420
agttaattg gctatgtata gttaaaattt ataggctagt atagagttag agcaaaaaaa 27480
aaaaaaaaa aaaaaaaaaa 27500

```

```

<210> SEQ ID NO 2
<211> LENGTH: 435
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus

```

```

<400> SEQUENCE: 2

```

```

tctaaagtc atgagacaga ggaagtggat gctgtaggca ttctctcact ttgttctttt 60
gcagtagatc ctgcggatac atattgtaaa tatgtggcag caggtaatca accttttagt 120
aactgtgtta aaatgttgac agtacataat gtagtggtt ttgcaataac atcaaagcca 180
agtccaactc cggatcagga ttcttatgga ggagcttctg tgtgtcttta ttgtagagca 240
catatagcac accttgccgg agcaggaaat ttagatggac gctgtcaatt taaaggttct 300
tttgtgcaaa tacctactac ggagaaagat cctgttggat tctgtctacg taacaagggt 360
tgcaactgtt gtcagtgttg gatttggtat ggatgtcagt gtgattcact tagacaacct 420
aaaccttctg ttcag 435

```

```

<210> SEQ ID NO 3
<211> LENGTH: 1563
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus

```

```

<400> SEQUENCE: 3

```

```

ggtacaggct tgtttaaaat ttgcaacaaa gagtttagtg gtgttcaccc agcttatgca 60
gtcacaacta aggctcttgc tgcaacttat aaagttaatg atgaacttgc tgcacttgtt 120
aacgtggaag ctggttcaga aataacatat aaacatctta tttctttgtt agggtttaag 180
atgagtggtt atgttgaagg ctgccacaac atgtttataa cagtgatga ggctatccgc 240

```

-continued

aacgtaagag gttgggtagg tttgatgta gaagcaacac atgcttgccg tactaacatt	300
ggtactaacc tgcctttcca agtaggttc tctactggtg cagactttgt agttacgcct	360
gagggacttg tagatacttc aataggcaat aattttgagc ctgtgaattc taaagcacct	420
ccaggtgaac aatttaatca cttgagagcg ttattcaaaa gtgctaaacc ttggcatgtt	480
gtaaggccaa ggattgtgca aatggttagcg gataacctgt gcaacgttc agattgtgta	540
gtgtttgtca cgtgggtgca tggcctagaa ctaaccactt tgcgctattt tgttaaaata	600
ggcaaggacc aagtttggtc ttgcggttct agagcaacaa cttttaattc tcatactcag	660
gcttatgctt gttggaagca ttgcttgggt ttgatttttg tttataatcc actcttagtg	720
gatattcaac agtgggggta ttctggtaac ctacaattta accatgattt gcattgtaat	780
gtgcatggac acgcacatgt agcttctgcg gatgctatta tgacgcgttg tcttgcaatt	840
aataatgcat tttgtcaaga tgtcaactgg gatttaactt accctcatat agcaaatgag	900
gatgaagtca attctagctg tagatattta caacgcctgt atcttaatgc atgtgttgat	960
gctcttaaag ttaacgttgt ctatgatata ggcaacccta aaggtattaa atgtgttaga	1020
cgtggagact taaatttttag attctatgat aagaatccaa tagtaccxaa tgtcaagcag	1080
tttgagtatg actataatca gcacaaagat aagtttgctg atggtctttg tatgttttgg	1140
aattgtaatg tggattgtta tcccgacaat tccttacttt gtaggtacga cacacgaaat	1200
ttgagtgtgt ttaacctacc tgggttgaat ggtggtagct tgtatgttaa caagcatgca	1260
ttccacacac ctaaatttga tcgcactagc ttctgtaatt tgaaagctat gccattcttt	1320
ttctatgact catcgcttg cgagaccatt caattggatg gagttgcga agaccttggtg	1380
tcattagcta cgaagattg tatcacaaaa tgcaacatag gcggtgctgt ttgtaaaaag	1440
cacgcacaaa tgtatgcaga ttttgtgact tcttataatg cagctgttac tgcgtgtttt	1500
actttttggg ttactaataa ttttaacca tataatttgt ggaaaagttt ttcagctctc	1560
cag	1563

<210> SEQ ID NO 4

<211> LENGTH: 1014

<212> TYPE: DNA

<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 4

tctatcgaca atattgctta taatatgtat aagggtggtc attatgatgc tattgcagga	60
gaaatgccca ctatcgtaac tggagataaa gtttttgcta tagatcaagg cgtagaaaaa	120
gcagtttttt ttaatcaaac aattctgcct acatctgtag cgtttgagct gtatgcgaag	180
agaaatattc gcacactgcc aaacaaccgt attttgaaag gtttgggtgt agatgtgact	240
aatggatttg taattttgga ttacacgaac caaacaccac tataccgtaa tactgttaag	300
gtatgtgcat atacagacat agaaccaaat ggccctaatag tgctgtatga tgatagatat	360
ggtgattacc agtcttttct agctgctgat aatgctgttt tagtttctac acagtgttac	420
aagcggatatt cgtatgtaga aataccgtca aacctgcttg ttcagaacgg tattccgtta	480
aaagatggag cgaacctgta tgtttataag cgtgttaatg gtgcgtttgt tacgctacct	540
aacacaataa acacacaggg tcgaagttat gaaacttttg aacctcgtag tgatgttgag	600
cgtgattttc tcgacatgct tgaggagagt tttgtagaaa agtatggtaa agaattaggt	660
ctacagcaca tactgtatgg tgaagttgat aagccccaat taggtgggtt ccacactgtt	720
ataggtatgt gcagactttt acgtgcgaat aagttgaacg caaagtctgt tactaattct	780

-continued

gattctgatg tcatgcaaaa ttattttgta ttggcagaca atggttccta caagcaagtg	840
tgtactgttg tggatttgc tcttgatgat ttcttagaac ttcttaggaa catactgaaa	900
gagtatggta ctaataagtc taaagttgta acagtgtcaa ttgattacca tagcataaat	960
tttatgactt ggtttgaaga tggcattatt aaaacatggt atccacagct tcaa	1014

<210> SEQ ID NO 5
 <211> LENGTH: 909
 <212> TYPE: DNA
 <213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 5

tcagcatgga cgtgtggtta taatatgcct gaactttata aagttcagaa ttgtgttatg	60
gaaccttgca acattcctaa ttatggtgtt ggaatagcgt tgccaagtgg tattatgatg	120
aatgtggcaa agtatacaca actctgtcaa tacctttcga aaacaacaat gtgtgtaccg	180
cataatatgc gagtaatgca ttttgagct ggaagtgcga aaggagtggg gccaggtagt	240
actgttctta aacaatggct ccagaaggg acactccttg tcgataatga tattgtagac	300
tatgtgtctg atgcacatgt ttctgtgctt tcagattgca ataaatataa gacagagcac	360
aagtttgatc ttgtgatatc tgatatgtat acagacaatg attcaaaaag aaagcatgaa	420
ggcgtgatag ccaataatgg caatgatgac gttttcatat atctctcaag ttttcttcgt	480
aataatttgg ctctaggtgg tagttttgct gtaaaagtga cagagacaag ttggcacgaa	540
gttttatatg acattgcaca ggattgtgca tgggtggacaa tgttttgtac agcagtgaat	600
gcctcttctt cagaagcatt cttgattggt gttaattatt tgggtgcaag tgaagaggtt	660
aagggttagtg gaaaaacgct gcacgcaa atatatattt ggaggaattg taattattta	720
caaacctctg cttatagtat atttgacgtt gctaagtttg atttgagatt gaaagcaacg	780
ccagttgtta atttgaaaac tgaacaaaag acagacttag tctttaattt aattaagtgt	840
ggtaagttac tggttaagaga tgttggtaac acctcttcta ctagtgaactc ttttgtgtgt	900
actatgtag	909

<210> SEQ ID NO 6
 <211> LENGTH: 145
 <212> TYPE: PRT
 <213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 6

Ser Lys Gly His Glu Thr Glu Glu Val Asp Ala Val Gly Ile Leu Ser	1	5	10	15
Leu Cys Ser Phe Ala Val Asp Pro Ala Asp Thr Tyr Cys Lys Tyr Val	20	25	30	
Ala Ala Gly Asn Gln Pro Leu Gly Asn Cys Val Lys Met Leu Thr Val	35	40	45	
His Asn Gly Ser Gly Phe Ala Ile Thr Ser Lys Pro Ser Pro Thr Pro	50	55	60	
Asp Gln Asp Ser Tyr Gly Gly Ala Ser Val Cys Leu Tyr Cys Arg Ala	65	70	75	80
His Ile Ala His Pro Gly Gly Ala Gly Asn Leu Asp Gly Arg Cys Gln	85	90	95	
Phe Lys Gly Ser Phe Val Gln Ile Pro Thr Thr Glu Lys Asp Pro Val	100	105	110	
Gly Phe Cys Leu Arg Asn Lys Val Cys Thr Val Cys Gln Cys Trp Ile				

-continued

115	120	125
Gly Tyr Gly Cys Gln Cys Asp Ser Leu Arg Gln Pro Lys Pro Ser Val		
130	135	140
Gln		
145		
<210> SEQ ID NO 7		
<211> LENGTH: 521		
<212> TYPE: PRT		
<213> ORGANISM: Infectious bronchitis virus		
<400> SEQUENCE: 7		
Gly Thr Gly Leu Phe Lys Ile Cys Asn Lys Glu Phe Ser Gly Val His		
1	5	10
Pro Ala Tyr Ala Val Thr Thr Lys Ala Leu Ala Ala Thr Tyr Lys Val		
20	25	30
Asn Asp Glu Leu Ala Ala Leu Val Asn Val Glu Ala Gly Ser Glu Ile		
35	40	45
Thr Tyr Lys His Leu Ile Ser Leu Leu Gly Phe Lys Met Ser Val Asn		
50	55	60
Val Glu Gly Cys His Asn Met Phe Ile Thr Arg Asp Glu Ala Ile Arg		
65	70	75
Asn Val Arg Gly Trp Val Gly Phe Asp Val Glu Ala Thr His Ala Cys		
85	90	95
Gly Thr Asn Ile Gly Thr Asn Leu Pro Phe Gln Val Gly Phe Ser Thr		
100	105	110
Gly Ala Asp Phe Val Val Thr Pro Glu Gly Leu Val Asp Thr Ser Ile		
115	120	125
Gly Asn Asn Phe Glu Pro Val Asn Ser Lys Ala Pro Pro Gly Glu Gln		
130	135	140
Phe Asn His Leu Arg Ala Leu Phe Lys Ser Ala Lys Pro Trp His Val		
145	150	155
Val Arg Pro Arg Ile Val Gln Met Leu Ala Asp Asn Leu Cys Asn Val		
165	170	175
Ser Asp Cys Val Val Phe Val Thr Trp Cys His Gly Leu Glu Leu Thr		
180	185	190
Thr Leu Arg Tyr Phe Val Lys Ile Gly Lys Asp Gln Val Cys Ser Cys		
195	200	205
Gly Ser Arg Ala Thr Thr Phe Asn Ser His Thr Gln Ala Tyr Ala Cys		
210	215	220
Trp Lys His Cys Leu Gly Phe Asp Phe Val Tyr Asn Pro Leu Leu Val		
225	230	235
Asp Ile Gln Gln Trp Gly Tyr Ser Gly Asn Leu Gln Phe Asn His Asp		
245	250	255
Leu His Cys Asn Val His Gly His Ala His Val Ala Ser Ala Asp Ala		
260	265	270
Ile Met Thr Arg Cys Leu Ala Ile Asn Asn Ala Phe Cys Gln Asp Val		
275	280	285
Asn Trp Asp Leu Thr Tyr Pro His Ile Ala Asn Glu Asp Glu Val Asn		
290	295	300
Ser Ser Cys Arg Tyr Leu Gln Arg Met Tyr Leu Asn Ala Cys Val Asp		
305	310	315
Ala Leu Lys Val Asn Val Val Tyr Asp Ile Gly Asn Pro Lys Gly Ile		
325	330	335

-continued

```

Lys Cys Val Arg Arg Gly Asp Leu Asn Phe Arg Phe Tyr Asp Lys Asn
      340                      345                      350

Pro Ile Val Pro Asn Val Lys Gln Phe Glu Tyr Asp Tyr Asn Gln His
      355                      360                      365

Lys Asp Lys Phe Ala Asp Gly Leu Cys Met Phe Trp Asn Cys Asn Val
      370                      375                      380

Asp Cys Tyr Pro Asp Asn Ser Leu Val Cys Arg Tyr Asp Thr Arg Asn
      385                      390                      395                      400

Leu Ser Val Phe Asn Leu Pro Gly Cys Asn Gly Gly Ser Leu Tyr Val
      405                      410                      415

Asn Lys His Ala Phe His Thr Pro Lys Phe Asp Arg Thr Ser Phe Arg
      420                      425                      430

Asn Leu Lys Ala Met Pro Phe Phe Phe Tyr Asp Ser Ser Pro Cys Glu
      435                      440                      445

Thr Ile Gln Leu Asp Gly Val Ala Gln Asp Leu Val Ser Leu Ala Thr
      450                      455                      460

Lys Asp Cys Ile Thr Lys Cys Asn Ile Gly Gly Ala Val Cys Lys Lys
      465                      470                      475                      480

His Ala Gln Met Tyr Ala Asp Phe Val Thr Ser Tyr Asn Ala Ala Val
      485                      490                      495

Thr Ala Gly Phe Thr Phe Trp Val Thr Asn Asn Phe Asn Pro Tyr Asn
      500                      505                      510

Leu Trp Lys Ser Phe Ser Ala Leu Gln
      515                      520

```

<210> SEQ ID NO 8

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 8

```

Ser Ile Asp Asn Ile Ala Tyr Asn Met Tyr Lys Gly Gly His Tyr Asp
1           5           10           15

Ala Ile Ala Gly Glu Met Pro Thr Ile Val Thr Gly Asp Lys Val Phe
20          25          30

Val Ile Asp Gln Gly Val Glu Lys Ala Val Phe Phe Asn Gln Thr Ile
35          40          45

Leu Pro Thr Ser Val Ala Phe Glu Leu Tyr Ala Lys Arg Asn Ile Arg
50          55          60

Thr Leu Pro Asn Asn Arg Ile Leu Lys Gly Leu Gly Val Asp Val Thr
65          70          75          80

Asn Gly Phe Val Ile Trp Asp Tyr Thr Asn Gln Thr Pro Leu Tyr Arg
85          90          95

Asn Thr Val Lys Val Cys Ala Tyr Thr Asp Ile Glu Pro Asn Gly Leu
100         105         110

Ile Val Leu Tyr Asp Asp Arg Tyr Gly Asp Tyr Gln Ser Phe Leu Ala
115         120         125

Ala Asp Asn Ala Val Leu Val Ser Thr Gln Cys Tyr Lys Arg Tyr Ser
130         135         140

Tyr Val Glu Ile Pro Ser Asn Leu Leu Val Gln Asn Gly Ile Pro Leu
145         150         155         160

Lys Asp Gly Ala Asn Leu Tyr Val Tyr Lys Arg Val Asn Gly Ala Phe
165         170         175

Val Thr Leu Pro Asn Thr Leu Asn Thr Gln Gly Arg Ser Tyr Glu Thr
180         185         190

```

-continued

Phe Glu Pro Arg Ser Asp Val Glu Arg Asp Phe Leu Asp Met Ser Glu
 195 200 205
 Glu Ser Phe Val Glu Lys Tyr Gly Lys Glu Leu Gly Leu Gln His Ile
 210 215 220
 Leu Tyr Gly Glu Val Asp Lys Pro Gln Leu Gly Gly Leu His Thr Val
 225 230 235 240
 Ile Gly Met Cys Arg Leu Leu Arg Ala Asn Lys Leu Asn Ala Lys Ser
 245 250 255
 Val Thr Asn Ser Asp Ser Asp Val Met Gln Asn Tyr Phe Val Leu Ala
 260 265 270
 Asp Asn Gly Ser Tyr Lys Gln Val Cys Thr Val Val Asp Leu Leu Leu
 275 280 285
 Asp Asp Phe Leu Glu Leu Leu Arg Asn Ile Leu Lys Glu Tyr Gly Thr
 290 295 300
 Asn Lys Ser Lys Val Val Thr Val Ser Ile Asp Tyr His Ser Ile Asn
 305 310 315 320
 Phe Met Thr Trp Phe Glu Asp Gly Ile Ile Lys Thr Cys Tyr Pro Gln
 325 330 335
 Leu Gln

<210> SEQ ID NO 9
 <211> LENGTH: 302
 <212> TYPE: PRT
 <213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 9

Ser Ala Trp Thr Cys Gly Tyr Asn Met Pro Glu Leu Tyr Lys Val Gln
 1 5 10 15
 Asn Cys Val Met Glu Pro Cys Asn Ile Pro Asn Tyr Gly Val Gly Ile
 20 25 30
 Ala Leu Pro Ser Gly Ile Met Met Asn Val Ala Lys Tyr Thr Gln Leu
 35 40 45
 Cys Gln Tyr Leu Ser Lys Thr Thr Met Cys Val Pro His Asn Met Arg
 50 55 60
 Val Met His Phe Gly Ala Gly Ser Asp Lys Gly Val Ala Pro Gly Ser
 65 70 75 80
 Thr Val Leu Lys Gln Trp Leu Pro Glu Gly Thr Leu Leu Val Asp Asn
 85 90 95
 Asp Ile Val Asp Tyr Val Ser Asp Ala His Val Ser Val Leu Ser Asp
 100 105 110
 Cys Asn Lys Tyr Lys Thr Glu His Lys Phe Asp Leu Val Ile Ser Asp
 115 120 125
 Met Tyr Thr Asp Asn Asp Ser Lys Arg Lys His Glu Gly Val Ile Ala
 130 135 140
 Asn Asn Gly Asn Asp Asp Val Phe Ile Tyr Leu Ser Ser Phe Leu Arg
 145 150 155 160
 Asn Asn Leu Ala Leu Gly Gly Ser Phe Ala Val Lys Val Thr Glu Thr
 165 170 175
 Ser Trp His Glu Val Leu Tyr Asp Ile Ala Gln Asp Cys Ala Trp Trp
 180 185 190
 Thr Met Phe Cys Thr Ala Val Asn Ala Ser Ser Ser Glu Ala Phe Leu
 195 200 205
 Val Gly Val Asn Tyr Leu Gly Ala Ser Glu Lys Val Lys Val Ser Gly
 210 215 220

-continued

Lys Thr Leu His Ala Asn Tyr Ile Phe Trp Arg Asn Cys Asn Tyr Leu
 225 230 235 240
 Gln Thr Ser Ala Tyr Ser Ile Phe Asp Val Ala Lys Phe Asp Leu Arg
 245 250 255
 Leu Lys Ala Thr Pro Val Val Asn Leu Lys Thr Glu Gln Lys Thr Asp
 260 265 270
 Leu Val Phe Asn Leu Ile Lys Cys Gly Lys Leu Leu Val Arg Asp Val
 275 280 285
 Gly Asn Thr Ser Phe Thr Ser Asp Ser Phe Val Cys Thr Met
 290 295 300

<210> SEQ ID NO 10
 <211> LENGTH: 145
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Mutated Nsp10 sequence

<400> SEQUENCE: 10

Ser Lys Gly His Glu Thr Glu Glu Val Asp Ala Val Gly Ile Leu Ser
 1 5 10 15
 Leu Cys Ser Phe Ala Val Asp Pro Ala Asp Thr Tyr Cys Lys Tyr Val
 20 25 30
 Ala Ala Gly Asn Gln Pro Leu Gly Asn Cys Val Lys Met Leu Thr Val
 35 40 45
 His Asn Gly Ser Gly Phe Ala Ile Thr Ser Lys Pro Ser Pro Thr Pro
 50 55 60
 Asp Gln Asp Ser Tyr Gly Gly Ala Ser Val Cys Leu Tyr Cys Arg Ala
 65 70 75 80
 His Ile Ala His Leu Gly Gly Ala Gly Asn Leu Asp Gly Arg Cys Gln
 85 90 95
 Phe Lys Gly Ser Phe Val Gln Ile Pro Thr Thr Glu Lys Asp Pro Val
 100 105 110
 Gly Phe Cys Leu Arg Asn Lys Val Cys Thr Val Cys Gln Cys Trp Ile
 115 120 125
 Gly Tyr Gly Cys Gln Cys Asp Ser Leu Arg Gln Pro Lys Pro Ser Val
 130 135 140
 Gln
 145

<210> SEQ ID NO 11
 <211> LENGTH: 521
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Mutated Nsp14 sequence

<400> SEQUENCE: 11

Gly Thr Gly Leu Phe Lys Ile Cys Asn Lys Glu Phe Ser Gly Val His
 1 5 10 15
 Pro Ala Tyr Ala Val Thr Thr Lys Ala Leu Ala Ala Thr Tyr Lys Val
 20 25 30
 Asn Asp Glu Leu Ala Ala Leu Val Asn Val Glu Ala Gly Ser Glu Ile
 35 40 45
 Thr Tyr Lys His Leu Ile Ser Leu Leu Gly Phe Lys Met Ser Val Asn
 50 55 60
 Val Glu Gly Cys His Asn Met Phe Ile Thr Arg Asp Glu Ala Ile Arg

-continued

65	70	75	80
Asn Val Arg Gly Trp Val Gly Phe Asp Val Glu Ala Thr His Ala Cys			
	85	90	95
Gly Thr Asn Ile Gly Thr Asn Leu Pro Phe Gln Val Gly Phe Ser Thr			
	100	105	110
Gly Ala Asp Phe Val Val Thr Pro Glu Gly Leu Val Asp Thr Ser Ile			
	115	120	125
Gly Asn Asn Phe Glu Pro Val Asn Ser Lys Ala Pro Pro Gly Glu Gln			
	130	135	140
Phe Asn His Leu Arg Ala Leu Phe Lys Ser Ala Lys Pro Trp His Val			
145	150	155	160
Val Arg Pro Arg Ile Val Gln Met Leu Ala Asp Asn Leu Cys Asn Val			
	165	170	175
Ser Asp Cys Val Val Phe Val Thr Trp Cys His Gly Leu Glu Leu Thr			
	180	185	190
Thr Leu Arg Tyr Phe Val Lys Ile Gly Lys Asp Gln Val Cys Ser Cys			
	195	200	205
Gly Ser Arg Ala Thr Thr Phe Asn Ser His Thr Gln Ala Tyr Ala Cys			
	210	215	220
Trp Lys His Cys Leu Gly Phe Asp Phe Val Tyr Asn Pro Leu Leu Val			
225	230	235	240
Asp Ile Gln Gln Trp Gly Tyr Ser Gly Asn Leu Gln Phe Asn His Asp			
	245	250	255
Leu His Cys Asn Val His Gly His Ala His Val Ala Ser Ala Asp Ala			
	260	265	270
Ile Met Thr Arg Cys Leu Ala Ile Asn Asn Ala Phe Cys Gln Asp Val			
	275	280	285
Asn Trp Asp Leu Thr Tyr Pro His Ile Ala Asn Glu Asp Glu Val Asn			
	290	295	300
Ser Ser Cys Arg Tyr Leu Gln Arg Met Tyr Leu Asn Ala Cys Val Asp			
305	310	315	320
Ala Leu Lys Val Asn Val Val Tyr Asp Ile Gly Asn Pro Lys Gly Ile			
	325	330	335
Lys Cys Val Arg Arg Gly Asp Leu Asn Phe Arg Phe Tyr Asp Lys Asn			
	340	345	350
Pro Ile Val Pro Asn Val Lys Gln Phe Glu Tyr Asp Tyr Asn Gln His			
	355	360	365
Lys Asp Lys Phe Ala Asp Gly Leu Cys Met Phe Trp Asn Cys Asn Val			
	370	375	380
Asp Cys Tyr Pro Asp Asn Ser Leu Leu Cys Arg Tyr Asp Thr Arg Asn			
385	390	395	400
Leu Ser Val Phe Asn Leu Pro Gly Cys Asn Gly Gly Ser Leu Tyr Val			
	405	410	415
Asn Lys His Ala Phe His Thr Pro Lys Phe Asp Arg Thr Ser Phe Arg			
	420	425	430
Asn Leu Lys Ala Met Pro Phe Phe Phe Tyr Asp Ser Ser Pro Cys Glu			
	435	440	445
Thr Ile Gln Leu Asp Gly Val Ala Gln Asp Leu Val Ser Leu Ala Thr			
	450	455	460
Lys Asp Cys Ile Thr Lys Cys Asn Ile Gly Gly Ala Val Cys Lys Lys			
465	470	475	480
His Ala Gln Met Tyr Ala Asp Phe Val Thr Ser Tyr Asn Ala Ala Val			
	485	490	495

-continued

Thr Ala Gly Phe Thr Phe Trp Val Thr Asn Asn Phe Asn Pro Tyr Asn
 500 505 510

Leu Trp Lys Ser Phe Ser Ala Leu Gln
 515 520

<210> SEQ ID NO 12

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Mutated Nsp15 sequence

<400> SEQUENCE: 12

Ser Ile Asp Asn Ile Ala Tyr Asn Met Tyr Lys Gly Gly His Tyr Asp
 1 5 10 15

Ala Ile Ala Gly Glu Met Pro Thr Ile Val Thr Gly Asp Lys Val Phe
 20 25 30

Val Ile Asp Gln Gly Val Glu Lys Ala Val Phe Phe Asn Gln Thr Ile
 35 40 45

Leu Pro Thr Ser Val Ala Phe Glu Leu Tyr Ala Lys Arg Asn Ile Arg
 50 55 60

Thr Leu Pro Asn Asn Arg Ile Leu Lys Gly Leu Gly Val Asp Val Thr
 65 70 75 80

Asn Gly Phe Val Ile Trp Asp Tyr Thr Asn Gln Thr Pro Leu Tyr Arg
 85 90 95

Asn Thr Val Lys Val Cys Ala Tyr Thr Asp Ile Glu Pro Asn Gly Leu
 100 105 110

Ile Val Leu Tyr Asp Asp Arg Tyr Gly Asp Tyr Gln Ser Phe Leu Ala
 115 120 125

Ala Asp Asn Ala Val Leu Val Ser Thr Gln Cys Tyr Lys Arg Tyr Ser
 130 135 140

Tyr Val Glu Ile Pro Ser Asn Leu Leu Val Gln Asn Gly Ile Pro Leu
 145 150 155 160

Lys Asp Gly Ala Asn Leu Tyr Val Tyr Lys Arg Val Asn Gly Ala Phe
 165 170 175

Val Thr Leu Pro Asn Thr Ile Asn Thr Gln Gly Arg Ser Tyr Glu Thr
 180 185 190

Phe Glu Pro Arg Ser Asp Val Glu Arg Asp Phe Leu Asp Met Ser Glu
 195 200 205

Glu Ser Phe Val Glu Lys Tyr Gly Lys Glu Leu Gly Leu Gln His Ile
 210 215 220

Leu Tyr Gly Glu Val Asp Lys Pro Gln Leu Gly Gly Leu His Thr Val
 225 230 235 240

Ile Gly Met Cys Arg Leu Leu Arg Ala Asn Lys Leu Asn Ala Lys Ser
 245 250 255

Val Thr Asn Ser Asp Ser Asp Val Met Gln Asn Tyr Phe Val Leu Ala
 260 265 270

Asp Asn Gly Ser Tyr Lys Gln Val Cys Thr Val Val Asp Leu Leu Leu
 275 280 285

Asp Asp Phe Leu Glu Leu Leu Arg Asn Ile Leu Lys Glu Tyr Gly Thr
 290 295 300

Asn Lys Ser Lys Val Val Thr Val Ser Ile Asp Tyr His Ser Ile Asn
 305 310 315 320

Phe Met Thr Trp Phe Glu Asp Gly Ile Ile Lys Thr Cys Tyr Pro Gln
 325 330 335

-continued

Leu Gln

<210> SEQ ID NO 13

<211> LENGTH: 302

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Mutated Nsp16 sequence

<400> SEQUENCE: 13

Ser Ala Trp Thr Cys Gly Tyr Asn Met Pro Glu Leu Tyr Lys Val Gln
 1 5 10 15

Asn Cys Val Met Glu Pro Cys Asn Ile Pro Asn Tyr Gly Val Gly Ile
 20 25 30

Ala Leu Pro Ser Gly Ile Met Met Asn Val Ala Lys Tyr Thr Gln Leu
 35 40 45

Cys Gln Tyr Leu Ser Lys Thr Thr Met Cys Val Pro His Asn Met Arg
 50 55 60

Val Met His Phe Gly Ala Gly Ser Asp Lys Gly Val Ala Pro Gly Ser
 65 70 75 80

Thr Val Leu Lys Gln Trp Leu Pro Glu Gly Thr Leu Leu Val Asp Asn
 85 90 95

Asp Ile Val Asp Tyr Val Ser Asp Ala His Val Ser Val Leu Ser Asp
 100 105 110

Cys Asn Lys Tyr Lys Thr Glu His Lys Phe Asp Leu Val Ile Ser Asp
 115 120 125

Met Tyr Thr Asp Asn Asp Ser Lys Arg Lys His Glu Gly Val Ile Ala
 130 135 140

Asn Asn Gly Asn Asp Asp Val Phe Ile Tyr Leu Ser Ser Phe Leu Arg
 145 150 155 160

Asn Asn Leu Ala Leu Gly Gly Ser Phe Ala Val Lys Val Thr Glu Thr
 165 170 175

Ser Trp His Glu Val Leu Tyr Asp Ile Ala Gln Asp Cys Ala Trp Trp
 180 185 190

Thr Met Phe Cys Thr Ala Val Asn Ala Ser Ser Ser Glu Ala Phe Leu
 195 200 205

Ile Gly Val Asn Tyr Leu Gly Ala Ser Glu Lys Val Lys Val Ser Gly
 210 215 220

Lys Thr Leu His Ala Asn Tyr Ile Phe Trp Arg Asn Cys Asn Tyr Leu
 225 230 235 240

Gln Thr Ser Ala Tyr Ser Ile Phe Asp Val Ala Lys Phe Asp Leu Arg
 245 250 255

Leu Lys Ala Thr Pro Val Val Asn Leu Lys Thr Glu Gln Lys Thr Asp
 260 265 270

Leu Val Phe Asn Leu Ile Lys Cys Gly Lys Leu Leu Val Arg Asp Val
 275 280 285

Gly Asn Thr Ser Phe Thr Ser Asp Ser Phe Val Cys Thr Met
 290 295 300

The invention claimed is:

1. A live, attenuated coronavirus comprising a variant replicase gene encoding polypeptides comprising a mutation in one or both of non-structural protein(s) nsp-10 and nsp-14, wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6, and/or wherein the variant replicase gene encodes a protein

60 comprising an amino acid mutation of Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7.

2. The coronavirus according to claim 1 wherein the variant replicase gene encodes a protein comprising one or more amino acid mutations selected from:

65 an amino acid mutation of Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and

95

an amino acid mutation of Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

3. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

4. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6; Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

5. The coronavirus according to claim 1 wherein the replicase gene comprises at least one nucleotide substitutions selected from:

C to Tat nucleotide position 12137; and

G to C at nucleotide position 18114;

compared to the sequence shown as SEQ ID NO: 1;

and optionally, comprises one or more nucleotide substitutions selected from T to A at nucleotide position 19047; and

G to A at nucleotide position 20139;

compared to the sequence shown as SEQ ID NO: 1.

6. The coronavirus according to claim 1 which is an infectious bronchitis virus (IBV).

7. The coronavirus according to claim 1 which is IBV M41.

8. The coronavirus according to claim 7, which comprises an S protein at least, part of which is from an IBV serotype other than M41.

9. The coronavirus according to claim 8, wherein the S1 subunit is from an IBV serotype other than M41.

10. The coronavirus according to claim 8, wherein the S protein is from an IBV serotype other than M41.

11. The coronavirus according to claim 1 which has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, wherein the virus is capable of replicating without being pathogenic to the embryo when administered to an embryonated egg.

96

12. A variant replicase gene as defined in claim 1.

13. A protein encoded by a variant coronavirus replicase gene according to claim 12.

14. A plasmid comprising a replicase gene according to claim 12.

15. A method for making the coronavirus according to claim 1 which comprises the following steps:

(i) transfecting a plasmid according to claim 14 into a host cell;

(ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;

(iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and

(iv) selecting for recombining virus comprising the modified replicase gene.

16. The method according to claim 15, wherein the recombining virus is a vaccinia virus.

17. The method according to claim 15 which also includes the step:

(v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

18. A cell capable of producing a coronavirus according to claim 1.

19. A vaccine comprising a coronavirus according to claim 1 and a pharmaceutically acceptable carrier.

20. A method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to claim 19 to the subject.

21. The method of claim 20, wherein the disease is infectious bronchitis (IB).

22. The method according to claim 20 wherein the method of administration is selected from the group consisting of; eye drop administration, intranasal administration, drinking water administration, post-hatch injection and in ovo injection.

23. The method according to claim 21 wherein the administration is in ovo vaccination.

24. A method for producing a vaccine according to claim 19, which comprises the step of infecting a cell according to claim 18 with a coronavirus according to claim 1.

25. The coronavirus according to claim 1, further comprising a mutation in one or both of nsp-15 and nsp-16.

* * * * *